NZ716914B2 - Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof - Google Patents
Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof Download PDFInfo
- Publication number
- NZ716914B2 NZ716914B2 NZ716914A NZ71691414A NZ716914B2 NZ 716914 B2 NZ716914 B2 NZ 716914B2 NZ 716914 A NZ716914 A NZ 716914A NZ 71691414 A NZ71691414 A NZ 71691414A NZ 716914 B2 NZ716914 B2 NZ 716914B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- domain
- seq
- cells
- dart
- diabody
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 132
- 102100018760 IL3RA Human genes 0.000 claims description 315
- 101700029869 IL3RA Proteins 0.000 claims description 315
- 210000004027 cells Anatomy 0.000 claims description 297
- 229920001184 polypeptide Polymers 0.000 claims description 181
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 103
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 101
- 125000005647 linker group Chemical group 0.000 claims description 69
- 102000004965 antibodies Human genes 0.000 claims description 61
- 108090001123 antibodies Proteins 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 230000014509 gene expression Effects 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 54
- 102000038129 antigens Human genes 0.000 claims description 54
- 108091007172 antigens Proteins 0.000 claims description 54
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 42
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 39
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 33
- 150000002500 ions Chemical class 0.000 claims description 31
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 16
- 102000018358 Immunoglobulins Human genes 0.000 claims description 16
- 108060003951 Immunoglobulins Proteins 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000001154 acute Effects 0.000 claims description 15
- 206010024324 Leukaemias Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 9
- 241000288906 Primates Species 0.000 claims description 8
- 201000006439 lymphocytic leukemia Diseases 0.000 claims description 7
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 6
- 108020001568 subdomains Proteins 0.000 claims description 6
- 230000001131 transforming Effects 0.000 claims description 6
- 208000006673 Asthma Diseases 0.000 claims description 5
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 5
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- 206010028549 Myeloid leukaemia Diseases 0.000 claims description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims description 4
- 201000002594 Richter's syndrome Diseases 0.000 claims description 3
- 201000010874 syndrome Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract description 17
- 210000001744 T-Lymphocytes Anatomy 0.000 description 131
- 241000282693 Cercopithecidae Species 0.000 description 49
- 238000004166 bioassay Methods 0.000 description 48
- 241000282567 Macaca fascicularis Species 0.000 description 45
- 102100008191 CD8A Human genes 0.000 description 44
- 101700054655 CD8A Proteins 0.000 description 44
- 102100013077 CD4 Human genes 0.000 description 42
- 101700022938 CD4 Proteins 0.000 description 42
- 241000424123 Trachinotus baillonii Species 0.000 description 41
- 238000000375 direct analysis in real time Methods 0.000 description 41
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 41
- 239000003981 vehicle Substances 0.000 description 39
- 210000003969 blast cell Anatomy 0.000 description 33
- 210000001185 Bone Marrow Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 230000001404 mediated Effects 0.000 description 31
- 230000002147 killing Effects 0.000 description 29
- 230000003442 weekly Effects 0.000 description 27
- 210000004369 Blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 26
- 230000003013 cytotoxicity Effects 0.000 description 23
- 231100000135 cytotoxicity Toxicity 0.000 description 23
- 239000002609 media Substances 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 21
- 230000020411 cell activation Effects 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 21
- 101700082799 IL2RA Proteins 0.000 description 20
- 101700015336 ISG20 Proteins 0.000 description 20
- 102100002950 ISG20 Human genes 0.000 description 20
- 210000000130 stem cell Anatomy 0.000 description 20
- 230000035492 administration Effects 0.000 description 19
- 108010002386 Interleukin-3 Proteins 0.000 description 17
- 102000000646 Interleukin-3 Human genes 0.000 description 17
- 229940076264 Interleukin-3 Drugs 0.000 description 17
- 210000001616 Monocytes Anatomy 0.000 description 17
- 102000004503 Perforin Human genes 0.000 description 17
- 108010056995 Perforin Proteins 0.000 description 17
- 230000001939 inductive effect Effects 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 108030007212 EC 3.4.21.79 Proteins 0.000 description 15
- 102100004391 GZMB Human genes 0.000 description 15
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 15
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 15
- -1 ene Chemical compound 0.000 description 15
- 230000001965 increased Effects 0.000 description 15
- 210000004544 DC2 Anatomy 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 210000002798 bone marrow cell Anatomy 0.000 description 14
- 238000005734 heterodimerization reaction Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 102100016493 CD33 Human genes 0.000 description 13
- 101700017647 CD33 Proteins 0.000 description 13
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000001225 therapeutic Effects 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000022534 cell killing Effects 0.000 description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 102100003268 CD14 Human genes 0.000 description 11
- 101700027514 CD14 Proteins 0.000 description 11
- 231100000673 dose–response relationship Toxicity 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000004881 tumor cells Anatomy 0.000 description 11
- 102100019764 PDCD1 Human genes 0.000 description 10
- 102100005499 PTPRC Human genes 0.000 description 10
- 101700059076 PTPRC Proteins 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 229920000023 polynucleotide Polymers 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 210000001519 tissues Anatomy 0.000 description 10
- 206010000830 Acute leukaemia Diseases 0.000 description 9
- 210000003719 B-Lymphocytes Anatomy 0.000 description 9
- 102000018883 Interleukin-3 Receptor alpha Subunit Human genes 0.000 description 9
- 108010052781 Interleukin-3 Receptor alpha Subunit Proteins 0.000 description 9
- 108091008153 T cell receptors Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 230000002354 daily Effects 0.000 description 9
- 230000003247 decreasing Effects 0.000 description 9
- 201000009277 hairy cell leukemia Diseases 0.000 description 9
- 239000004005 microsphere Substances 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 230000003827 upregulation Effects 0.000 description 9
- 108060001251 CD34 Proteins 0.000 description 8
- 102100016492 CD34 Human genes 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 230000000259 anti-tumor Effects 0.000 description 8
- 230000000779 depleting Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000006011 modification reaction Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- 101710027066 ALB Proteins 0.000 description 7
- 210000003651 Basophils Anatomy 0.000 description 7
- 101700080416 CD69 Proteins 0.000 description 7
- 102100005832 CD69 Human genes 0.000 description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 7
- 102100016384 HAVCR2 Human genes 0.000 description 7
- 101710004393 HAVCR2 Proteins 0.000 description 7
- 230000036499 Half live Effects 0.000 description 7
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 7
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 7
- 241000229754 Iva xanthiifolia Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 108091006028 chimera Proteins 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000011132 hemopoiesis Effects 0.000 description 7
- 230000003389 potentiating Effects 0.000 description 7
- 230000001052 transient Effects 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000003979 Eosinophils Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 201000009910 diseases by infectious agent Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 102100019461 CD28 Human genes 0.000 description 5
- 101700033362 CD28 Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 5
- 101700081293 LMX1A Proteins 0.000 description 5
- 239000007759 RPMI Media 1640 Substances 0.000 description 5
- 101700008936 Tim8 Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002441 reversible Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000002459 sustained Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000004450 types of analysis Methods 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000006306 Antigen Receptors Human genes 0.000 description 4
- 108010083359 Antigen Receptors Proteins 0.000 description 4
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 4
- 102100005826 CD19 Human genes 0.000 description 4
- 101700087100 CD19 Proteins 0.000 description 4
- 102100003279 CD38 Human genes 0.000 description 4
- 101700044948 CD38 Proteins 0.000 description 4
- 102100010782 EGFR Human genes 0.000 description 4
- 101700039191 EGFR Proteins 0.000 description 4
- 210000000265 Leukocytes Anatomy 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 210000004379 Membranes Anatomy 0.000 description 4
- 206010025310 Other lymphomas Diseases 0.000 description 4
- 102000014961 Protein Precursors Human genes 0.000 description 4
- 108010078762 Protein Precursors Proteins 0.000 description 4
- 102000004584 Somatomedin Receptors Human genes 0.000 description 4
- 108010017622 Somatomedin Receptors Proteins 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 230000001472 cytotoxic Effects 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002934 lysing Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003285 pharmacodynamic Effects 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 230000003362 replicative Effects 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 201000008736 systemic mastocytosis Diseases 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 102100001249 ALB Human genes 0.000 description 3
- 208000007502 Anemia Diseases 0.000 description 3
- 210000003229 CMP Anatomy 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 229960000684 Cytarabine Drugs 0.000 description 3
- 210000004405 Cytokine-Induced Killer Cells Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 210000002889 Endothelial Cells Anatomy 0.000 description 3
- 102100016439 FAS Human genes 0.000 description 3
- 101700079540 FAS Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 101700037237 SD18 Proteins 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 3
- 229940050528 albumin Drugs 0.000 description 3
- 230000002494 anti-cea Effects 0.000 description 3
- 230000000719 anti-leukaemic Effects 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 108090000514 blinatumomab Proteins 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000001747 exhibiting Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003394 haemopoietic Effects 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- LZMSXDHGHZKXJD-WPOPZESYSA-O (2S)-2-azaniumyl-5-[[(4R)-4-[[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino]-5,8,19,22-tetraoxo-1,2-dithia-6,9,18,21-tetraza-13-azoniacyclotetracos-23-yl]amino]-5-oxopentanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC(=O)NC1CSSC[C@H](NC(=O)CC[C@H]([NH3+])C([O-])=O)C(=O)NCC(=O)NCCC[NH2+]CCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-WPOPZESYSA-O 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 2
- 102100011842 CEACAM5 Human genes 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 108010000640 CSL360 Proteins 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- 230000037242 Cmax Effects 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 102100015540 FCGR1A Human genes 0.000 description 2
- 101710003440 FCGR1A Proteins 0.000 description 2
- 102100015541 FCGR3A Human genes 0.000 description 2
- 101710044656 FCGR3A Proteins 0.000 description 2
- 101710044657 FCGR3B Proteins 0.000 description 2
- 102100008634 FGF2 Human genes 0.000 description 2
- 101700082364 FGF2 Proteins 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102400001066 Growth hormone-binding protein Human genes 0.000 description 2
- 101800000194 Growth hormone-binding protein Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 210000002332 Leydig Cells Anatomy 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100000165 MS4A1 Human genes 0.000 description 2
- 101710010909 MS4A1 Proteins 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101700059678 SCG2 Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229960005322 Streptomycin Drugs 0.000 description 2
- 102100008333 THY1 Human genes 0.000 description 2
- 101700026084 THY1 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 101700018328 ccdB Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001461 cytolytic Effects 0.000 description 2
- 231100000050 cytotoxic potential Toxicity 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000000925 erythroid Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000002489 hematologic Effects 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 210000003071 memory T lymphocyte Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 229920001690 polydopamine Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000001177 retroviral Effects 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 230000035500 two compartment model Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- XMSHRLOQLUNKSN-UHFFFAOYSA-N 4-(2,4-Dichlorobenzoyl)-1,3-dimethyl-5-hydroxypyrazole Chemical compound CC1=NN(C)C(O)=C1C(=O)C1=CC=C(Cl)C=C1Cl XMSHRLOQLUNKSN-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102100017923 ACOT12 Human genes 0.000 description 1
- 101710008266 ACOT12 Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- 210000003165 Abomasum Anatomy 0.000 description 1
- 101710027538 Aper1 Proteins 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000004958 Brain cells Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 101710014631 CHURC1 Proteins 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- UVYVLBIGDKGWPX-SPPYGRLSSA-N Digitonin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H](O)C[C@]3(C)[C@@H]4[C@H]([C@@H]5[C@H](O)[C@@H]6O[C@]7([C@@H](C)[C@@H]6[C@@]5(C)CC4)OC[C@H](C)CC7)CC[C@H]3C2)O[C@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1 UVYVLBIGDKGWPX-SPPYGRLSSA-N 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 206010015281 Erythroleukaemia Diseases 0.000 description 1
- 101710044640 FCGR2A Proteins 0.000 description 1
- 101710044641 FCGR2B Proteins 0.000 description 1
- 102100015544 FCGR2C Human genes 0.000 description 1
- 101710044642 FCGR2C Proteins 0.000 description 1
- 241000233756 Fabriciana elisa Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 210000003709 Heart Valves Anatomy 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 101710006689 ITGAX Proteins 0.000 description 1
- 102100019437 ITGAX Human genes 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 1
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 208000009503 Leukemia, Erythroblastic, Acute Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 230000036948 MRT Effects 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 206010027175 Memory impairment Diseases 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 210000004253 Multipotent Stem Cells Anatomy 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- 210000003643 Myeloid Progenitor Cells Anatomy 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 210000004693 NK cell Anatomy 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 230000036016 PAAP Effects 0.000 description 1
- 101710043771 PDCL Proteins 0.000 description 1
- 241000164466 Palaemon adspersus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000036045 Renal clearance Effects 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710015019 SRM Proteins 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 229960004249 Sodium Acetate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010055514 Streptococcus IgG Fc-binding protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 238000011126 anti-leukemic therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000000536 complexating Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000009108 consolidation therapy Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000000139 costimulatory Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000000913 erythropoietic Effects 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001031 immunopharmacological Effects 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910000659 lithium lanthanum titanates (LLT) Inorganic materials 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 101700083995 speE1 Proteins 0.000 description 1
- 101700019481 speE2 Proteins 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention is directed to sequence-optimized CD 123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
Description
Title of the Invention:
Bi-Specific Monovalent Diabodies That Are Capable
Of Binding CD123 And CD3, And Uses Thereof
Cross-Reference to Related Applications
This Application claims priority to United States Patent Applications No.
61/869,510 (filed on August 23, 2013; pending), 61/907,749 (filed on November 22,
2013; pending), and 61/990,475 (filed on May 8, 2014; pending), and European
Patent Application No. 13198784 (filed on December 20, 2013), each of which
applications is herein incorporated by reference in its entirety.
nce to Sequence Listing:
This ation includes one or more Sequence gs pursuant to 37
C.F.R. 1.821 et seq., which are disclosed in both paper and computer-readable media,
and which paper and computer-readable disclosures are herein incorporated by
reference in their entirety.
Background of the Invention:
Field of the Invention:
The present invention is directed to CD123 X CD3 cific monovalent
diabodies that are capable of simultaneous binding to CD123 and CD3, and to the
uses of such molecules in the ent of hematologic malignancies.
Description of Related Art:
I. CD123
CD123 leukin 3 receptor alpha, IL-3Ra) is a 40 kDa le and is
part of the interleukin 3 receptor complex (Stomski, F.C. et al. (1996) “Human
Interleukin-3 (IL-3) Induces Disulfide-Linked IL-3 Receptor Alpha- And Beta-Chain
Heterodimerization, Which Is ed For Receptor tion But Not High-Afinity
Binding,” M01. Cell. Biol. 16(6):3035-3046). Interleukin 3 (IL-3) drives early
differentiation of multipotent stem cells into cells of the erythroid, myeloid and
lymphoid progenitors. CD123 is expressed on CD34+ committed progenitors
(Taussig, D.C. et al. (2005) “Hematopoietic Stem Cells Express Multiple Myeloid
Markers.‘ Implications For The Origin And Targeted Therapy 0f Acute Myeloid
ia,” Blood 106:4086-4092), but not by CD34+/CD38- normal hematopoietic
stem cells. CD123 is expressed by basophils, mast cells, plasmacytoid dendritic cells,
some expression by monocytes, macrophages and eosinophils, and low or no
expression by neutrophils and ryocytes. Some non-hematopoietic tissues
(placenta, Leydig cells of the testis, certain brain cell elements and some endothelial
cells) express CD123; however expression is mostly cytoplasmic.
CD123 is reported to be expressed by leukemic blasts and leukemia stem
cells (LSC) (Jordan, C.T. et al. (2000) “The Interleukin-3 Receptor Alpha Chain Is A
Unique Marker For Human Acute Myelogenous Leukemia Stem Cells,” ia
14:1777-1784; Jin, W. et al. (2009) “Regulation 0f ThI7 Cell Difi’erentiation And
EAE Induction By MAP3K NIK,” Blood 113:6603-6610) (Figure 1). In human
normal precursor tions, CD123 is expressed by a subset of hematopoietic
progenitor cells (HPC) but not by normal hematopoietic stem cells (HSC). CD123 is
also expressed by plasmacytoid dendritic cells (pDC) and basophils, and, to a lesser
extent, monocytes and eosinophils (Lopez, A.F. et al. (1989) “Reciprocal Inhibition
0fBinding Between eukin 3 And Granulocyte-Macrophage Colony-Stimulating
Factor To Human Eosinophils,” Proc. Natl. Acad. Sci. (USA) 86:7022-7026; Sun,
Q. et al. (1996) “Monoclonal Antibody 7G3 Recognizes The N-Terminal Domain Of
The Human Interleukin-3 (IL-3) Receptor Alpha Chain And ons As A Specific
IL-3 Receptor Antagonist,” Blood 87:83-92; Munoz, L. et al. (2001) “Interleukin-3
Receptor Alpha Chain (CD123) Is Widely Expressed In Hematologic Malignancies,”
Haematologica 86(12):1261-1269; Masten, B]. et al. (2006) cterization 0f
Myeloid And cytoid Dendritic Cells In Human Lung,” J. Immunol. 177:7784-
7793; Korpelainen, E.I. et al. (1995) “Interferon-Gamma Upregulates Interleukin-3
(IL-3) Receptor Expression In Human Endothelial Cells And Synergizes With IL-3 In
ating Major ompatibility Complex Class II sion And Cytokine
Production,” Blood 86:176-182).
CD123 has been reported to be overexpressed on malignant cells in a wide
range of hematologic ancies including acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS) (Munoz, L. et al. (2001) “Interleukin-3 Receptor
Alpha Chain (CD123) Is Widely sed In Hematologic Malignancies,”
Haematologica 86(12):1261-1269). Overexpression of CD123 is associated with
poorer prognosis in AML (Tettamanti, M.S. et al. (2013) ting 0f Acute
Myeloid Leukaemia By Cytokine-Induced Killer Cells Redirected With A Novel
CD123-Specific Chimeric Antigen Receptor,” Br. J. Haematol. 161 :389-401).
AML and MDS are thought to arise in and be perpetuated by a small
population of leukemic stem cells (LSCs), which are lly dormant (i.e., not
rapidly dividing cells) and therefore resist cell death (apoptosis) and tional
chemotherapeutic agents. LSCs are characterized by high levels of CD123
expression, which is not present in the corresponding normal poietic stem cell
population in normal human bone marrow (Jin, W. et al. (2009) “Regulation 0f Th] 7
Cell Difi’erentiation And EAE Induction By MAP3K NIK,” Blood 113:6603-6610;
, C.T. et al. (2000) “The Interleukin-3 Receptor Alpha Chain Is A Unique
Marker For Human Acute Myelogenous Leukemia Stem Cells,” Leukemia 14:1777-
1784). CD123 is expressed in 45%-95% of AML, 85% of Hairy cell leukemia
(HCL), and 40% of acute B lymphoblastic leukemia (B-ALL). CD123 sion is
also associated with multiple other malignancies/pre-malignancies: chronic myeloid
leukemia (CML) itor cells (including blast crisis CML); n’s Reed
rg (RS) cells; transformed non-Hodgkin’s lymphoma (NHL); some chronic
lymphocytic leukemia (CLL) (CD11c+); a subset of acute T lymphoblastic leukemia
(T-ALL) (16%, most immature, mostly adult), plasmacytoid dendritic cell (pDC)
(DC2) malignancies and CD34+/CD38- myelodysplastic syndrome (MDS) marrow
cell malignancies.
AML is a clonal disease terized by the proliferation and accumulation
of transformed myeloid progenitor cells in the bone marrow, which ultimately leads to
hematopoietic failure. The incidence of AML increases with age, and older patients
typically have worse treatment outcomes than do younger patients (Robak, T. et al.
(2009) “Current And Emerging Therapies For Acute Myeloid Leukemia,” Clin. Ther.
2:2349-2370). Unfortunately, at present, most adults with AML die from their
disease.
Treatment for AML initially s in the induction of ion (induction
therapy). Once remission is achieved, treatment shifts to focus on securing such
ion (post-remission or consolidation therapy) and, in some instances,
maintenance therapy. The standard ion induction paradigm for AML is
chemotherapy with an anthracycline/cytarabine combination, followed by either
consolidation herapy (usually with higher doses of the same drugs as were
used during the induction period) or human stem cell transplantation, depending on
the patient's ability to tolerate intensive treatment and the likelihood of cure with
chemotherapy alone (see, e.g., Roboz, G.J. (2012) “Current Treatment Of Acute
Myeloid Leukemia,” Curr. Opin. Oncol. -719).
Agents ntly used in induction therapy include cytarabine and the
anthracyclines. Cytarabine, also known as AraC, kills cancer cells (and other rapidly
dividing normal cells) by interfering with DNA synthesis. Side effects associated
with AraC treatment include decreased ance to infection, a result of decreased
white blood cell production; bleeding, as a result of decreased platelet production; and
anemia, due to a potential reduction in red blood cells. Other side effects include
nausea and vomiting. Anthracyclines (e.g., daunorubicin, doxorubicin, and
idarubicin) have several modes of action ing inhibition of DNA and RNA
synthesis, disruption of higher order structures of DNA, and production of cell
damaging free oxygen radicals. The most uential adverse effect of
anthracyclines is cardiotoxicity, which considerably limits administered life-time dose
and to some extent their ness.
Thus, unfortunately, e substantial progress in the treatment of newly
diagnosed AML, 20% to 40% of patients do not achieve remission with the standard
induction chemotherapy, and 50% to 70% of patients entering a first complete
remission are expected to relapse within 3 years. The optimum strategy at the time of
relapse, or for patients with the resistant disease, remains uncertain. Stem cell
transplantation has been established as the most ive form of anti-leukemic
therapy in patients with AML in first or subsequent remission (Roboz, G]. (2012)
“Current Treatment OfAcute Myeloid Leukemia,” Curr. Opin. Oncol. 24:711-719).
11. CD3
CD3 is a T cell co-receptor composed of four distinct chains
(Wucherpfennig, KW. et al. (2010) “Structural Biology Of The T-Cell Receptor:
Insights Into or Assembly, Ligand Recognition, And tion 0f Signaling,”
Cold Spring Harb. Perspect. Biol. 2(4):a005140; pages 1-14). In s, the
complex contains a CD3}! chain, a CD38 chain, and two CD38 chains. These chains
associate with a le known as the T cell receptor (TCR) in order to generate an
activation signal in T lymphocytes. In the absence of CD3, TCRs do not assemble
properly and are degraded (Thomas, S. et al. (2010) “Molecular Immunology Lessons
From eutic T-Cell Receptor Gene Transfer,” Immunology l29(2):170—l77).
CD3 is found bound to the membranes of all mature T cells, and in virtually no other
cell type (see, Janeway, CA. et al. (2005) In: IMMUNOBIOLOGY: THE IMMUNE SYSTEM
IN HEALTH AND E,” 6th ed. Garland Science Publishing, NY, pp. 214- 216;
Sun, Z. J. et al. (2001) “Mechanisms Contributing To T Cell Receptor Signaling And
Assembly Revealed By The Solution Structure OfAn Ectodomain Fragment Of The
CD383)» Heterodimer,” Cell 105(7):913-923; Kuhns, M.S. et al. (2006)
“Deconstructing The Form And Function Of The TCR/CD3 x,” Immunity.
2006 Feb;24(2):l33-l39).
III. Bi-Specific Diabodies
The ability of an intact, unmodified antibody (e.g., an IgG) to bind an epitope
of an antigen depends upon the presence of variable domains on the immunoglobulin
light and heavy chains (i.e., the VL and VH domains, respectively). The design of a
diabody is based on the single chain Fv construct (scFv) (see, e.g., Holliger et al.
(1993) “’Diabodies Small Bivalent And Bispecific Antibody Fragments,” Proc. Natl.
Acad. Sci. (USA) 90:6444-6448; US 2004/0058400 (Hollinger et al.); US
2004/0220388 (Mertens et al.); Alt et al. (1999) FEBS Lett. 454(1-2):90-94; Lu, D. et
al. (2005) “A Fully Human Recombinant IgG-Like Bispecific Antibody To Both The
Epidermal Growth Factor Receptor And The Insulin-Like Growth Factor Receptor
For Enhanced mor ty,” J. Biol. Chem. 280(20):19665-19672; WO
02/02781 (Mertens et al.); n, T. et al. (2004) “Covalent Disulfide-Linked Anti-
CEA Diabody Allows Site-Specific Conjugation And Radiolabeling For Tumor
Targeting Applications,” Protein Eng. Des. Sel. 17(1):21-27; Wu, A. et al. (2001)
“Multimerization Of A Chimeric Anti-CD20 Single Chain Fv-Fv Fusion Protein Is
Mediated h Variable Domain Exchange,” Protein Engineering 14(2):1025-
1033; Asano et al. (2004) “A Diabody For Cancer Immunotherapy And Its Functional
Enhancement By Fusion Of Human Fc Domain,” Abstract 3P-683, J. Biochem.
76(8):992; Takemura, S. et al. (2000) “Construction Of A Diabody (Small
inant Bispecific Antibody) Using A Refolding System,” Protein Eng.
13(8):.583-588; le, P.A. et al. (2009) “Bispecific T-Cell Engaging Antibodies
For Cancer Therapy,” Cancer Res. 69(12):4941-4944).
ction of an antibody light chain and an antibody heavy chain and, in
particular, ction of its VL and VH domains forms one of the epitope binding
sites of the antibody. In contrast, the scFv construct comprises a VL and VH domain
of an antibody contained in a single polypeptide chain wherein the domains are
separated by a flexible linker of sufficient length to allow ssembly of the two
domains into a fianctional epitope binding site. Where self-assembly of the VL and
VH domains is rendered impossible due to a linker of insufficient length (less than
about 12 amino acid residues), two of the scFv constructs interact with one another
other to form a bivalent molecule in which the VL of one chain associates with the
VH of the other wed in Marvin et al. (2005) “Recombinant Approaches To IgG-
Like Bispecific Antibodies, ” Acta Pharmacol. Sin. 26:649-658).
Natural antibodies are capable of binding to only one epitope s (i.e.,
mono-specific), although they can bind multiple copies of that species (i.e., exhibiting
bi-Valency or multi-valency). The art has noted the capability to produce diabodies
that differ from such natural antibodies in being capable of binding two or more
different epitope species (i. e., exhibiting bi-specif1city or multispecif1city in addition
to bi-Valency or multi-valency) (see, e.g., er et al. (1993) “’Diabodies’. Small
Bivalent And Bispecific Antibody Fragments,” Proc. Natl. Acad. Sci. (USA)
90:6444-6448; US 2004/0058400 (Hollinger et al.); US 220388 (Mertens et
al.); Alt et al. (1999) FEBS Lett. 454(1-2):90-94; Lu, D. et al. (2005) “A Fully Human
Recombinant IgG-Like ific dy To Both The Epidermal Growth Factor
Receptor And The Insulin-Like Growth Factor Receptor For Enhanced Antitumor
Activity,” J. Biol. Chem. 280(20):19665-19672; WO 02/02781 (Mertens et al.);
Mertens, N. et al., “New Recombinant Bi- and Trispecific Antibody Derivatives,” In:
NOVEL FRONTIERS IN THE PRODUCTION OF COMPOUNDS FOR BIOMEDICAL USE, A.
VanBroekhoven et al. (Eds.), Kluwer Academic Publishers, cht, The
Netherlands (2001), pages 195-208; Wu, A. et al. (2001) “Multimerization Of A
Chimeric Anti-CD20 Single Chain Fv-Fv Fusion Protein Is ed Through
Variable Domain ge,” Protein Engineering 14(2):1025-1033; Asano et al.
(2004) “A Diabody For Cancer Immunotherapy And Its Functional Enhancement By
Fusion OfHuman Fc Domain,” Abstract , J. Biochem. 992; Takemura,
S. et al. (2000) ruction OfA Diabody (Small Recombinant ific Antibody)
Using A Refolding System,” n Eng. 13(8):583-588; Baeuerle, P.A. et al. (2009)
“Bispecific T-Cell Engaging Antibodies For Cancer Therapy,” Cancer Res.
69(12):4941-4944).
The provision of non-monospecific diabodies provides a significant
advantage: the capacity to co-ligate and co-localize cells that express different
epitopes. Bi-specific ies thus have wide-ranging applications including therapy
and immunodiagnosis. Bi-specificity allows for great lity in the design and
engineering of the diabody in various applications, providing enhanced avidity to
multimeric antigens, the cross-linking of ing antigens, and directed targeting to
specific cell types relying on the presence of both target antigens. Due to their
increased valency, low dissociation rates and rapid clearance from the circulation (for
diabodies of small size, at or below ~50 kDa), diabody molecules known in the art
have also shown ular use in the field of tumor imaging (Fitzgerald et al. (1997)
“Improved Tumour Targeting By Disulphide Stabilized Diabodies Expressed In
Pichia pastoris, ” Protein Eng. 10:1221). Of particular importance is the co-ligating
of differing cells, for example, the cross-linking of cytotoxic T cells to tumor cells
(Staerz et al. (1985) “Hybrid Antibodies Can Target Sites For Attack By T Cells, ”
Nature 8-631, and Holliger et al. (1996) “Specific Killing OfLymphoma Cells
By Cytotoxic T-Cells Mediated By A Bispecific Diabody, ” Protein Eng. 9:299-305).
Diabody epitope g domains may also be directed to a surface
determinant of any immune effector cell such as CD3, CD16, CD32, or CD64, which
are expressed on T lymphocytes, natural killer (NK) cells or other mononuclear cells.
In many s, diabody binding to effector cell determinants, e. g., Fcy receptors
(FcyR), was also found to activate the effector cell (Holliger et al. (1996) fic
Killing 0fLymphoma Cells By Cytotoxic T-Cells Mediated By A Bispecific y, ”
Protein Eng. 305; er et al. (1999) “Carcinoembryonic Antigen (CEA)-
Specific T-cell Activation In Colon Carcinoma Induced By Anti-CD3 x EA
Bispecific ies And B7 x Anti-CEA Bispecific Fusion Proteins, ” Cancer Res.
9-2916; WO 2006/113665; WO 2008/157379; WO 2010/080538; WO
2012/018687; ). Normally, effector cell activation is triggered by
the binding of an antigen bound antibody to an effector cell via Fc-FcyR interaction;
thus, in this regard, diabody molecules may exhibit Ig-like fianctionality independent
of whether they se an Fc Domain (e. g., as assayed in any or function
assay known in the art or exemplified herein (e.g., ADCC assay)). By cross-linking
tumor and effector cells, the diabody not only brings the effector cell within the
proximity of the tumor cells but leads to effective tumor killing (see e. g., Cao et al.
(2003) “Bispecific Antibody Conjugates In Therapeutics,” Adv. Drug. DeliV. ReV.
55:171-197).
r, the above advantages come at a salient cost. The formation of
such non-monospecif1c diabodies requires the successful assembly of two or more
distinct and different ptides (i. e., such formation requires that the diabodies be
formed through the heterodimerization of different polypeptide chain species). This
fact is in contrast to mono-specific diabodies, which are formed h the
homodimerization of identical polypeptide chains. Because at least two dissimilar
polypeptides (i.e., two polypeptide species) must be provided in order to form a nonmonospecific
diabody, and because homodimerization of such polypeptides leads to
inactive molecules (Takemura, S. et al. (2000) “Construction OfA Diabody (Small
Recombinant Bispecific Antibody) Using A Refolding System,” Protein Eng.
l3(8):583-588), the production of such polypeptides must be accomplished in such a
way as to prevent covalent bonding between polypeptides of the same species (i.e., so
as to prevent homodimerization) (Takemura, S. et al. (2000) “Construction Of A
Diabody (Small Recombinant ific Antibody) Using A Refolding System,”
Protein Eng. l3(8):583-588). The art has ore taught the non-covalent
association of such polypeptides (see, e.g., Olafsen et al. (2004) “Covalent Disulfide-
Linked Anti-CEA Diabody Allows Site-Specific ation And Radiolabeling For
Tumor Targeting Applications,” Prot. Engr. Des. Sel. 17:21-27; Asano et al. (2004)
“A Diabody For Cancer Immunotherapy And Its Functional Enhancement By Fusion
OfHuman Fc Domain,” Abstract 3P-683, J. Biochem. 76(8):992; Takemura, S. et al.
(2000) “Construction OfA y (Small Recombinant Bispecific Antibody) Using
A Refolding System,” Protein Eng. l3(8):583-588; Lu, D. et al. (2005) “A Fully
Human Recombinant IgG-Like Bispecific Antibody To Both The Epidermal Growth
Factor Receptor And The Insulin-Like Growth Factor Receptor For Enhanced
Antitumor Activity,” J. Biol. Chem. 280(20): 19665-19672).
However, the art has recognized that bi-specific diabodies composed of non-
ntly associated polypeptides are unstable and readily dissociate into non-
functional monomers (see, e.g., Lu, D. et al. (2005) “A Fully Human Recombinant
ke Bispecific Antibody To Both The Epidermal Growth Factor Receptor And
The Insulin-Like Growth Factor Receptor For Enhanced Antitumor Activity,” J. Biol.
Chem. 280(20):l9665-l9672).
In the face of this challenge, the art has succeeded in developing stable,
covalently bonded heterodimeric non-monospecific diabodies (see, e.g., WO
2006/113665; WO/2008/157379; WO 2010/080538; WO 2012/018687;
WO/2012/162068; Johnson, S. et al. (2010) “Eflector Cell Recruitment With Novel
Fv-Based Dual-Afiinity Re-Targeting Protein Leads To Potent Tumor Cytolysis And
In Vivo B—Cell Depletion,” J. Molec. Biol. 399(3):436-449; Veri, MC. et al. (2010)
peutic Control OfB Cell tion Via Recruitment Ochgamma Receptor Hb
(CD323) Inhibitory Function With A Novel ific Antibody Scaflold,” Arthritis
Rheum. 62(7):l933-l943; Moore, P.A. et al. (2011) “Application Of Dual Afiinity
eting les To Achieve Optimal Redirected T-Cell Killing 0f B-Cell
Lymphoma,” Blood ll7(l7):4542-4551). Such approaches e engineering one
or more cysteine residues into each of the employed polypeptide s. For
example, the addition of a ne residue to the C-terminus of such constructs has
been shown to allow disulfide bonding between the polypeptide chains, stabilizing the
resulting heterodimer without interfering with the binding characteristics of the
bivalent molecule.
Notwithstanding such s, the tion of stable, fianctional
heterodimeric, non-monospecif1c diabodies can be fiarther optimized by the careful
consideration and placement of cysteine residues in one or more of the employed
polypeptide chains. Such optimized diabodies can be produced in higher yield and
with greater activity than non-optimized diabodies. The present invention is thus
directed to the problem of providing polypeptides that are particularly designed and
optimized to form heterodimeric ies. The invention solves this problem
through the provision of exemplary, zed CD123 X CD3 diabodies.
Summary of the ion:
The t invention is directed to CD123 X CD3 bi-specif1c diabodies that
are capable of simultaneous binding to CD123 and CD3, and to the uses of such
molecules in the treatment of disease, in particular hematologic malignancies.
The CD123 X CD3 bi-specific diabodies of the ion comprise at least
two different ptide chains that ate with one another in a heterodimeric
manner to form one binding site specific for an epitope of CD 123 and one binding site
specific for an epitope of CD3. A CD123 X CD3 diabody of the invention is thus
lent in that it is capable of binding to only one copy of an epitope of CD123
and to only one copy of an epitope of CD3, but bi-specif1c in that a single diabody is
able to bind simultaneously to the epitope of CD123 and to the epitope of CD3. The
individual polypeptide chains of the diabodies are covalently bonded to one another,
for example by disulfide bonding of cysteine residues located within each polypeptide
chain. In particular embodiments, the diabodies of the present invention fiarther have
an immunoglobulin Fc Domain or an Albumin-Binding Domain to extend half-life in
vivo .
In detail, the invention also provides a sequence-optimized CD123 X CD3 bi-
c monovalent diabody capable of specific binding to an epitope of CD123 and
to an epitope of CD3, wherein the diabody comprises a first polypeptide chain and a
second polypeptide chain, covalently bonded to one another, wherein:
A. the first polypeptide chain comprises, in the inal to C-terminal ion:
i. a Domain 1, comprising:
(1) a sub-Domain (1A), which comprises a VL Domain of a
monoclonal antibody capable of binding to CD3 (VLCD3) (SEQ
ID ; and
(2) a main (1B), which comprises a VH Domain of a
monoclonal dy capable of binding to CD123 (VHCDm)
(SEQ ID NO:26);
wherein the sub-Domains 1A and 1B are ted from one another
by a peptide linker (SEQ ID NO:29);
ii. a Domain 2, wherein the Domain 2 is an E-coil Domain (SEQ ID
NO:34) or a K-coil Domain (SEQ ID NO:35), wherein the Domain 2
is separated from the Domain 1 by a peptide linker (SEQ ID NO:30);
the second polypeptide chain comprises, in the N-terminal to C-terminal
direction:
i. a Domain 1, comprising:
(1) a sub-Domain (1A), which comprises a VL Domain of a
monoclonal antibody capable of binding to CD123 (VLCDm)
(SEQ ID NO:25); and
(2) a sub-Domain (1B), which ses a VH Domain of a
monoclonal antibody capable of binding to CD3 (VHCDg) (SEQ
ID NO:22);
wherein the sub-Domains 1A and 1B are separated from one another
by a peptide linker (SEQ ID NO:29);
ii. a Domain 2, wherein the Domain 2 is a K-coil Domain (SEQ ID
NO:35) or an E-coil Domain (SEQ ID NO:34), wherein the Domain 2
is separated from the Domain 1 by a peptide linker (SEQ ID NO:30);
and wherein the Domain 2 of the first and the second polypeptide
chains are not both E-coil Domains or both K-coil Domains;
-1]-
and wherein:
(a) said VL Domain of said first polypeptide chain and said VH Domain of said
second polypeptide chain form an Antigen Binding Domain capable of
specifically binding to an e of CD3; and
(b) said VL Domain of said second polypeptide chain and said VH Domain of
said first polypeptide chain form an Antigen Binding Domain capable of
cally binding to an epitope of CD123.
The invention also provides a non-sequence-optimized CD123 X CD3 bi-
specific monovalent diabody capable of specific binding to an epitope of CD123 and
to an epitope of CD3, wherein the diabody comprises a first polypeptide chain and a
second polypeptide chain, covalently bonded to one another, wherein:
A. the first polypeptide chain comprises, in the inal to C-terminal
direction:
i. a Domain 1, sing:
(1) a sub-Domain (1A), which comprises a VL Domain of a
monoclonal antibody capable of binding to CD3 (VLCD3) (SEQ
ID NO:23); and
(2) a sub-Domain (1B), which comprises a VH Domain of a
monoclonal antibody capable of binding to CD123 )
(SEQ ID NO:28);
wherein the sub-Domains 1A and 1B are separated from one another
by a peptide linker (SEQ ID NO:29);
ii. a Domain 2, wherein the Domain 2 is an E-coil Domain (SEQ ID
NO:34) or a K-coil Domain (SEQ ID , n the Domain 2
is separated from the Domain 1 by a peptide linker (SEQ ID NO:30);
B. the second ptide chain comprises, in the N-terminal to C-terminal
direction:
i. a Domain 1, comprising:
(1) a sub-Domain (1A), which comprises a VL Domain of a
monoclonal antibody capable of binding to CD123 (VLCDm)
(SEQ ID NO:27); and
(2) a sub-Domain (1B), which comprises a VH Domain of a
monoclonal antibody capable of binding to CD3 (VHCDg) (SEQ
ID ;
wherein the sub-Domains 1A and 1B are separated from one another
by a peptide linker (SEQ ID NO:29);
ii. a Domain 2, wherein the Domain 2 is a K-coil Domain (SEQ ID
NO:35) or an E-coil Domain (SEQ ID NO:34), wherein the Domain 2
is separated from the Domain 1 by a peptide linker (SEQ ID NO:30);
and wherein the Domain 2 of the first and the second polypeptide
chains are not both E-coil Domains or both K-coil Domains
and wherein:
(a) said VL Domain of said first polypeptide chain and said VH Domain of said
second polypeptide chain form an Antigen Binding Domain capable of
specifically binding to an epitope of CD3; and
(b) said VL Domain of said second polypeptide chain and said VH Domain of
said first polypeptide chain form an Antigen Binding Domain capable of
specifically binding to an epitope of CDl23.
The invention onally provides the embodiment of the above-described
cific monovalent ies, wherein the first or second ptide chain
additionally comprises an Albumin-Binding Domain (SEQ ID NO:36) , C-
terminally to Domain 2 or N-terminally to Domain 1, via a peptide linker (SEQ ID
NO:31).
The invention additionally provides the embodiment of the above-described
bi-specific monovalent diabodies wherein the first or second polypeptide chain
additionally comprises a Domain 3 sing a CH2 and CH3 Domain of an
immunoglobulin IgG Fc Domain (SEQ ID NO:37), wherein the Domain 3 is linked,
N—terminally, to the Domain lA via a peptide linker (SEQ ID NO:33).
The invention onally provides the embodiment of the above-described
bi-specific monovalent ies wherein the first or second polypeptide chain
additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an
immunoglobulin IgG Fc Domain (SEQ ID NO:37), wherein the Domain 3 is linked,
C-terminally, to the Domain 2 via a peptide linker (SEQ ID NO:32).
The invention additionally es the embodiment of any of the abovedescribed
bi-specific monovalent diabodies wherein the Domain 2 of the first
polypeptide chain is a K-coil Domain (SEQ ID NO:35) and the Domain 2 of the
second polypeptide chain is an E-coil Domain (SEQ ID NO:34).
The invention additionally provides the embodiment of any of the above-
described bi-specific monovalent diabodies n the Domain 2 of the first
polypeptide chain is an E-coil Domain (SEQ ID NO:34) and the Domain 2 of the
second polypeptide chain is a K-coil Domain (SEQ ID NO:35).
The invention additionally provides the embodiment of a bi-specific
monovalent diabody capable of specific binding to an e of CD123 and to an
epitope of CD3, wherein the diabody comprises a first polypeptide chain and a second
ptide chain, covalently bonded to one r, wherein: said bi-specific
y comprises:
A. a first polypeptide chain having the amino acid sequence of SEQ ID
NO:1; and
B. a second ptide chain having the amino acid sequence of SEQ ID
NO:3;
wherein said first and said second polypeptide chains are covalently bonded to one
r by a disulfide bond.
The ies of the invention exhibit unexpectedly enhanced functional
activities as further described below.
The diabodies of the invention are preferably capable of cross-reacting with
both human and primate CD123 and CD3 proteins, preferably cynomolgus monkey
CD123 and CD3 proteins.
The diabodies of the invention are preferably capable of depleting, in an in
vitro cell-based assay, plasmacytoid dendritic cells (pDC) from a culture of primary
PBMCs with an ICSO of about 1 ng/ml or less, about 0.8 ng/ml or less, about 0.6
ng/ml or less, about 0.4 ng/ml or less, about 0.2 ng/ml or less, about 0.1 ng/ml or less,
about 0.05 ng/ml or less, about 0.04 ng/ml or less, about 0.03 ng/ml or less, about
0.02 ng/ml or less or about 0.01ng/ml or less. Preferably, the IC50 is about 0.01ng/ml
or less. In the above-described assay, the e of primary PBMCs may be from
cynomolgus monkey in which case said depletion is of cynomolgus monkey
plasmacytoid tic cells (pDC). Optionally the diabodies of the invention may be
capable of depleting plasmacytoid dendritic cells (pDC) from a y culture of
PBMCs as described above wherein the assay is conducted by or in accordance with
the protocol of e 14, as herein described, or by modification of such assay as
would be understood by those of ordinary skill, or by other means known to those of
ordinary skill.
The diabodies of the invention preferably exhibit cytotoxicity in an in vitro
Kasumi-3 assay with an EC50 of about 0.05 ng/mL or less. Preferably, the EC50 is
about 0.04 ng/mL or less, about 0.03 ng/mL or less, about 0.02 ng/mL or less, or
about 0.01 ng/mL or less. Optionally the diabodies of the invention may exhibit
cytotoxicity as described above wherein the assay is conducted by or in ance
with the protocol of Example 3 as herein described, or by modification of such assay
as would be understood by those of ry skill, or by other means known to those
of ordinary skill.
The diabodies of the invention preferably exhibit cytotoxicity in an in vitro
3 assay with an EC50 of about 5 ng/mL or less. Preferably, the EC50 is about
3 ng/mL or less, about 2 ng/mL or less, about 1 ng/mL or less, about 0.75 ng/mL or
less, or about 0.2 ng/mL or less. Optionally the diabodies of the invention may
exhibit cytotoxicity as described above wherein the assay is conducted by or in
accordance with the protocol of Example 3 as herein described, or by modification of
such assay as would be tood by those of ordinary skill, or by other means
known to those of ordinary skill.
The diabodies of the invention are preferably capable of inhibiting the
growth of a MOLM-l3 tumor xenograft in a mouse. Preferably the diabodies of the
invention may be capable of inhibiting the growth of a MOLM-l3 tumor xenograft in
a mouse at a concentration of at least about 20 ug/kg, at least about 4 ug/kg, at least
about 0.8 ug/kg, at least about 0.6 ug/kg or at least about 0.4 ug/kg. Preferred
antibodies of the invention will t growth of a MOLM-l3 tumor xenograft in a
mouse by at least 25%, but possibly by at least about 40% or more, by at least about
50% or more, by at least about 60% or more, by at least about 70% or more, by at
least about 80% or more, by at least about 90% or more, or even by completely
inhibiting MOLM-l3 tumor growth after some period of time or by causing tumor
regression or disappearance. This inhibition will take place for at least an NSG
mouse strain. ally, the ies of the invention may be capable of inhibiting
the growth of a MOLM-l3 tumor xenograft in a mouse in the above-described
manner by or in accordance with the protocol of Example 6 as herein described, or by
modification of such assay as would be understood by those of ordinary skill, or by
other means known to those of ry skill.
The diabodies of the invention are preferably capable of inhibiting the
growth of an RS4-ll tumor xenograft in a mouse. Preferably the diabodies of the
invention may be capable of inhibiting the growth of a RS4-ll tumor xenograft in a
mouse at a concentration of at least about 0.5 mg/kg, at least about 0.2 mg/kg, at least
about 0.1 mg/kg, at least about 0.02 mg/kg or at least about 0.004 mg/kg. Preferred
antibodies of the invention will inhibit growth of a RS4-ll tumor xenograft in a
mouse by at least about 25%, but possibly at least about 40%, at least about 50%, at
least about 60%, at least about 70%, at least about 80%, at least about 90%, or even
by completely inhibiting RS4-ll tumor growth after some period of time or by
causing tumor regression or disappearance. This inhibition will take place for at least
an NSG mouse . Optionally, the diabodies of the invention may be capable of
inhibiting the growth of a RS4-11 tumor xenograft in a mouse in the above-described
manner by or in accordance with the protocol of e 6 as herein bed, or by
modification of such assay as would be understood by those of ordinary skill, or by
other means known to those of ordinary skill.
The diabodies of the invention are preferably capable of depleting leukemic
blast cells in vitro in a primary culture of AML bone marrow cells. Preferably the
diabodies of the ion may be capable of depleting leukemic blast cells in vitro in
a primary culture of AML bone marrow cells at trations of at least about 0.01
ng/ml, at least about 0.02 ng/ml, at least about 0.04 ng/ml, at least about 0.06 ng/ml,
at least about 0.08 ng/ml or at least about 0.1 ng/ml. Preferably, the diabodies of the
invention may be capable of depleting leukemic blast cells in vitro in a primary
culture ofAML bone marrow cells to less than 20% of the total population of primary
leukemic blast cells at diabody concentrations of at least about 0.01 ng/ml, at least
about 0.02 ng/ml, at least about 0.04 ng/ml, at least about 0.06 ng/ml, at least about
0.08 ng/ml or at least about 0.1 ng/ml, optionally following incubation of the primary
e with diabody for about 120 hours. ably leukemic blast cells are depleted
in vitro in a primary culture of AML bone marrow cells to less than 20% of the total
tion of primary leukemic blast cells at diabody concentrations of about 0.01
ng/ml or 0.1 ng/ml following tion of the primary culture with diabody for about
120 hours.
The diabodies of the invention are preferably capable of inducing an
expansion of a T cell population in vitro in a primary culture of AML bone marrow
cells. Preferably, such expansion may be to about 70% or more of the maximum T
cell population which can be expanded in the assay. Preferably the ies of the
ion may be capable of inducing an expansion of a T cell population in vitro in a
y culture ofAML bone marrow cells to about 70% or more of the maximum T
cell population which can be expanded in the assay at diabody concentrations of at
least about 0.01 ng/ml, at least about 0.02 ng/ml, at least about 0.04 ng/ml, at least
about 0.06 ng/ml, at least about 0.08 ng/ml or at least about 0.1 ng/ml, optionally
following incubation of the primary culture with diabody for about 120 hours.
Preferably, a T cell population is expanded in vitro in a primary culture ofAML bone
marrow cells to about 70% or more of the maximum T cell population which can be
expanded in the assay at diabody concentrations of about 0.01 ng/ml or about 0.1
ng/ml following incubation of the primary culture with diabody for about 120 hours.
The diabodies of the invention are preferably capable of inducing an
activation of a T cell population in vitro in a primary culture of AML bone marrow
cells. Such activation may occur at y concentrations of at least about 0.01
ng/ml, at least about 0.02 ng/ml, at least about 0.04 ng/ml, at least about 0.06 ng/ml,
at least about 0.08 ng/ml or at least about 0.1 ng/ml, optionally following incubation
of the primary culture with diabody for about 72 hours. Such activation may be
measured by the expression of a T cell tion marker such as CD25. Preferably,
activation of a T cell population in vitro in a primary culture of AML bone marrow
cells as measured by expression of CD25 may occur at diabody concentrations of
about 0.01 ng/ml or about 0.1 ng/ml following tion of the primary culture with
diabody for about 72 hours.
The ies of the invention are preferably capable of depleting leukemic
blast cells in vitro in a primary culture ofAML bone marrow cells to less than 20% of
the total population of primary leukemic blast cells and at the same time inducing an
expansion of the T cell population in vitro in the primary culture of AML bone
marrow cells to about 70% or more of the maximum T cell population which can be
expanded in the assay at diabody concentrations of at least about 0.01 ng/ml, at least
about 0.02 ng/ml, at least about 0.04 ng/ml, at least about 0.06 ng/ml, at least about
0.08 ng/ml or at least about 0.1 ng/ml, optionally following incubation of the y
culture with diabody for about 120 hours. Preferably, the diabody concentrations are
about 0.01 ng/ml or about 0.1 ng/ml and the primary culture is incubated with diabody
for about 120 hours.
The diabodies of the invention may be capable of depleting ic blast
cells in vitro in a primary culture of AML bone marrow cells and/or inducing an
ion of a T cell population in vitro in a primary culture of AML bone marrow
cells and/or inducing an activation of a T cell population in vitro in a primary culture
of AML bone marrow cells in the above-described manner by or in accordance with
the protocol of Example 8 as herein described, or by ation of such assay as
would be tood by those of ordinary skill, or by other means known to those of
ordinary skill.
For the avoidance of any doubt, the diabodies of the invention may exhibit
one, two, three, more than three or all of the onal attributes described herein.
Thus the diabodies of the invention may exhibit any combination of the fianctional
utes described herein.
The ies of the invention may be for use as a pharmaceutical.
Preferably, the diabodies are for use in the treatment of a disease or condition
associated with or characterized by the expression of CD123. The invention also
relates to the use of diabodies of the invention in the manufacture of a pharmaceutical
composition, preferably for the treatment of a disease or condition ated with or
characterized by the expression of CD123 as fiarther defined herein.
The disease or condition associated with or characterized by the expression
of CD123 may be cancer. For example, the cancer may be selected from the group
consisting of: acute myeloid leukemia (AML), c myelogenous leukemia
(CML), including blastic crisis of CML and Abelson oncogene associated with CML
(Bcr-ABL translocation), myelodysplastic syndrome (MDS), acute B lymphoblastic
leukemia ), chronic lymphocytic leukemia (CLL), including Richter’s
syndrome or Richter’s transformation of CLL, hairy cell leukemia (HCL), blastic
plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL),
ing mantel cell leukemia (MCL), and small lymphocytic lymphoma (SLL),
Hodgkin’s lymphoma, systemic mastocytosis, and Burkitt’s lymphoma.
The e or condition associated with or characterized by the sion
of CD123 may be an atory condition. For e, the inflammatory
condition may be selected from the group consisting of: mune Lupus (SLE),
allergy, asthma and rheumatoid arthritis.
The invention additionally provides a pharmaceutical composition
comprising any of the above-described diabodies and a physiologically acceptable carrier.
The invention additionally es a use of the above-described
pharmaceutical composition in the treatment of a disease or condition ated with
or characterized by the expression of CD123.
The invention is particularly directed to the embodiment of such use,
wherein the disease or condition associated with or characterized by the expression of
CD123 is cancer (especially a cancer selected from the group consisting of: acute
myeloid leukemia (AML), chronic myelogenous leukemia (CML), including blastic
crisis of CML and n oncogene associated with CML (Bcr-ABL translocation),
myelodysplastic syndrome (MDS), acute B lymphoblastic leukemia (B-ALL), c
lymphocytic leukemia (CLL), ing r’s syndrome or Richter’s
transformation of CLL, hairy cell leukemia (HCL), blastic plasmacytoid tic cell
neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), including mantel cell
leukemia (MCL), and small lymphocytic lymphoma (SLL), Hodgkin’s lymphoma,
systemic mastocytosis, and Burkitt’s lymphoma).
The invention is also particularly directed to the embodiment of such use,
n the disease or condition associated with or characterized by the expression of
CD123 is an inflammatory condition (especially an inflammatory condition selected
from the group consisting of: Autoimmune Lupus (SLE), allergy, asthma, and
rheumatoid arthritis).
Terms such as “about” should be taken to mean within 10%, more preferably
within 5%, of the specified value, unless the context requires otherwise.
Brief ption of the Drawings:
Figure 1 shows that CD123 was known to be expressed on leukemic stem
cells.
Figure 2 illustrates the structures of the first and second polypeptide chains
of a two chain CD123 X CD3 cific lent diabody of the present invention.
Figures 3A and 3B illustrate the structures of two versions of the first,
second and third polypeptide chains of a three chain CD123 X CD3 cific
monovalent Fc diabody of the present invention (Version 1, Figure 3A; Version 2,
Figure 3B).
Figure 4 (Panels A-E) shows the ability of different CD123 X CD3 bi-
specific diabodies to mediate T cell cted killing of target cells displaying
varying amount of CD123. The Figure provides dose-response curves indicating that
the sequence-optimized CD123 X CD3 bi-specific diabody (“DART-A”) having an
Albumin-Binding Domain (DART-A with ABD “w/ABD”) exhibited greater
cytotoxicity than a control bi-specif1c diabody (Control DART) or a non-sequenceoptimized
CD123 X CD3 bi-specific diabody (“DART-B”) in le target cell
types: RS4-ll (Panel A); TF-l (Panel B); Molm-l3 (Panel C); Kasumi-3 (Panel D);
and THP-l (Panel E) at an E:T (effector : target) ratio of 10: 1.
Figure 5 (Panels A-D) shows the y of the sequence-optimized CD123
X CD3 bi-specif1c diabody (DART-A), sequence-optimized CD123 X CD3 bi-specif1c
diabody having an Albumin-Binding Domain (DART-A with ABD “w/ABD”) and
ce-optimized CD123 X CD3 bi-specif1c diabody having an immunoglobulin
IgG Fc Domain (DART-A with Fe “w/Fc”) to mediate T cell activation during
cted killing of target cells. The Figure ts esponse curves showing
the cytotoxicity mediated by DART-A, DART-A w/ABD and DART-A w/Fc in
Kasumi-3 (Panel A) and THP-l (Panel B) cells and purified CD8 T cells at an E:T
tor cell : target cell) ratio of 10:1 (18 hour incubation). Panels C and D show
dose-response curves of T cell activation using the marker CD25 on CD8 T cells in
the presence (Panel D) and absence (Panel C) of target cells.
Figure 6 (Panels A-B) shows Granzyme B and Perforin levels in CD4 and
CD8 T cells after treatment with the sequence-optimized CD123 X CD3 bi-specific
diabody (DART-A) (Panel A) or a control bi-specif1c diabody (Control DART)
(Panel B) in the presence of Kasumi-3 target cells and resting T cells at an E:T ratio
of10:l.
Figure 7 (Panels A-B) shows the in viva antitumor activity of the sequence-
zed CD123 X CD3 bi-specif1c diabody (DART-A) at nanogram per kilogram
dosing levels. MOLM-l3 cells (intermediate CD123 expression) were co-mixed with
T cells and implanted subcutaneously (T:E 1:1) in NSG mice. Intravenous treatment
was once daily for 8 days (QDX8) starting at tation. Various concentrations of
DART-A were compared to a control bi-specific diabody (Control DART). Panel A
shows the Molm-l3 cells alone or with T cells, and the effect of various doses of
DART-A on tumor volume even to times beyond 30 days. Panel B shows the effect
of increasing doses of DART-A on tumor volume seen in NSG mice receiving
MOLM-l3 cells and T cells (T:E 1:1) for a time course of 0-18 days.
-2]-
Figure 8 shows the in viva antitumor activity of the sequence-optimized
CD123 X CD3 bi-specific diabody A) on RS4-11 cells (ALL with monocytic
features). Cells were co-mixed with T cells and implanted subcutaneously (T:E 1:1)
in NSG mice. Intravenous treatment was once daily for 4 days (QDx4) starting at
implantation. Various concentrations of DART-A were compared to a control bi-
specific diabody (Control DART).
Figure 9 (Panels A-B) shows CD123+ blasts in bone marrow
cleocytes (BM MNC) and peripheral blood mononucleocytes (PBMCs) from
AML patient 1 (Panel A) ed to Kasumi-3 AML cell line (Panel B).
Figure 10 (Panels A-C) shows the y of the sequence-optimized CD123
X CD3 bi-specific diabody (DART-A) to mediate blast reduction in primary AML at
120h (Panel A), drive T cell expansion in primary AML at 120h (Panel B) and
induce T cell activation in AML at 48h and 72 h (Panel C).
Figure 11 (Panels A-H) shows the identification of the CD123+ blast
population in a primary sample of ALL PBMCs. Panels A and E show the forward
and side scatter of the input population of normal PBMC (Panel A) and ALL PBMCs
(Panel E). Panels B and F show the identification of the cyte population as
primarily B cells (Panel B) and leukemic blast cells (Panel F). Panels C and G show
identification of the population of lymphocytes that are CD123+. Panels D and H
show the identification of CD19+ cells and CD123+ cells.
Figure 12 (Panels A-B) shows the identification of the CD4 and CD8
populations of T cells in a primary sample of ALL PBMCs. Panel A shows the
forward and side scatter of the input ALL PBMCs. Panel B shows the CD4 or CD8
tions of T cells present in the samples. The numbers indicate that CD4 T cells
represent approximately 0.5% of the total cells and CD8 T cells ent
approximately 0.4% of the total cells present in the ALL PBMC sample.
Figure 13 (Panels A-H) shows the y of the sequence-optimized CD123
X CD3 bi-specific diabody (DART-A) to mediate ALL blast depletion with
autologous CTL. Panels A and E show the forward and side scatter of the input
population of normal PBMC (Panel A) and ALL PBMCs (Panel E). The PBMCs
were untreated (Panels B and F), treated with a control bi-specific diabody (Control
DART) (Panels C and G) or treated with DART-A (Panels D and H) and ted
for 7 days followed by staining for CD34 and CD19.
Figure 14 (Panels A-L) shows the ability of the ce-optimized CD123
X CD3 bi-specific diabody A) to mediate T cell expansion (Panels A, B, C,
G, H and I) and activation (Panels D, E, F, J, K and L) in normal PBMC (Panels A-
F) and ALL PBMC (Panels G-L). The cells were untreated (Panels A, D, G and J),
or treated with a control cific diabody (Control DART) (Panels B, E, H and K)
or DART-A (Panels C, F, I and L) for 7 days.
Figure 15 (Panels A-C) shows the identification of the AML blast
population and T cells in a y AML sample. Panel A shows the forward and
side r of the input AML PBMCs. Panel B shows the identification of the AML
blast tion in the AML sample. Panel C shows the identification of the T cell
population in the AML sample.
Figure 16 (Panels A-C) shows the ability of the sequence-optimized CD123
X CD3 bi-specific diabody (DART-A) to mediate AML blast depletion with
autologous CTL and T cell expansion. Primary AML PBMCs from patient 2 were
incubated with PBS, a control bi-specific diabody (Control DART) or DART-A for
144h. Blast cells (Panel A), CD4 T cells (Panel B) and CD8 T cells (Panel C) were
counted.
Figure 17 (Panels A-D) shows the ability of the sequence-optimized CD123
X CD3 bi-specific diabody (DART-A) to mediate T cell activation in AML. CD25
(Panel A) and Ki-67 (Panel B) expression was determined for the CD4 and CD8 T
cells from AML patient 2 following incubation with a control bi-specific diabody
ol DART) or DART-A with autologous PBMCs. The level of perforin (Panel
C) and granzyme B (Panel D) was determined for the CD4 and CD8 T cells from
AML t 2 following incubation with Control DART or DART-A with
autologous PBMCs.
Figure 18 (Panels A-D) shows that the sequence-optimized CD123 X CD3
bi-specific diabody (DART-A) is capable of cross-reacting with both human and
primate CD123 and CD3 proteins. The panels show BIACORETM sensogram traces
of the results of analyses conducted to assess the ability of DART-A to bind to human
(Panels A and C) and non-human primate (Panels B and D) CD3 (Panels A and B)
and CD123 (Panels C and D) proteins. The KD values are ed.
Figure 19 (Panels A-B) shows the ability of the sequence-optimized CD123
X CD3 bi-specific diabody (DART-A) to mediate gous monocyte depletion in
vitro with human and cynomolgus monkey PBMCs. The Panels present the s of
dose-response curves of DART-A-mediated cytotoxicity with primary human PBMCs
(Panel A) or cynomolgus monkey PBMCs (Panel B).
Figure 20 (Panels A-N) shows the ability of the sequence-optimized CD123
X CD3 bi-specific y A) to mediate the depletion ofpDC in cynomolgus
monkeys without systemic cytokine induction. Panels A-D show control results
obtained at 4h and 4d with vehicle and carrier. Panels E-H show control results
ed at 4h and 4d with a control bi-specific diabody ol DART). Panels I-N
show results obtained at 4h and 4d at 10 ng/kg/d and at 4d with 30 ng/kg/d of DART-
Figure 21 (Panels A-D) shows the ability of the sequence-optimized CD123
X CD3 cific diabody (DART-A) to mediate dose-dependent depletion ofpDC in
cynomolgus s. Cynomolgus monkeys were dosed with DART-A at 0.1, 1, 10,
100, 300, or 1000 ng/kg. PBMCs were evaluated at the indicated time and total B
cells (Panel A), monocytes (Panel B), NK cells (Panel C) and pDC (Panel D) were
counted.
Figure 22 (Panels A-D) shows the ability of the sequence-optimized CD123
X CD3 bi-specific diabody (DART-A) to intermittently modulate T cells in
cynomolgus monkeys. Cynomolgus s were dosed with DART-A at at 0.1, 1,
, 30 100, 300, or 1000 ng/kg. PBMCs were evaluated at the indicated time and
total T cells (Panel A), CD4 T cells (Panel B), CD69 cells (Panel C) and CD8 T cells
(Panel D) were counted.
Figure 23 shows the SDS-PAGE analysis of purified DART-A protein under
reducing (left) and non-reducing (right) conditions.
Figures 24A-24B show the physicochemical characterization of purified
DART-A. Figure 24A: SEC profile of DART-A protein on a calibrated TSK
G3000SWXL column. Figure 24B: Mass um of DART-A n.
Figures 25A-25D show SPR is of DART-A binding to immobilized
human or cynomolgus monkey CD123 and CD3. Dashed lines represent the global fit
to a 1:1 Langmuir model of the experimental binding curves obtained at DART-A
concentrations of 0, 6.25, 12.5, 25, 50 or 100nM (continuous lines). The data are
representative of three independent experiments.
Figures 26A-26E show that DART-A was capable of simultaneously
binding both CD3 and CD123. Figure 26A-26B provides the results of a tional
ELISA and demonstrates simultaneous engagement of both target antigens of DART-
A. ELISA plates were coated with human CD123 (Figure 26A) or cynomolgus
monkey CD123 (Figure 26B). Titrating DART-A and Control DART concentrations
were followed by ion with human CD3-biotin. Figures 26C-26E demonstrate
cell-surface binding of DART-A on CD123+ Molm—13 target cell (Figure 26C),
human T cells (Figure 26D) and cynomolgus T cells e 26E). Binding was
detected by FACS analysis using a monoclonal antibody specific to E-coil and K-coil
region of the DART-A or Control DART molecule.
Figures H show the ability of DART-A to mediate redirected target
cell killing by human or monkey effector cells against CD123+ Kasumi-3 leukemic
cell lines, trate the ability of the les to bind to subsets of normal
circulating leukocytes, including pDCs and monocytes and demonstrate the y of
the molecules to deplete CD14'CD123high cells (pDC and ils) without affecting
tes (CD14+ cells). Figure 27A shows the relative anti-CD123-PE binding
sites on U937 and Kasumi-3 leukemic cell lines as determined by QFACS analysis.
Figure 27B shows the relatively low percent cytotoxicity mediated by DART-A or
Control DART on an AML cell line (U937 cells) which, as shown in Figure 27A
have relatively few CD123 binding sites). Figure 27C shows the percent cytotoxicity
ed by DART-A or Control DART in the presence of purified human T cells (as
effector cells) on an AML cell line (Kasumi-3 cells) which, as shown in Figure 27A
have a substantial number of CD123 binding sites. In Figures 27B-27C, the ET ratio
is 10: 1. Figure 27D shows the percent cytotoxicity mediated by DART-A or Control
DART in the presence of purified cynomolgus monkey PBMCs (as effector cells) on
Kasumi-3 cells (the ET ratio is 15:1), and demonstrates that DART-A can bind
cynomolgus monkey T cells. Figure 27E shows the relative anti-CD123-PE binding
sites on Kasumi-3 cells, human tes, human plasmacytoid dendritic cells
(“pDC”), cynomolgus monkey monocytes and cynomolgus monkey plasmacytoid
dendritic cells as determined by QFACS analysis. Figure 27F shows the y of
DART-A to deplete CD14’ CD12310 cells. Figure 27G shows the ability of DART-A
to deplete human CD14’ CD123Hi cells. Figure 27H shows the ability of DART-A
to deplete lgus monkey CD14’ CD123Hi cells. xicity was determined
by LDH release, with ECSO values ined using GraphPad PRISM® software.
Figure 28 shows the use of a two-compartment model to estimate
pharmacokinetic parameters of . The data show the end of infilsion (EOI)
serum concentrations of DART-A in cynomolgus monkeys after receiving a 96-hour
infiJsion at 100 ng/kg/day 300 ng/kg/day, 600 ng/kg/day, and 1000 ng/kg/day Dose.
Each point represents an individual animal; horizontal lines represent the mean value
for the dose group.
Figures 29A-29C show the effect of DART-A ons on the production
of the cytokine, IL-6. Serum IL-6 levels (mean :: SEM) in monkeys infilsed with
DART-A are shown by treatment group. Cynomolgus monkeys were treated with
vehicle control on Day 1, followed by 4 weekly infusions of either vehicle (Group 1)
(Figure 29A) or DART-A stered as 4-day weekly infilsions ng on Days 8,
, 22, and 29 s 2-5) (Figure 29B) or as a 7-day/week infusion for 4 weeks
starting on Days 8 (Group 6) (Figure 29C). Treatment intervals are indicated by the
filled gray bars.
Figures 30A-30F show the effect of DART-A infilsions on the depletion of
CD14-/CD123+ cells (Figures 30A-30C) and CD303+ cells (Figures 30D-30F). The
mean :: SEM of the circulating levels of CDl4-/CD123+ (Figures 30A-30C) or
CD303+ (Figures 30D-30F) by Study Day and by group is shown. Cynomolgus
monkeys were treated with vehicle control on Day 1, ed by 4 weekly infiJsions
of either vehicle (Group 1) (Figures 30A and 30D) or DART-A administered as 4-
day weekly infilsions starting on Days 8, 15, 22, and 29 (Groups 2-5) (Figures 30A
and 30E) or as a 7-day/week infiJsion for 4 weeks starting on Days 8 (Group 6)
(Figures 30C and 30F). Treatment intervals are indicated by the filled gray bars.
Figures 31A-311 show the observed changes in T cell populations es
31A-31C), CD4+ cell tions (Figures 31D-31F) and CD8+ cell populations
(Figures 31G-311) ing DART-A administered as 4-day infusions starting on
Days 8, 15, 22, and 29. Legend: CD25+ (gray squares); CD69+ (gray triangles), PD-
1+ (white triangles); Tim-3+ (white squares). T cells were enumerated via the CD4
and CD8 markers, rather than the canonical CD3, to eliminate possible interference
the DART-A. lgus s were treated with vehicle control on Day 1,
followed by 4 weekly infiJsions of either vehicle (Group 1) or DART-A administered
as 4-day weekly infilsions ng on Days 8, 15, 22, and 29 (Group 5) or as a 7-
day/week infilsion for 4 weeks starting on Days 8 (Group 6). Treatment intervals are
indicated by the filled gray bars. The mean :: SEM of the absolute number of total
circulating T cells by Study Day and group is shown (Figures 31A-31C). Relative
values (mean percent :: SEM) of CD25+, CD69+, PD-1+ and Tim-3+ of CD4
(Figures 31D-31E) or CD8 T cells (Figures 31F-31H) by Study Day and by group is
shown.
Figures 32A-32F show the observed changes in T CD4+ cell populations
(Figures 32A-32C) and CD8+ cell populations (Figures 32D-32F) during and after a
uous 7-day infiasion of DART-A. The mean :: SEM percent of CD25+, CD69+,
PD-1+ and Tim-3+ on CD4 (Figures C) or CD8 (Figures 32D-32F) T cells
by Study Day for Groups 2, 3 and 4 are shown. Treatment intervals are indicated by
the filled gray bars. Legend: CD25+ (gray squares); CD69+ (gray triangles), PD-1+
(white triangles); Tim-3+ (white squares).
Figures 33A-33F show the observed changes in T CD4+ cell populations
(Figures C) and CD8+ cell tions (Figures 33D-33F) during and after a
continuous 7-day infilsion of DART-A. The mean :: SEM percent of CD4+ Naive
(CD95-/CD28+), CMT (CD95+/CD28+), and EMT /CD28-) T cells in CD4+
population (Figures 33A-33C) or CD8 population (Figures 33D-33F) by Study Day
for Groups 2, 3 and 4 are shown. Cynomolgus monkeys were treated with vehicle
control on Day 1, ed by 4 weekly infilsions of or DART-A administered as 4-
day weekly infusions starting on Days 8, 15, 22, and 29 (Groups 2-4). Treatment
als are indicated by the filled gray bars. Legend: Naive (white triangles); CMT
(black triangles), EMT (gray squares).
Figure 34 shows DART-A-mediated cytotoxicity against -3 cells with
PBMCs from either naive monkeys or monkeys treated with multiple infilsions of
DART-A.
Figures F show that DART-A exposure increased the relative
frequency of central memory CD4 cells and or memory CD8+ cells at the
expense of the corresponding naive T cell population. The mean :: SEM percent of
CD4+ Naive (CD95-/CD28+), CMT (CD95+/CD28+), and EMT (CD95+/CD28-) T
cells in CD4+ population (Figures 35A-35C) or in CD8+ population (Figures 35D-
35F) by Study Day and by Group is shown. Cynomolgus monkeys were treated with
vehicle control on Day 1, followed by 4 weekly infusions of either e (Group 1)
or DART-A administered as 4-day weekly infilsions ng on Days 8, 15, 22, and
29 (Group 5) or as a 7-day/week lI‘lfiISlOIl for 4 weeks starting on Days 8 (Group 6).
Treatment intervals are indicated by the filled gray bars. Legend: Naive (white
triangles); CMT (black triangles), EMT (gray squares).
Figures 36A-36F show the effect of DART-A on red cell parameters in
monkeys that had received infusions of the molecules. Circulating RBCs (Figures
36A-36C) or reticulocytes (Figures 36D-36F) levels (mean :: SEM) in samples
ted at the indicated time points from monkeys treated with DART-A are shown.
Figures 37A-37B show that the frequency (mean percent :: SEM) of
CDl23+ cells (Figure 37A) or HSC (CD34+/CD38-/CD45-/CD90+ cells) (Figure
373) within the Lin- cell population in bone marrow samples collected at the
indicated time points from monkeys treated with DART-A. Cynomolgus monkeys
were treated with vehicle control on Day 1, followed by 4 weekly infusions of either
vehicle (Group 1) or DART-A administered as 4-day weekly infusions starting on
Days 8, 15, 22, and 29 (Groups 2-5) or as a 7-day/week infusion for 4 weeks starting
on Days 8 (Group 6).
Detailed Description of the Invention:
The t invention is directed to sequence-optimized CD123 X CD3 bi-
specific lent diabodies that are capable of simultaneous binding to CD123 and
CD3, and to the uses of such molecules in the treatment of hematologic malignancies.
Although non-optimized CD123 X CD3 bi-specific diabodies are fully functional,
analogous to the improvements obtained in gene sion through codon
optimization (see, e.g., Grosjean, H. et al. (1982) rential C0d0n Usage In
Prokaryotic Genes: The Optimal C0d0n-Anticod0n Interaction Energy And The
Selective C0d0n Usage In Efiiciently Expressed Genes” Gene 18(3):l99-209), it is
possible to further enhance the stability and/or on of CD123 X CD3 bi-specif1c
diabodies by modifying or refining their sequences.
The preferred CD123 X CD3 cif1c ies of the present invention
are composed of at least two polypeptide chains that associate with one another to
form one binding site specific for an epitope of CD123 and one binding site specific
for an epitope of CD3 (Figure 2). The individual ptide chains of the diabody
are covalently bonded to one another, for example by disulf1de g of cysteine
residues located within each polypeptide chain. Each polypeptide chain contains an
Antigen Binding Domain of a Light Chain le Domain, an Antigen Binding
Domain of a Heavy Chain Variable Domain and a heterodimerization domain. An
intervening linker peptide (Linker 1) separates the n Binding Domain of the
Light Chain Variable Domain from the Antigen Binding Domain of the Heavy Chain
Variable Domain. The Antigen Binding Domain of the Light Chain Variable Domain
of the first polypeptide chain interacts with the Antigen Binding Domain of the Heavy
Chain Variable Domain of the second polypeptide chain in order to form a first
functional antigen binding site that is specific for the first antigen (i. e., either CD123
or CD3). Likewise, the n Binding Domain of the Light Chain Variable
Domain of the second polypeptide chain cts with the Antigen Binding Domain
of the Heavy Chain Variable Domain of the first ptide chain in order to form a
second filnctional antigen binding site that is specific for the second antigen (i.e.,
either CD123 or CD3, depending upon the identity of the first n). Thus, the
selection of the Antigen Binding Domain of the Light Chain Variable Domain and the
Antigen Binding Domain of the Heavy Chain Variable Domain of the first and second
polypeptide chains are coordinated, such that the two polypeptide chains collectively
comprise Antigen g Domains of light and Heavy Chain Variable Domains
capable of g to CD123 and CD3.
The formation of heterodimers of the first and second polypeptide chains can
be driven by the heterodimerization domains. Such domains include GVEPKSC (SEQ
ID NO:50) (or VEPKSC; SEQ ID NO:51) on one polypeptide chain and GFNRGEC
(SEQ ID NO:52) (or FNRGEC; SEQ ID NO:53) on the other polypeptide chain
(US2007/0004909). atively, such domains can be engineered to contain coils
of opposing charges. The heterodimerization domain of one of the polypeptide chains
comprises a sequence of at least six, at least seven or at least eight positively charged
amino acids, and the heterodimerization domain of the other of the polypeptide chains
comprises a sequence of at least six, at least seven or at least eight negatively charged
amino acids. For example, the first or the second heterodimerization domain will
preferably comprise a sequence of eight positively charged amino acids and the other
of the heterodimerization domains will preferably comprise a sequence of eight
negatively charged amino acids. The positively charged amino acid may be lysine,
arginine, histidine, etc. and/or the negatively charged amino acid may be glutamic
acid, aspartic acid, etc. The positively charged amino acid is ably lysine and/or
the negatively charged amino acid is ably glutamic acid.
The CD123 X CD3 bi-specific diabodies of the present invention are
engineered so that such first and second polypeptide chains covalently bond to one
r via cysteine residues along their length. Such cysteine residues may be
introduced into the intervening linker that separates the VL and VH domains of the
polypeptides. Alternatively, and more preferably, a second peptide (Linker 2) is
introduced into each polypeptide chain, for example, at the amino-terminus of the
polypeptide chains or a position that places Linker 2 between the heterodimerization
domain and the Antigen Binding Domain of the Light Chain Variable Domain or
Heavy Chain Variable Domain.
In ular embodiments, the sequence-optimized CD123 X CD3 bi-specific
monovalent diabodies of the present invention filrther have an immunoglobulin Fc
Domain or an Albumin-Binding Domain to extend half-life in viva.
The CD123 X CD3 bi-specific monovalent diabodies of the present ion
that comprise an immunoglobulin Fc Domain (2'.e., CD123 X CD3 bi-specific
monovalent Fc ies) are composed of a first ptide chain, a second
polypeptide chain and a third polypeptide chain. The first and second polypeptide
chains associate with one another to form one g site specific for an epitope of
CD123 and one binding site specific for an epitope of CD3. The first polypeptide
chain and the third polypeptide chain associate with one another to form an
immunoglobulin Fc Domain (Figure 3A and Figure 3B). The first and second
polypeptide chains of the bi-specific monovalent Fc diabody are covalently bonded to
one another, for example by disulfide bonding of cysteine residues located within
each polypeptide chain.
The first and third polypeptide chains are covalently bonded to one another,
for example by disulfide g of cysteine residues located within each polypeptide
chain. The first and second polypeptide chains each contain an Antigen Binding
Domain of a Light Chain Variable Domain, an Antigen Binding Domain of a Heavy
Chain Variable Domain and a heterodimerization domain. An intervening linker
peptide r 1) separates the Antigen Binding Domain of the Light Chain le
Domain from the Antigen g Domain of the Heavy Chain Variable Domain.
The Antigen Binding Domain of the Light Chain Variable Domain of the first
polypeptide chain interacts with the Antigen Binding Domain of the Heavy Chain
Variable Domain of the second polypeptide chain in order to form a first functional
n binding site that is specific for the first n (2'.e., either CD123 or CD3).
Likewise, the Antigen Binding Domain of the Light Chain Variable Domain of the
second polypeptide chain interacts with the Antigen Binding Domain of the Heavy
Chain Variable Domain of the first polypeptide chain in order to form a second
functional antigen binding site that is c for the second antigen (i.e., either CD3
or CD123, ing upon the identity of the first antigen). Thus, the selection of the
n Binding Domain of the Light Chain Variable Domain and the Antigen
Binding Domain of the Heavy Chain Variable Domain of the first and second
polypeptide chains are coordinated, such that the two polypeptide chains collectively
comprise Antigen Binding Domains of light and Heavy Chain le Domains
capable of binding to CD123 and CD3. The first and third polypeptide chains each
contain some or all of the CH2 Domain and/or some or all of the CH3 Domain of a
te immunoglobulin Fc Domain and a cysteine-containing peptide. The some
or all of the CH2 Domain and/or the some or all of the CH3 Domain associate to form
the immunoglobulin Fc Domain of the bi-specific monovalent Fc diabodies of the
present invention. The first and third polypeptide chains of the cific
monovalent Fc diabodies of the present invention are ntly bonded to one
another, for example by disulfide g of cysteine residues located within the
cysteine-containing peptide of the polypeptide chains.
1. The Sequence-Optimized CD123 x CD3 Bi-Specific Diabody, “DART-A”
The invention provides a sequence-optimized bi-specific diabody e of
simultaneously and specifically binding to an epitope of CD123 and to an epitope of
CD3 (a “CD123 x CD3” bi-specific diabody or DART-A). As discussed below,
DART-A was found to exhibit enhanced filnctional activity relative to other non-
sequence-optimized CD123 X CD3 bi-specific diabodies of similar composition, and
is thus termed a “sequence-optimized” CD123 X CD3 bi-specific diabody.
The sequence-optimized CD123 X CD3 bi-specific diabody (DART-A)
comprises a first polypeptide chain and a second polypeptide chain. The first
polypeptide chain of the bi-specific diabody will comprise, in the N-terminal to C-
terminal direction, an N—terminus, a Light Chain le Domain (VL Domain) of a
monoclonal antibody capable of g to CD3 (VLCDg), an intervening linker
peptide (Linker l), a Heavy Chain Variable Domain (VH Domain) of a monoclonal
antibody capable of binding to CD123 (VHCDm), and a C-terminus. A red
sequence for such a VLCD3 Domain is SEQ ID NO:21:
QAVVTQ?A PSLTVS LTCRS S TGAVTT SWYANWVQQKPGQAPRGL 22GG
TNKRAPWT PARFSGSLLGGKAALT: TGAQA*12D *iADYYCALWYSNLWVFGGGT
KLTVLG
The Antigen g Domain of VLCD3 comprises CDRl SEQ ID NO:38:
RSSTGAVTTSNYAN, CDRZ SEQ ID NO:39: P, and CDR3 SEQ ID
NO:40: ALWYSNLWV.
A preferred sequence for such Linker l is SEQ ID NO:29: GGGSGGGG. A
red ce for such a VHCDm Domain is SEQ ID NO:26:
EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGT.*1W GD
9SNGATFYNQKFKGRVT 22TV2DKSTSTAYM'.T. SST.RS *iDTAVYYCA'RSl-ILLRA
SWFAYWGQGTLVTVSS
The Antigen Binding Domain ofVHCDm comprises CDRl SEQ ID NO:47:
DYYMK, CDR2 SEQ ID NO:48: 2D PSNGATFYNQKFKG, and CDR3 SEQ ID
NO:49: SHLLRAS.
The second polypeptide chain will comprise, in the N—terminal to C-terminal
direction, an N—terminus, a VL domain of a monoclonal antibody capable of binding
to CD123 (VLCDm), an intervening linker peptide (e.g., Linker l), a VH domain of a
monoclonal antibody capable of binding to CD3 (VHCDg), and a C-terminus. A
preferred sequence for such a VLCDm Domain is SEQ ID NO:25:
2DFVMTQS 92DSLAVSLGERVTMSC{SSQSLLNSGNQ <NYLTWYQQ<PGQ29PKL
L2. YWAST {.L'SGVPDRFSGSGSGT 2DFTT.T SSTQA*.2DVAVYYCQNDYSY?YTF
GQGTKT *1 <
The Antigen Binding Domain ofVLCDm comprises CDRl SEQ ID NO:44:
KSSQSLLNSGNQKNYLT, CDR2 SEQ ID NO:45: WASTRES, and CDR3 SEQ ID
NO:46: QNDYSYPYT.
A preferred sequence for such a VHCD3 Domain is SEQ ID NO:22:
'.VQT.V'...SGGGTVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGTWIVGR R
ATYYADSVKDRFT SRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNF
GNSYVSWFAYWGQGTLVTVS S
The Antigen Binding Domain of VHCD3 comprises CDRl SEQ ID NO:41:
TYAMN, CDR2 SEQ ID NO:42: RIIRSKYNNYATYYADSVKD, and CDR3 SEQ ID
N(h43:HGNFGNSYVSWFAY.
The ce-optimized CD123 X CD3 bi-specif1c diabodies of the present
invention are engineered so that such first and second polypeptides covalently bond to
one another via cysteine residues along their length. Such cysteine residues may be
introduced into the intervening linker (e.g., Linker 1) that separates the VL and VH
domains of the polypeptides. Alternatively, and more preferably, a second peptide
(Linker 2) is introduced into each polypeptide chain, for example, at a position N-
terminal to the VL domain or C-terminal to the VH domain of such polypeptide chain.
A red sequence for such Linker 2 is SEQ ID NO:30: GGCGGG.
The formation of heterodimers can be driven by further ering such
polypeptide chains to contain polypeptide coils of opposing charge. Thus, in a
preferred embodiment, one of the polypeptide chains will be engineered to contain an
“E-coil” domain (SEQ ID NO:34: EVAALEKEVAALEKEVAALEKEVAALEK) whose
residues will form a negative charge at pH 7, while the other of the two polypeptide
chains will be engineered to contain an “K-coil” domain (SEQ ID NO:35:
EVAN.E'JEVAAT.E'JEVAATETEVAATE?) whose residues will form a positive charge
at pH 7. The presence of such d domains promotes association n the
first and second polypeptides, and thus fosters heterodimerization.
It is immaterial which coil is provided to the first or second polypeptide
chains. However, a preferred sequence-optimized CD123 X CD3 bi-specif1c diabody
of the present invention -A”) has a first ptide chain having the
sequence (SEQ ID NO:1):
QAVVTQIEPSLTVSPGGTVTLTCRSSTGAVTTSWYANWVQQKPGQAPRGLIIGG
TNKRAPWTPARFSGSLLGGKAALTI TGAQA*DfiADYYCALWYSWLWVFGGGT
KLTVLGGGGSGGGGIEVQLVQSGAIELKKPGASV{VSC{ASGYTFTDYYM<WVR
Tfi'W GD ?SNGATFYNQKFKGRVTIITVDKSTSTAYM*TSST{8&3
TAVYYCAIRSHLLRASWFAYWGQGTLVTVSSGGCGGGfi'VAALfiKmVAALfiKfiV
AALfiKfi'VAAT.m<
DART-A Chain 1 is composed of: SEQ ID NO:21 — SEQ ID NO:29 —
SEQ ID NO:26 — SEQ ID NO:30 — SEQ ID NO:34. A DART-A Chain 1 encoding
polynucleotide is SEQ ID NO:2:
caggctgtggtgac:caggagccttcactgaccg,g,ccccaggcggaactg
tgaccctgacatgcagatccagcacaggcgcagtgaccaca:ctaactacgc
caattgggtgcagcagaagccaggacaggcaccaaggggcc,gaccgggggt
acaaacaaaagggc:ccctggacccctgcacgg,,,,c,ggaag:ctgctgg
gcggaaaggccgcchgaccacLaccggggcacaggccgaggacgaagccga
,Lac,aLLngchcgcgg,a,agcaa,chngg,gc“cgggggtggcaca
aaaccgacchgccgggagggggcggacccggcggcggaggcgaggtgcagc
cgngcagcccggggccgagccgaagaaacccggagcccccgcgaaggtgtc
ttgcaaagccagtggc:acacct:cacagacLacLa,a,gaag,ggchagg
caggctccaggacagggac,ggaa,ggachgcgaLa,ca,Lch,ccaacg
gggccacccchacaaccagaagccLaaaggcagggcgaccaccaccgcgga
caaatcaacaagcac,ch,aca,ggachgagc,cchgcgccccgaagat
acagccgcgcacLaL,g,chcgg,cacacctgc:gagagccagc,gg,L,g
CL,a,ngggacagggcaccc,gg,gacagchc,Lccggaggatgtggcgg
tggagaag:ggccgcac:ggagaaagaggt:gctgctttggagaaggagg:c
cL,gaaaaggaggtcgcagccctggagaaa
The second polypeptide chain of DART-A has the sequence (SEQ ID
th3)
DFVMTQS?DSLAVSLG.§{VTMSCKSSQSLLNSGNQ<NYLTWYQQKPGQ?P{L
L: YWAST{LSGVRDRFSGSGSGTDFTTT SSTQA*.DVAVYYCQNDYSY?YTF
GQGT<Pm <GGGSGGGGfiVQPVfiSGGGTVQPGGSLRLSCAASGFTFSTYA N
WVRQA?G<GP*'WVG{ YATYYADSVKDRFT SRDDSKNSLYLQMWS
LKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSSGGCGGGKVAALK.EK
VAAT.<7KVAAT.K7KVAAT.Km
DART-A Chain 2 is composed of: SEQ ID NO:25 — SEQ ID NO:29 —
SEQ ID NO:22 — SEQ ID NO:30 — SEQ ID NO:35. A DART-A Chain 2 ng
polynucleotide is SEQ ID NO:4:
gac,ch,gaLgacacachLcc,gaLag,chgccgtgagtctgggggagc
ggg,gac,a,g,cL,gcaagagc:cccag:cactgctgaacagcggaaatca
gaaaaaccacccgaccEggcaccagcagaagccaggccagccccccaaaccg
aLcgggc,Lccaccagggaa,c,ggcg,gcccgacaga:tcagcg
gcagcggcagcggcacaga,LSnaccc,gacaaL,Lc,achLgcaggccga
ggachggc,g,gLac,aL,gccagaa,ga,Lacagc,aLcchacacLL,c
ggccaggggaccaagc:ggaaa:taaaggaggcggatccggcggcggaggcg
aggtgcagccggcggachcgggggagchcggcccagcc:ggagggccccc
gagac,chch,gcagcc,chgaL,cachLcagcaca,accha,gaa,
tgggtccgccaggc2ccagggaaggggccggagcgggccggaaggaccaggc
ccaagtacaacaattatgcaaccLac,a,gccgactc:gtgaagga,agaL,
cacca:ctcaagagatgattcaaagaac,caccg,aLc,gcaaa:gaacagc
ctgaaaaccgaggacacggccgLgLa,Lachcg,gagacacgg:aacttcg
gcaa,,c,,achch,ngLLuchLaLngggacaggggacactggtgac
,g,g,cL,ccggagga:gtggcggtggaaaagtggccgcactgaaggagaaa
gL,gc,gc,LLgaaagagaaggtcgccgcact:aaggaaaaggtcgcagccc
:gaaagag
As discussed below, the sequence-optimized CD123 X CD3 bi-specific
diabody (DART-A) was found to have the ability to simultaneously bind CD123 and
CD3 as arrayed by human and monkey cells. Provision of DART-A was found to
cause T cell activation, to mediate blast reduction, to drive T cell expansion, to induce
T cell activation and to cause the redirected killing of target cancer cells.
11. Comparative Non-Sequence-Optimized CD123 x CD3 Bi-Specific
y, “DART-B”
DART-B is a non-sequence-optimized CD123 X CD3 bi-specific diabody
having a gross structure that is similar to that of . The first polypeptide
chain of DART-B will comprise, in the N—terminal to C-terminal direction, an N-
terminus, a VL domain of a monoclonal antibody capable of binding to CD3 (VLCDg),
an intervening linker peptide (Linker l), a VH domain of a monoclonal antibody
capable of g to CD123 (VHCDm), an intervening Linker 2, an E-coil Domain,
and a C-terminus. The VLCD3 Domain of the first polypeptide chain of DART-B has
the sequence (SEQ ID NO:23):
DIQLTQS?AIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIIYDTS<
VASGVPYQFSGSGSGTSYSTT SSMmAfiDAATYYCQQWSSNPLTFGAGTKLE
The VHCDm Domain of the first polypeptide chain of DART-B has the ce
(SEQ ID NO:28):
SGAIELKKPGASVKVSCKASGYTFTDYYMKWVQQAPGQGT*W GD
PSNGATFYNQKFKGRVTIITVDKSTSTAYM*TSSTRSmDTAVYYCAQSHLLRA
SWFAYWGQGTLVTVSS
] Thus, DART-B Chain 1 is composed of: SEQ ID NO:23 — SEQ ID NO:29
— SEQ ID NO:28 — SEQ ID NO:30 — SEQ ID NO:34. The sequence of the first
polypeptide chain of DART-B is (SEQ ID NO:5):
QS?AIMSASPGEKVTMTCQASSSVSYMNWYQQKSGTSPKQW_ YDTS A
VASGVPYQFSGSGSGTSYSTT SSM*A*DAATYYCQQWSSWPLTFGAGTKLLL-El
LKGGGSGGGGQVQLVQSGAIELKK ?GASV{VSCKASGYTFTDYYM<WVQQAPG
QGLfi'W GD PSNGATFYNQKFKGRVTITVDKSTSTAYM*TSST{SfiDTAVY
YCARSHLLRASWFAYWGQGTLVTVSSGGCGGGfiVAALfiKfiVAALfiKfiVAAPfl
KfiVAALfiK
A DART-B Chain 1 encoding polynucleotide is SEQ ID NO:6:
gacattcagc:gacccachLccagcaaLcaLchLgcaLchcaggggaga
aggtcaccatgacctgcagagccagLLcaagLgLaagLLacaLgaachgLa
ccagcagaagtcaggcacctcccccaaaagangaLLLaLgacacatccaaa
ngchLCngachch,achcL,canggcangggLC,gggacctcat
actctc:cacaa:cagcagcatggaggCCgaagaLgCLgccaCLLa,Lach
ccaacanggagLagLaacccchcacg chngchggaccaagc2ggag
ctgaaaggaggcgga:ccggcggcggaggccagg:gcagcngLgcachcg
gggc:gagctgaagaaacccggagcLLcchgaagngLcLLgcaaagccag
tggCCacaccttcacagacLacLaLa,gaagngchaggcaggctccagga
cagggac,ggaa,ggachgcgaLa,caLLch,ccaacggggccaCLLLCL
acaatcagaagLLLaaaggcaggngacLaLLacchggacaaatcaacaag
caCLchLaLa,ggachgagc,cchgcchc,gaagatacagcchgLac
chcgg,cacacctgc:gagagccagc,ggLL,chLaLngggac
agggcacccngLgacangLcLLccggaggatgtggcggtggagaagtggc
cgcaCngagaaagaggt:gctgctttggagaaggagg,cgc,gcacL,gaa
aaggaggtcgcagccctggagaaa
The second polypeptide chain of DART-B will comprise, in the N—terminal
to C-terminal direction, an N—terminus, a VL domain of a monoclonal dy
capable of binding to CD123 ), an intervening linker peptide (Linker l) and a
VH domain of a monoclonal antibody capable of g to CD3 (VHCDg), an
intervening Linker 2, a K-coil Domain, and a C-terminus.
The VLCDm Domain of the second ptide chain of DART-B has the
sequence (SEQ ID NO:27):
DFVMTQS9DSLAVSLGERVTMSC{SSQSLLNSGNQ<NYLTWYQQ<PGQ?PKL
L: YWAST<£SGVPDRFSGSGSGTDFTTT SSTQAmDVAVYYCQNDYSY?YTF
GQGTKT.m <
The VHCD3 Domain of the second polypeptide chain of DART-B has the ce
(SEQ ID NO:24):
D: {LQQSGAELARLDGASVKMSCKT SGYTFTRYTMHWV <QRPGQGT. *1W GY N
?S?GYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCAQYYDDHY
CLDYWGQGTTLTVSS
Thus, DART-B Chain 2 is composed of: SEQ ID NO:27 — SEQ ID NO:29
— SEQ ID NO:24 — SEQ ID NO:30 — SEQ ID NO:35. The sequence of the second
polypeptide chain of DART-B is (SEQ ID NO:7):
DFVMTQS9DSLAVSLG.§{VTMSC{SSQSLLNSGNQ<NYLTWYQQ<PGQ9PKL
L: YWAST{LSGVPDRFSGSGSGTDFTTT .DVAVYYCQNDYSY9YTF
GQGTKTfi' {GGGSGGGGI <LQQSGA.ELAR9GASV{MSCKTSGYTFTRYTMI
WV<QRPGQGT*'W GY N9S{GYTWYNQKFKDKATLTTDKSSSTAYMQLSSLT
SEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSGGCGGGKVAAPKEKVAAPK?
KVAAT.K9KVAAPK?
A DART-B Chain 2 encoding polynucleotide is SEQ ID NO:8:
,gaLgacacachLcc,gaLag,chgccgtgagtctgggggagc
ggg,gac,a,g,cL,gcaagagc:cccag:cactgctgaacagcggaaatca
gaaaaaccacccgacccggcaccagcagaagccaggccagccccccaaaccg
chaLcLaLcgggc,Lccaccagggaa,c,ggcg,gcccgacaga:tcagcg
gcagcggcagcggcacaga,Lguaccc,gacaaL,Lc,achLgcaggccga
ggachggc,g,gLac,aL,gccagaa,ga,Lacagc,aLcchacacLL,c
gggaccaagc:ggaaa:taaaggaggcgga:ccggcggcggaggcg
atatcaaaCCgcagcagtcaggggccgaaccggcaagacc:ggggcc:cagt
gaagaLg,cc,gcaagacL,chgc,acach,,ac,agg,acacga:gcac
tgggtaaaacagaggcc:ggacagggLC,ggaa,ggaL,ggaLacaL,aa,c
ctagccgcggccacaccaaccacaaccagaagc“caaggacaaggccacacc
gac:acagacaaaccccccagcacagcccacacgcaac:gagcagcc:gaca
:ctgaggach,gcag,cLacLachLgcaaga,a,,a,ga,gacca,Lac,
gccccgacLaccggggccaaggcaccac:ctcacagccccccccggaggatg
tggcggtggaaaagtggccgcactgaaggagaaag,,chchL,gaaagag
aaggtcgccgcacttaaggaaaaggtcgcagccctgaaagag
111. Modified Variants of Sequence-Optimized CD123 x CD3 Bi-Specific
Diabody (DART-A)
A. ce-Optimized CD123 x CD3 Bi-Specific Diabody Having
An Albumin-Binding Domain A with ABD “w/ABD”)
In a second embodiment of the invention, the sequence-optimized CD123 X
CD3 bi-specific diabody (DART-A) will comprise one or more Albumin-Binding
Domain (“ABD”) (DART-A with ABD ”) on one or both of the polypeptide
chains of the diabody.
] As disclosed in WO 2012/018687, in order to improve the in viva
pharmacokinetic properties of ies, the diabodies may be modified to contain a
polypeptide portion of a serum-binding protein at one or more of the termini of the
diabody. Most preferably, such polypeptide portion of a serum-binding protein will
be installed at the C-terminus of the y. A particularly preferred polypeptide
portion of a binding protein for this purpose is the Albumin-Binding Domain
(ABD) from streptococcal protein G. The Albumin-Binding Domain 3 (ABD3) of
protein G of Streptococcus strain G148 is particularly preferred.
The Albumin-Binding Domain 3 (ABD3) of protein G of Streptococcus
strain G148 consists of 46 amino acid residues forming a stable three-helix bundle
and has broad albumin-binding specificity (Johansson, M.U. et al. (2002) “Structure,
Specificity, And Mode 0f Interaction For Bacterial Albumin-Binding Modules,” J.
Biol. Chem. 277(10):8114-8120). Albumin is the most nt protein in plasma
and has a half-life of 19 days in humans. Albumin possesses several small molecule
binding sites that permit it to non-covalently bind to other ns and thereby extend
their serum half-lives.
Thus, the first polypeptide chain of such a ce-optimized CD123 X
CD3 bi-specific diabody having an Albumin-Binding Domain contains a third linker
r 3), which separates the E-coil (or K-coil) of such polypeptide chain from the
Albumin-Binding Domain. A preferred sequence for such Linker 3 is SEQ ID
NO:31: GGGS. A preferred Albumin-Binding Domain (ABD) has the sequence (SEQ
H)N(h36kPAEAKVPANREPDKYGVSDYYKNL:DNAKSAEGVKAP Dd PAAPR
Thus, a preferred first chain of a sequence-optimized CD123 X CD3 bi-
specif1c diabody having an Albumin-Binding Domain has the sequence (SEQ ID
NO:9):
QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSWYANWVQQKPGQAPRGL: GG
TNKRAPWTPARFSGSLLGGKAALTI TGAQAfi'DmADYYCALWYSWLWVFGGGT
KLTVLGGGGSGGGG_EVQLVQSGA_ELK<PGASV<VSC{ASGYTFTDYYM<WVR
QAPGQGTfi'W GD 9SNGATbYNQKb<G<VT TVDKSTSTAYMTSST<SfiD
TAVYYCARS{LLRASWFAYWGQGTLVTVSSGGCGGGWVAATfiKVAATfiKfiV
VAAPm<GGGSTAGAKVTANRGTDKYGVSDYYKNLIDNAKSAAGV<A
T. )0 PAAP?
A sequence-optimized CD123 X CD3 diabody having an Albumin-Binding
Domain is composed of: SEQ ID NO:21 — SEQ ID NO:29 — SEQ ID NO:26 —
SEQ ID NO:30 — SEQ ID NO:34 — SEQ ID NO:31 — SEQ ID NO:36. A
mflmemmmngmmhasammweommnmflCIH23XCD3dfihflyhmflgan
Albumin-Binding Domain derivative is SEQ ID NO:10:
caggctgtggtgactcaggagccttcactgaccgtgtccccaggcggaactg
tgaccctgacatgcagatccagcacaggcgcagtgaccaca:ctaactacgc
caattgggtgcagcagaagccaggacaggcaccaaggggcc,gaecgggggt
aaaagggc:ccctggacccctgcacgg,L,Lceggaagtctgctgg
gcggaaaggccgcechaceaeLaccggggcacaggccgaggacgaagccga
e,ac,aLLngc,cegeggea,agcaaech,ggg,geecgggggtggcaca
acengcegggagggggeggaeccggcggcggaggcgaggtgcagc
egngcag,ccggggcegagcegaagaaacccggagceecchgaaggtgtc
eegcaaagccageggceacaccttcacagaceacLaeaegaageggchagg
caggctccaggacagggaceggaa,ggachgcgaLaecaeLch,ccaacg
c,L,cLacaa,cagaag,,Laaaggcaggg,gac,aLeaccgegga
caaatcaacaagcac,ch,aea,ggachgagc,cchgcgcecegaagat
acagccgegeacLaLegechcgg,cacacctgc:gagagccagc,gg,,,g
CL,a,ngggacagggcacccegg,gacagech,Lccggaggatgtggcgg
ag:ggccgcac:ggagaaagaggLechchLeggagaaggaggtc
gcegcaceegaaaaggaggtcgcagccctggagaaaggcggcgggechegg
ccgaagcaaaagtgctggccaaccgcgaaceggaLaaa,angcg,gagcga
L,aLeaLaagaacc:gattgacaacgcaaaatccgcggaaggcgtgaaagca
c,ga,LgaLgaaaL,chgccgccctgcct
The second polypeptide chain of such a sequence-optimized CD123 X CD3
diabody having an Albumin-Binding Domain has the sequence described above (SEQ
ID NO:3) and is encoded by a polynucleotide having the ce of SEQ ID NO:4.
B. Sequence-Optimized CD123 x CD3 Bi-Specific Diabodies Having
An IgG Fc Domain (DART-A with Fe “w/Fc”)
In a third embodiment, the invention provides a sequence-optimized CD123
X CD3 bi-specific diabody ed of three polypeptide chains and possessing an
IgG Fc Domain (DART-A with Fe “W/Fc” Version 1 and Version 2) (Figure 3A-3B).
In order to form such IgG Fc Domain, the first and third polypeptide chain of
the diabodies n, in the N-terminal to C-terminal direction, a cysteine-containing
peptide, (most preferably, Peptide 1 having the amino acid sequence (SEQ ID
NO:55): DKTHTCPPCP), some or all of the CH2 Domain and/or some or all of the
CH3 Domain of a complete immunoglobulin Fc Domain, and a C-terminus. The
some or all of the CH2 Domain and/or the some or all of the CH3 Domain associate
to form the immunoglobulin Fc Domain of the bi-specific monovalent Fc Domain-
containing diabodies of the present invention. The first and second polypeptide
chains of the bi-specific monovalent Fc diabodies of the present invention are
covalently bonded to one another, for e by disulfide bonding of cysteine
residues located within the cysteine-containing peptide of the polypeptide chains.
The CH2 and/or CH3 Domains of the first and third polypeptides need not be
identical, and advantageously are modified to foster complexing between the two
polypeptides. For example, an amino acid substitution (preferably a substitution with
an amino acid comprising a bulky side group forming a ‘knob’, e.g., tryptophan) can
be introduced into the CH2 or CH3 Domain such that steric interference will prevent
ction with a similarly mutated domain and will obligate the d domain to
pair with a domain into which a complementary, or accommodating mutation has
been engineered, i.e., “the hole’ (e.g., a substitution with glycine). Such sets of
mutations can be ered into any pair of polypeptides comprising the bi-specific
monovalent Fc diabody molecule, and fiarther, engineered into any portion of the
polypeptides chains of said pair. Methods of protein engineering to favor
heterodimerization over homodimerization are well known in the art, in particular
with respect to the engineering of globulin-like molecules, and are
encompassed herein (see e. g., Ridgway et al. (1996) “‘Knobs-Into-Holes’
Engineering 0f Antibody CH3 Domains For Heavy Chain Heterodimerization,”
Protein Engr. 9:6l7-621, Atwell et al. (1997) e Heterodimers From
ling The Domain Interface Of A Homodimer Using A Phage Display
Library,” J. Mol. Biol. 270: 26-35, and Xie et al. (2005) “A New Format 0f
Bispecific Antibody: Highly nt Heterodimerization, Expression And Tamor Cell
Lysis, ” J. Immunol. Methods 296:95-101; each of which is hereby incorporated herein
by reference in its entirety). Preferably the ‘knob’ is engineered into the CH2-CH3
Domains of the first polypeptide chain and the ‘hole’ is engineered into the CH2-CH3
Domains of the third ptide chain. Thus, the ‘knob’ will help in preventing the
first polypeptide chain from merizing Via its CH2 and/or CH3 Domains. As
the third polypeptide chain preferably contains the ‘hole’ substitution it will
heterodimerize with the first polypeptide chain as well as homodimerize with itself
A preferred knob is created by modifying a native IgG Fc Domain to contain the
modification T366W. A preferred hole is created by modifying a native IgG Fc
Domain to n the modification T366S, L368A and Y407V. To aid in purifying
the third polypeptide chain homodimer from the final bi-specific monovalent Fc
y comprising the first, second and third polypeptide chains, the protein A
binding site of the CH2 and CH3 s of the third polypeptide chain is preferably
mutated by amino acid substitution at position 435 (H435R). Thus, the third
ptide chain homodimer will not bind to protein A, Whereas the bi-specific
monovalent Fc diabody will retain its y to bind protein A via the protein A
binding site on the first polypeptide chain.
] A preferred sequence for the CH2 and CH3 Domains of an antibody Fc
Domain present in the first polypeptide chain is (SEQ ID NO:56):
APLAAGGPSVFLFPPKPKDTL VTCVVVDVSH4DP*‘V<EWWYV3GV
LUVTNAKTK9<4'QYWSTYRVVSVLTVL{QDWLNG<LYKC<VSN<AL9A9 4K
:SKAKGQ9{L9QVYTTWP9SRL*MTKVQVSLWCLV<GEY9SD AV4W4SWGQ
-3WNYKTT 99VLDSDGSFFLYS<LTVD<S9WQQGWVFSCSV HEALTVTYTQ
<SLSLSPG<
A preferred sequence for the CH2 and CH3 Domains of an antibody Fc
Domain present in the third polypeptide chain is (SEQ ID NO: 11):
GPSVFLFPPKPKDTT SRTPLVTCVVVDVSH4DP4V<EWWYVJGV
'UI—IILUVTNAKTK9<4'QYWSTYRVVSVLTVL{QDWLNG<LYKC<VSN<AL9A9 4K
:SKAKGQW9{L9QVYTTP9SRL*MTKVQVSLSCAV<GEY9SD AV4W4SWGQ
.3WNYKTT 99VLDSDGSFFLVS<LTVD<S9WQQGWVFSCSV HLALTV<YTQ
<SLSLSPG<
C. DART-A w/Fc Version 1 Construct
In order to illustrate such Fc diabodies, the invention provides a DART-A
W/Fc version 1 construct. The first polypeptide of the DART-A w/Fc version 1
uct comprises, in the N—terminal to C-terminal direction, an N—terminus, a VL
domain of a monoclonal antibody capable of binding to CD123 (VLCDm), an
intervening linker e (Linker l), a VH domain of a monoclonal antibody capable
of binding to CD3 (VHCDg), a Linker 2, an E—coil Domain, a Linker 5, Peptide l, a
polypeptide that contains the CH2 and CH3 Domains of an Fc Domain and a C-
terminus. A preferred Linker 5 has the sequence (SEQ ID NO:32): GGG. A preferred
polypeptide that contains the CH2 and CH3 Domains of an Fc Domain has the
sequence (SEQ ID NO:37):
APEAAGGPSVFLFPPKPKDTP VTCVVVDVSH4DPL1V<EWWYVDGV
'Ul—ZIL-ljViNAKTK9&4L1QYNSTY9VVSVLTVL{QDWLNG<EYKC<VSN<AL9A9 4K
:SKAKGQW9{_L9QVYTTP9SRLLMTKNQVSLWCLV<GEY9SD AV4W4SWGQ
.3WNYKTT99VLDSDGSFFLYS<LTVD<S9WQQGWVFSCSV HEALdWiYTQ
Thus, the first polypeptide of such a DART-A W/Fc version 1 construct is
ed of: SEQ ID NO:25 — SEQ ID NO:29 — SEQ ID NO:22 — SEQ ID
NO:30 — SEQ ID NO:34 — SEQ ID NO:32 — SEQ ID NO:55 — SEQ ID NO:37.
A preferred sequence of the first polypeptide of such a DART-A w/Fc
version 1 construct has the sequence (SEQ ID NO:13):
DFVMTQS9DSLAVSLG.£{VTMSC{SSQSLLNSGNQ<NYLTWYQQ<PGQ9PKL
L: YWAST<LSGVP39FSGSGSGTDFTTT MSTQAL.DVAVYYCQNDYSY9YTF
GQGT<P4 <GGGSGGGG4VQPVLSGGGTVQPGGSLRLSCAASGFTFSTYAMW
WVRQA9G<GPL1WVG< RS<YNNYATYYADSVKDRFT SRDDSKNSLYLQ NS
LKTEDTAVYYCVR{GWFGWSYVSWFAYWGQGTLVTVSSGGCGGGLVAATLK4
4VAAPLKLVAAT4<GGGD<TdTC99C9APLAAGG9SVFLFPPK9KD
TR S<TP4VTCVVVDVS{4DP4V<EWWYVDGVEV{NAKT<9<4L1QYWSTY9
VVSVLTVL{QDWLWG<EY<C<VSW<AP9A9 4<T 9<L9QVYTLP9
SR4L1MTKWQVSLWCLV<GEY9SD AV4W4SWGQ 9EWNYKTT99VLDSDGSFF
LYS<LTVD<S9WQQGWVFSCSV {EALdeYTQ<SLSLSPG<
A preferred polynucleotide encoding such a polypeptide is (SEQ ID
NO:14):
gac,chLgaLgacacachLcc,gaLag,chgccgtgagtctgggggagc
ggngaCLaLgLCL,gcaagagc:cccag:cactgctgaacagcggaaatca
gaaaaacvaLCLgachggLaccagcagaagccaggccagccccc:aaactg
chaLcLaLnggc,LccaccagggaaLC,ggchgcccgacagattcagcg
gcagcggcagcggcacagaLLLLaCCCLgacaaLLLCLagLCLgcaggccga
ggachggCLngLaCLaL,gvcagaa,ga,Lacagc:atccctacactttc
ggccaggggaccaagc:ggaaa:taaaggaggcggatccggcggcggaggcg
aggtgcagcngvggechnggggagchngvccagcc:ggagggvcccv
gagacLCLCCLngcegCCLCngaL,cach,cagcacaLacchaLgaa,
cgccaggc2ccagggaaggggcngagvgggvngaaggavcaggv
ccaagtacaacaattetgcaachacLa,gccgactc:gtgaagga,agaLL
caccaLCLcaagagatgattcaaagaacLcachLaLchcaaa:gaacagc
ctgaaaaccgaggacecggcchgLaLLachLngagacacggLaacLch
gcaa,LC,LachgLCLngLLLchLa,ngggacaggggacactggtgac
LngLcLLccggagge:gtggcggtggagaagtggccgcac:ggagaaagag
gLLchgCLLngageaggaggvcchgcacLLgaaaaggaggtcgcagccc
:ggagaaaggcggcggggacaaaac:cacacatgcccaccgtgcccagcacc
:gaagccgcggggggecchcachLLCCLCLLccccccaaaacccaaggac
accctcatgatctcccggacccc,gagchacaLgchgngg,ggacgtga
gccacgaagacchgegchaag,Lcaac,ggLachggacggcgtggaggt
gcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccg'(I
gtggtcagcgtcc:caccgtcctgcaccaggactggc:gaatggcaaggag'(I
acaagtgcaaggtctccaacaaagccctcccagccccca:cgagaaaacca(I
agccaaagggcagccccgagaaccacaggtg:acaccctgccccca
tcccgggaggagatgaccaagaaccaggtcagccchggchcvggvcaaag
ch,cLa,cccagcgacatcgccgtggag:gggagagcaatgggcagccgga
gaacaac2acaagaccacgccLccchgccggac ,ccgacggc,cc,Lc,Lc
agcaagctcaccg:ggacaagagcaggtggcagcaggggaacg:ct
gc,ccg,gaLgca,gaggctctgcacaaccactacacgcagaagag
cc,chcc,ch,ccgggtaaa
The second chain of such a DART-A W/Fc version 1 construct will comprise,
in the N—terminal to C-terminal direction, an N—terminus, a VL domain of a
monoclonal antibody capable of binding to CD3 (VLCDg), an intervening linker
e (Linker l), a VH domain of a monoclonal antibody capable of binding to
CD123 (VHCDm), a Linker 2, a K—coil Domain, and a C-terminus. Thus, the second
polypeptide of such a DART-A W/Fc version 1 construct is composed of: SEQ ID
NO:21 — SEQ ID NO:29 — SEQ ID NO:26 — SEQ ID NO:30 — SEQ ID NO:35.
Such a polypeptide has the sequence (SEQ ID NO:15):
EPSLTVSPGGTVTLTCRSSTGAVTTSWYANWVQQKPGQAPRGL_IGG
TNKRAPWTPARFSGSLLGGKAALTI TGAQAfiDfiADYYCALWYSWLWVFGGGT
KLTVLGGGGSGGGG_EVQLVQSGA_ELKKPGASV{VSCKASGYTFTDYYMKWVR
Tfi'W GD FYNQKFKGRVT--TVDKSTSTAY *TSSTRSmD
TAVYYCARSHLLRASWFAYWGQGTLVTVSSGGCGGGKVAATK:‘J <VAAT.Km<V
AAPKTKVAATKm
A preferred polynucleotide encoding such a polypeptide has the sequence
(SEQ ID NO:16):
caggctgtggtgactcaggagccttcactgaccgtgtccccaggcggaactg
tgaccctgacatgcagatccagcacaggcgcag:gaccaca:ctaactacgc
caattgggtgcagcagaagccaggacaggcaccaaggggcc “gaucgggggt
acaaacaaaagggc:ccctggacccctgcacgg ,L,Lc,ggaag:ctgctgg
gcggaaaggccgcchgaccavLaccggggcacaggccgaggacgaagccga
,,ac,aLLngc,cvgvgg,a,agcaa,ch,ggg,gv“cgggggtggcaca
aaaccgacchgccgggagggggvggavccggcggcggaggcgaggtgcagc
,gngcag,ccggggc“gagc,gaagaaacccggagcv“cchgaaggtgtc
vcgcaaagccagvggcvacaccttcacagacvacLavaGgaagGggchagg
caggctccaggacagggac,ggaa,ggachgcgaLa,ca, LCCL,ccaacg
gggccac,L,cLacaa,cagaag,,Laaaggcaggg,gac,aLvaccg,gga
caaatcaacaagcacvchcavavggachgagc ,cchgcgc,c,gaagat
acagccg,g,acLaL,g,chcgg,cacacctgc:gagagccagcvgngvg
ctta:tggggacagggcaccccgg,gacag,ch vLccggaggatgtggcgg
tggaaaag1ggccgcac:gaaggagaaagt:gctgctttgaaagagaagg:c
gccgcacvvaaggaaaaggtcgcagccctgaaagag
The third polypeptide chain of such a DART-A w/Fc version 1 will comprise
the CH2 and CH3 Domains of an IgG Fc Domain. A preferred polypeptide that is
ed of Peptide l (SEQ ID NO:55) and the CH2 and CH3 Domains of an Fc
Domain (SEQ ID NO:11) and has the sequence of SEQ ID NO:54:
D<T{TC99CPA9EAAGGPSVFLFPPKPK3TL SRTPfi'VTCVVVDVSH4DPfi
V<FWWYVDGVEVINAKTK9<m'QYWSTYRVVSVLTVLIQDWLNG<EYKC<VS
W<AL9A9 4KT SKAKGQ9<j9QVYTTP9SRfiHfiMTKVQVSLSCAV<GFY9S3
AVfiWfiSWGQ 9EWNYKTT99VLDSDGSFFLVS<LTVD<S9WQQGWVFSCSV
{jAL{W{YTQ<SLSLSPG<
A preferred polynucleotide that encodes such a polypeptide has the sequence
(SEQ ID NO:12):
gacaaaac:cacacatgcccaccgtgcccagcacctgaagccgcggggggac
chcag,c3Lcc,cLoccccccaaaacccaaggacaccctcatgatctcccg
gacccc,gagchacaLgchggngngacgtgagccacgeagaccc:gag
chaagoLcaac,gg,acgngacggcgtggaggtgcataatgccaagacaa
agccgcgggaggagcagtacaacagcacgLaccg,gogchegcgtcc:cac
cgtcctgcaccaggactggc:gaatggcaaggag:acaagtgcaaggtctcc
aacaaagccctcccagcccccatcgagaaaaccacccccaaegccaaagggc
agccccgagaaccacaggtg:acaccctgcccccatcccgggaggagatgac
caagaaccaggtcagccogagL,gcgcagtcaaaggcttcte:cccagcgac
atcgccgtggag:gggagagcaatgggcagccggagaacaac:acaagacca
cgchccchgc,ggac,ccgacgchcc,Lchchcgocegcaagctcac
cg:ggacaagagcaggtggcagcaggggaacg“CLLC,caLgcoccg,gaLg
catgaggctctgcacaaccgctacacgcagaagagcc,cocccoch,ccgg
gtaaa
D. DART-A w/Fc Version 2 Construct
] As a second example of such a DART-A w/Fc diabody, the invention
provides a three chain y, “DART-A w/Fc Diabody Version 2” (Figure 3B).
] The first polypeptide of such a DART-A W/Fc version 2 construct comprises,
in the N—terminal to inal ion, an N—terminus, a peptide linker (Peptide l),
a polypeptide that contains the CH2 and CH3 s of an Fc Domain linked (via a
Linker 4) to the VL domain of a monoclonal dy capable of binding to CD123
(VLCDm), an intervening linker peptide (Linker l), a VH domain of a monoclonal
antibody capable of binding to CD3 (VHCDg), a Linker 2, a K—coil Domain, and a C-
terminus .
] A preferred polypeptide that contains the CH2 and CH3 Domains of an Fc
Domain has the sequence (SEQ ID NO:37):
APEAAGGPSVFLFPPKPKDTP SRTP*‘VTCVVVDVSH4DP4'V<EWWYV3GV
'Ul—ZIL-ljV4NAKTK994'QYWSTY9VVSVLTVL{QDWLNG<EYKC<VSN<AP9A9 4K
:SKAKGQ9949QVYTTWP9SR4*MTKWQVSLWCLV<GEY9SD AV4W4SWGQ
-3WNYKTT 99VLDSDGSFFLYS<LTVD<S9WQQGWVFSCSV HEAL4W4YTQ
<SLSLSPG<
“Linker 4” will ably se the amino acid sequence (SEQ ID
NO:57): APSSS. A preferred r 4” has the sequence (SEQ ID NO:33):
ME. Thus, the first polypeptide of such a DART-A W/Fc version 2 construct
is composed of: SEQ ID NO:55 — SEQ ID NO:37 — SEQ ID NO:33 — SEQ ID
NO:25 — SEQ ID NO:29 — SEQ ID NO:22 — SEQ ID NO:30 — SEQ ID NO:35.
A polypeptide having such a sequence is (SEQ ID NO:17):
D<T{TC99CPAPEAAGGPSVFLFPPKP{DTP SRTP4VTCVVVDVSH4DP4
V<FWWYVJGVEV4NAKTK994'QYWSTY9VVSVLTVL{QDWLNG<EYKC{VS
W<AP9A9 4KT SKAKGQ99.49QVYTT 99SR*H*MT<WQVSLWCLV<GFY9SD
AV4W4SWGQ9EWNYKTT 99VLDSDGSFFLYS<LTVD<S9WQQGWVFSCSV
{EAL4W4YTQ<SLSLSPG<A9SSS9 Lti DFVMTQS9DSLAVSLG49VTMSC<S
SQSLLWSGNQ<WYLTWYQQ<9GQ99<LLI_YWAST94SGV9D9FSGSGSGT3F
TTT SSTQA4.3VAVYYCQWDYSY9YTFGQGT<14 <GGGSGGGG4VQPV4SG
GGLVQPGGSL9LSCAASGFTFSTYA NWVRQA9G<GP4WVG9 {SKYNNYAT
YYADSVKDRFT SRDDSKWSLYLQMWSLKT4DTAVYYCV9HGNFGNSYVSWF
AYWGQGTLVTVSSGGCGGGKVAAT.K4KVAAT.<4KVAAT.K4KVAATK4
A preferred polynucleotide encoding such a polypeptide has the sequence
(SEQ ID NO:18):
ac:cacacatgcccaccgtgcccagcacctgaagccgcggggggac
chcag,c4Lcc,cL,ccccccaaaacccaaggacaccctcatgatctcccg
gacccc,gagchacaLgchggngngacgtgagccacgeagaccc:gag
chaag,Lcaac,gg,acgngacggcgtggaggtgcataatgccaagacaa
agccgcgggaggagcagtacaacagcacgLaccg,g,gchegcgtcc:cac
cgtcctgcaccaggactggc:gaatggcaaggag:acaagtgcaaggtctcc
aacaaagccctcccagcccccatcgagaaaaccacccccaaegccaaagggc
agccccgagaaccacaggtg:acaccctgcccccatcccgggaggagatgac
caagaaccaggtcagcc,ngg,gcc,gg,caaagch,cLe,cccagcgac
atcgccgtggag:gggagagcaatgggcagccggagaacaac:acaagacca
chgc,ggac,ccgacggc,cc,Lchchc,acegcaagctcac
cg:ggacaagagcaggtggcagcaggggaacg“CLLC,caLgc,ccg,gaLg
catgaggc4ccgcacaaccactacacgcagaagagcc4c“cccchccccgg
gtaaagcccc:tccagctcccc:atggaagac,,cg,ga,gacacag:ctcc
,gaLag,c,ggccgtgagtctgggggagcggg,gac,acg,cL,gcaagagc
:cccag,cac,gcLgaacagcggaaatcagaaaaac,a,c,gachggLacc
agcagaagccaggccagccccc,aaachcha,cLaL,gggc,Lccaccag
ggaa,chgcg,gcccgacagattcagcggcagcggcagcggcacaga,Lo,
aCCCCgacaa,,Lc,agochcaggccgaggacgoggc,ngLac,aL,g,c
agaa,gaoLacagc:atccctacactttcggccaggggaccaagc:ggaaa:
taaaggaggcggatccggcggcggaggcgaggtgcagcngvggachvggg
ggagchngvccagcc2ggagggvcccLgagacchchngcagccvcvg
gattcaccttcagcaca,accha,gaa,ngchcgccagg02ccagggaa
ggggcvggagvgggvngaaggavcagg“ccaagtacaacaattatgcaacc
Lac,augccgactc:gtgaagga,agaL“caccaococaagagatgattcaa
agaacvcacLgvaLcLgcaaa:gaacagcc:gaaaaccgaggacacggccg:
chogogagacacgguaac,chgcaa,,c,,achchungLL,
ch,a,ngggacaggggacachg,gac,gugocL,ccggaggatgtggcg
gtggaaaagtggccgcactgaaggagaaag3LgcvgchLgaaagagaagg:
cgccgcact:aaggaaaaggtcgcagccc:gaaagag
The second polypeptide chain of such a DART-A w/Fc version 2 construct
comprises, in the N—terminal to C-terminal direction, the VL domain of a monoclonal
antibody capable of binding to CD3 ), an intervening linker e (Linker l)
and a VH domain of a monoclonal antibody capable of binding to CDl23 (VHCDm).
This portion of the molecule is linked (via Linker 2) to an E-coil Domain. Thus, the
third polypeptide of such a DART-A w/Fc version 2 construct is composed of: SEQ
ID NO:21 — SEQ ID NO:29 — SEQ ID NO:26 — SEQ ID NO:30 — SEQ ID
NO:34. A polypeptide having such a ce is (SEQ ID NO:1), and is preferably
encoded by a polynucleotide having the sequence of SEQ ID NO:2.
] The third polypeptide chain will comprise the CH2 and CH3 Domains of an
IgG Fc Domain. A preferred ptide is ed of Peptide l (SEQ ID NO:55)
and the CH2 and CH3 Domains of an Fc Domain (SEQ ID NO:11) and has the
sequence of SEQ ID NO:54.
In order to assess the activity of the above-mentioned CD123 X CD3 bi-
specific diabodies (DART-A, DART-A w/ABD, DART-A w/Fc, DART-B), a control
bi-specific diabody (Control DART) was produced. The Control DART is capable of
simultaneously binding to FITC and CD3. Its two polypeptide chains have the
ing respective sequences:
Control DART Chain 1 (SEQ ID NO: 19).
DVVMTQTPFSL9VSLGDQAS: SCRSSQSLVHSNGWTYLRWYLQKPGQSPKVL
:YKVSWRFSGV9DRFSGSGSGTDETTK S<VfiAfiDTGVYFCSQSTHVPWTFG
GGTKT.*' KGGGSGGGGfi'VQLVmSGGGLVQ9GGSLRLSCAASGFTFNTYAMNW
VRQAPGKGTfi'WVA{ RSKYNNYATYYADSVKDRFT SRDDSKNSLYLQMNSL
VYYCVR{GNFGWSYVSWFAYWGQGTLVTVSSGGCGGGfiVAALfiKfiV
AALfiKfiVAALfiKfiVAALfiK
Control DART Chain 2 (SEQ ID NO:20):
QAVVTQ_EPSLTVSPGGTVTLTCRSSTGAVTTSWYANWVQQKPGQAPRGL_IGG
TN<RAPWTPARFSGSLLGG<AALTI TGAQAmD*ADYYCALWYSNLWVFGGGT
{LTVLGGGGSGGGGfi'VKTDfiTGGGTVQPGR? SGFTFSDYW NWVR
QS?*KGT*WVAQ RW<PYWYETYYSDSVKG<ET SRDDSKSSVYLQMWNLRV
fl) G YYCTGSYYG DYWGQGTSVTVSSGGCGGGKVAALKTKVAALKTKVAA
L<T<VAAT.Km
IV. Pharmaceutical Compositions
The itions of the invention include bulk drug itions useful in
the manufacture of pharmaceutical compositions (e.g., impure or non-sterile
compositions) and pharmaceutical compositions (z'.e., compositions that are suitable
for administration to a subject or patient) which can be used in the ation of unit
dosage forms. Such compositions comprise a prophylactically or therapeutically
effective amount of the sequence-optimized CD123 X CD3 bi-specific diabodies of
the present invention, or a combination of such agents and a ceutically
acceptable carrier. Preferably, compositions of the invention comprise a
prophylactically or therapeutically effective amount of the ce-optimized
CD123 X CD3 bi-specific diabody of the invention and a pharmaceutically acceptable
carrier.
] The ion also encompasses pharmaceutical compositions comprising
sequence-optimized CD123 X CD3 bi-specific ies of the invention, and a
second therapeutic antibody (e.g., tumor specific monoclonal antibody) that is specific
for a particular cancer antigen, and a pharmaceutically acceptable carrier.
In a specific embodiment, the term “pharmaceutically acceptable” means
ed by a regulatory agency of the Federal or a state government or listed in the
US. Pharmacopeia or other generally recognized pharmacopeia for use in animals,
and more particularly in humans. The term “carrier” refers to a diluent, adjuvant
(e. g., Freund’s adjuvant (complete and incomplete), excipient, or vehicle with which
the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids,
such as water and oils, ing those of petroleum, animal, vegetable or synthetic
origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a
preferred carrier when the pharmaceutical composition is administered intravenously.
Saline solutions and aqueous dextrose and glycerol solutions can also be employed as
liquid carriers, particularly for able solutions. Suitable pharmaceutical
ents include starch, e, lactose, sucrose, gelatin, malt, rice, flour, chalk,
silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim
milk, glycerol, ene, glycol, water, ethanol and the like. The composition, if
desired, can also contain minor amounts of wetting or emulsifying agents, or pH
buffering agents. These compositions can take the form of solutions, suspensions,
emulsion, tablets, pills, capsules, powders, sustained-release formulations and the
like.
lly, the ingredients of compositions of the invention are supplied
either separately or mixed together in unit dosage form, for example, as a dry
lyophilized powder or water free trate in a hermetically sealed container such
as an ampoule or sachette ting the quantity of active agent. Where the
composition is to be administered by infusion, it can be dispensed with an infiJsion
bottle ning sterile pharmaceutical grade water or saline. Where the composition
is administered by ion, an ampoule of sterile water for injection or saline can be
ed so that the ingredients may be mixed prior to administration.
The compositions of the invention can be formulated as neutral or salt forms.
Pharmaceutically acceptable salts include, but are not d to those formed with
anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, ic
acids, etc, and those formed with cations such as those derived from sodium,
potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-
ethylamino ethanol, histidine, procaine, etc.
The invention also provides a pharmaceutical pack or kit comprising one or
more containers filled with sequence-optimized CD123 X CD3 bi-specif1c diabodies
of the invention alone or with such pharmaceutically acceptable carrier. Additionally,
one or more other prophylactic or therapeutic agents useful for the treatment of a
disease can also be included in the pharmaceutical pack or kit. The invention also
provides a pharmaceutical pack or kit sing one or more containers filled with
one or more of the ingredients of the pharmaceutical compositions of the invention.
Optionally associated with such ner(s) can be a notice in the form prescribed by
a governmental agency regulating the manufacture, use or sale of pharmaceuticals or
biological products, which notice s approval by the agency of manufacture, use
or sale for human administration.
The present invention provides kits that can be used in the above s. A
kit can comprise sequence-optimized CD123 X CD3 bi-specif1c diabodies of the
ion. The kit can fiarther comprise one or more other lactic and/or
therapeutic agents useful for the treatment of cancer, in one or more containers; and/or
the kit can fiarther comprise one or more cytotoxic antibodies that bind one or more
cancer antigens associated with cancer. In certain embodiments, the other
prophylactic or therapeutic agent is a chemotherapeutic. In other embodiments, the
prophylactic or therapeutic agent is a biological or hormonal therapeutic.
V. Methods of Administration
The compositions of the t invention may be provided for the treatment,
prophylaxis, and amelioration of one or more symptoms associated with a disease,
disorder or infection by administering to a subject an effective amount of a fusion
protein or a conjugated molecule of the invention, or a pharmaceutical composition
comprising a fiJsion n or a conjugated molecule of the invention. In a preferred
aspect, such compositions are substantially purified (z'.e., ntially free from
substances that limit its effect or produce undesired side effects). In a specific
embodiment, the t is an animal, preferably a mammal such as non-primate (e.g.,
bovine, equine, feline, canine, rodent, etc.) or a primate (e. g., monkey such as, a
cynomolgus monkey, human, etc.). In a preferred embodiment, the subject is a
human.
Various delivery systems are known and can be used to ster the
compositions of the invention, e.g, encapsulation in liposomes, microparticles,
microcapsules, recombinant cells e of expressing the antibody or fusion protein,
receptor-mediated endocytosis (See, e.g., Wu et al. (1987) “Receptor-Mediated In
Vitro Gene Transformation By A e DNA Carrier System,” J. Biol. Chem.
262:4429-4432), uction of a nucleic acid as part of a retroviral or other vector,
etc.
Methods of administering a molecule of the invention include, but are not
limited to, parenteral administration (e.g., intradermal, uscular, intraperitoneal,
intravenous and subcutaneous), epidural, and mucosal (e.g, intranasal and oral
routes). In a specific embodiment, the sequence-optimized CD123 X CD3 bi-speciflc
diabodies of the invention are administered intramuscularly, intravenously, or
subcutaneously. The compositions may be administered by any convenient route, for
example, by on or bolus injection, by absorption through epithelial or
mucocutaneous s (e.g., oral mucosa, rectal and inal mucosa, etc.) and may
be administered er with other biologically active . Administration can be
systemic or local. In addition, ary administration can also be employed, e.g.,
by use of an inhaler or zer, and formulation with an aerosolizing agent. See,
e.g., US. Patent Nos. 6,019,968; 5,985, 320; 309; 5,934,272; 5,874,064;
,855,913; 540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO
97/32572; WO 97/44013; WO 98/31346; and WO 99/66903, each of which is
incorporated herein by reference in its entirety.
The invention also provides that the sequence-optimized CD123 X CD3 bi-
specific diabodies of the invention are packaged in a hermetically sealed container
such as an e or sachette indicating the quantity of the molecule. In one
embodiment, the sequence-optimized CD123 X CD3 bi-specif1c diabodies of the
invention are supplied as a dry sterilized lyophilized powder or water free concentrate
in a hermetically sealed container and can be reconstituted, e.g., with water or saline
to the appropriate concentration for administration to a subject. Preferably, the
sequence-optimized CD123 X CD3 bi-speciflc diabodies of the invention are supplied
as a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage
of at least 5 ug, more preferably at least 10 ug, at least 15 ug, at least 25 ug, at least
50 ug, at least 100 ug, or at least 200 ug.
The lyophilized sequence-optimized CD123 X CD3 bi-specif1c diabodies of
the invention should be stored at between 2 and 8°C in their original container and the
molecules should be administered within 12 hours, preferably within 6 hours, within 5
hours, within 3 hours, or within 1 hour after being reconstituted. In an alternative
embodiment, sequence-optimized CD123 X CD3 bi-specific diabodies of the
invention are ed in liquid form in a hermetically sealed container indicating the
quantity and concentration of the molecule, fusion protein, or conjugated molecule.
Preferably, the liquid form of the sequence-optimized CD123 X CD3 bi-specific
diabodies of the ion are supplied in a hermetically sealed container in which the
molecules are t at a concentration of least 1 ug/ml, more preferably at least 2.5
ug/ml, at least 5 ug/ml, at least 10 ug/ml, at least 50 ug/ml, or at least 100 ug/ml.
The amount of the composition of the invention which will be ive in
the treatment, prevention or amelioration of one or more symptoms associated with a
disorder can be determined by standard clinical techniques. The precise dose to be
employed in the formulation will also depend on the route of administration, and the
seriousness of the condition, and should be decided according to the judgment of the
practitioner and each patient’s circumstances. Effective doses may be extrapolated
from esponse curves derived from in vitro or animal model test systems.
For sequence-optimized CDl23 X CD3 bi-specific diabodies assed
by the invention, the dosage administered to a patient is preferably determined based
upon the body weight (kg) of the recipient subject. The dosage administered is
typically from at least about 0.3 ng/kg per day to about 0.9 ng/kg per day, from at
least about 1 ng/kg per day to about 3 ng/kg per day, from at least about 3 ng/kg per
day to about 9 ng/kg per day, from at least about 10 ng/kg per day to about 30 ng/kg
per day, from at least about 30 ng/kg per day to about 90 ng/kg per day, from at least
about 100 ng/kg per day to about 300 ng/kg per day, from at least about 200 ng/kg per
day to about 600 ng/kg per day, from at least about 300 ng/kg per day to about 900
ng/kg per day, from at least about 400 ng/kg per day to about 800 ng/kg per day, from
at least about 500 ng/kg per day to about 1000 ng/kg per day, from at least about 600
ng/kg per day to about 1000 ng/kg per day, from at least about 700 ng/kg per day to
about 1000 ng/kg per day, from at least about 800 ng/kg per day to about 1000 ng/kg
per day, from at least about 900 ng/kg per day to about 1000 ng/kg per day, or at least
about 1,000 ng/kg per day.
In another ment, the patient is administered a treatment regimen
comprising one or more doses of such lactically or eutically effective
amount of the sequence-optimized CD123 X CD3 bi-specif1c diabodies encompassed
by the invention, wherein the treatment regimen is administered over 2 days, 3 days, 4
days, 5 days, 6 days or 7 days. In certain embodiments, the treatment regimen
comprises intermittently administering doses of the prophylactically or therapeutically
effective amount of the sequence-optimized CD123 X CD3 bi-specif1c ies
encompassed by the invention (for example, administering a dose on day 1, day 2, day
3 and day 4 of a given week and not administering doses of the prophylactically or
therapeutically effective amount of the sequence-optimized CD123 X CD3 bi-specific
diabodies encompassed by the invention on day 5, day 6 and day 7 of the same week).
Typically, there are 1, 2, 3, 4, 5 or more courses of ent. Each course may be the
same n or a different regimen.
In r embodiment, the administered dose escalates over the first
quarter, first half or first two-thirds or three-quarters of the regimen(s) (e.g., over the
first, second, or third regimens of a 4 course treatment) until the daily prophylactically
or therapeutically effective amount of the sequence-optimized CD123 X CD3 bi-
specific diabodies encompassed by the invention is achieved.
Table 1 provides 5 examples of different dosing regimens described above
for a typical course of treatment.
Table 1
Regimen ND “93“02% D1abody Dosage (ng d1abody per k sub} ect we1 ht per day)'.
p—A \14; 100 100 100 100 100
3 mimNm -—, 300 500
none none none none none
1, “N 300 500 700 900
u 1,000
U‘I @0300.) hN-h none none none none none
The dosage and frequency of administration of sequence-optimized CD123 X
CD3 bi-specif1c diabodies of the ion may be reduced or altered by enhancing
uptake and tissue penetration of the sequence-optimized CD123 X CD3 bi-specif1c
diabodies by modifications such as, for example, lipidation.
] The dosage of the sequence-optimized CD123 X CD3 bi-specif1c diabodies
of the invention administered to a patient may be calculated for use as a single agent
therapy. Alternatively, the sequence-optimized CD123 X CD3 bi-specif1c diabodies
of the invention are used in combination with other therapeutic compositions and the
dosage administered to a patient are lower than when said molecules are used as a
single agent therapy.
The pharmaceutical compositions of the ion may be administered
locally to the area in need of treatment; this may be achieved by, for example, and not
by way of limitation, local 111fi1S1011, by injection, or by means of an implant, said
implant being of a porous, non-porous, or gelatinous material, including membranes,
such as sialastic membranes, or fibers. Preferably, when stering a molecule of
the invention, care must be taken to use als to which the le does not
absorb.
The compositions of the invention can be delivered in a vesicle, in particular
a liposome (See Langer (1990) “New Methods OfDrag Delivery,” e 249: 1527-
1533); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer,
Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-
Berestein, ibid., pp. 3 17-327; see generally ibid.).
The compositions of the invention can be red in a controlled-release or
sustained-release system. Any technique known to one of skill in the art can be used
to produce sustained-release formulations comprising one or more sequence-
optimized CD123 X CD3 bi-specif1c ies of the invention. See, e.g., US. Patent
No. 4,526,938; PCT publication WO 91/05548; PCT publication WO 98; Ning
et al. (1996) “Intratamoral Radioimmanotherapby Of A Human Colon Cancer
aft Using A Sustained-Release Gel,” Radiotherapy & Oncology 39:179-189,
Song et al. (1995) “Antibody Mediated Lang ing 0f Long-Circulating
Emulsions, ” PDA Journal of Pharmaceutical e & Technology 50:372-397;
Cleek et al. (1997) “Biodegradable Polymeric Carriers For A bFGF Antibody For
Cardiovascular Application, ” Pro. Int’l. Symp. Control. Rel. Bioact. Mater.
24:853-854; and Lam et al. (1997) “Microencapsulation 0fRecombinant Humanized
Monoclonal Antibody For Local Delivery, ” Proc. Int’l. Symp. Control Rel. Bioact.
Mater. 24:759-760, each of which is incorporated herein by reference in its entirety.
In one embodiment, a pump may be used in a controlled-release system (See Langer,
supra; Sefton, (1987) “Implantable Pumps,” CRC Crit. Rev. Biomed. Eng. 14:201-
240; Buchwald et al. (1980) “Long-Term, Continuous Intravenous Heparin
Administration By An Implantable Infusion Pump In Ambulatory Patients With
Recurrent Venous osis,” Surgery 88:507-516; and Saudek et al. (1989) “A
inary Trial Of The Programmable Implantable tion System For Insulin
Delivery,” N. Engl. J. Med. 321:574-579). In another embodiment, polymeric
materials can be used to achieve controlled-release of the molecules (see e. g.,
MEDICAL ATIONS OF CONTROLLED RELEASE, Langer and Wise (eds.), CRC
Pres., Boca Raton, Florida (1974); CONTROLLED DRUG BIOAVAILABILITY, DRUG
PRODUCT DESIGN AND PERFORMANCE, Smolen and Ball (eds.), Wiley, New York
(1984); Levy et al. (1985) “Inhibition 0f cation rosthetic Heart Valves
By Local Controlled-Release Diphosphonate, ” Science 228:190-192; During et al.
(1989) “Controlled Release 0fDopamine From A Polymeric Brain Implant.‘ In Vivo
Characterization,” Ann. Neurol. 25:351-356; Howard et al. (1989) “Intracerebral
Drug Delivery In Rats With Lesion-Induced Memory Deficits, ” J. Neurosurg.
7(1):105-112); US. Patent No. 5,679,377; US. Patent No. 5,916,597; US. Patent No.
,912,015; US. Patent No. 5,989,463; US. Patent No. 5,128,326; PCT Publication
No. W0 99/15154; and PCT Publication No. WO 99/20253). Examples of polymers
used in sustained-release formulations e, but are not limited to, poly(2-hydroxy
ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-
vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N—
vinyl pyrrolidone), poly(vinyl alcohol), rylamide, poly(ethylene glycol),
polylactides (PLA), actide-co-glycolides) (PLGA), and polyorthoesters. A
lled-release system can be placed in ity of the therapeutic target (e.g.,
the , thus requiring only a fraction of the systemic dose (see, e.g., n, in
MEDICAL APPLICATIONS OF CONTROLLED RELEASE, supra, vol. 2, pp. 115-138
(1984)). Polymeric compositions useful as controlled-release implants can be used
according to Dunn et al. (See US. 5,945,155). This ular method is based upon
the therapeutic effect of the in situ lled-release of the bioactive material from
the polymer system. The implantation can generally occur anywhere within the body
of the patient in need of therapeutic treatment. A non-polymeric sustained delivery
system can be used, whereby a non-polymeric t in the body of the subject is
used as a drug delivery system. Upon implantation in the body, the organic solvent of
the implant will dissipate, disperse, or leach from the composition into surrounding
tissue fluid, and the non-polymeric material will gradually coagulate or precipitate to
form a solid, microporous matrix (See US. 5,888,533).
Controlled-release systems are discussed in the review by Langer (1990,
“New Methods OfDrug Delivery, ” Science 249:1527-1533). Any technique known
to one of skill in the art can be used to produce ned-release formulations
comprising one or more therapeutic agents of the invention. See, e.g., US. Patent No.
4,526,938; International Publication Nos. WO 91/05548 and WO 98; Ning et
al. (1996) “Intratumoral Radioimmunotberapby Of A Human Colon Cancer
Xenograft Using A Sustained-Release Gel,” Radiotherapy & Oncology 39:179-189,
Song et al. (1995) “Antibody Mediated Lung Targeting 0f Long-Circulating
Emulsions,” PDA Journal of Pharmaceutical Science & Technology 50:372-397;
Cleek et al. (1997) “Biodegradable Polymeric rs For A bFGF Antibody For
Cardiovascular Application, ” Pro. Int’l. Symp. Control. Rel. Bioact. Mater.
24:853-854; and Lam et al. (1997) “Microencapsulation 0fRecombinant zed
Monoclonal Antibody For Local Delivery, ” Proc. Int’l. Symp. Control Rel. Bioact.
Mater. 24:759-760, each of which is orated herein by nce in its entirety.
Where the composition of the invention is a nucleic acid encoding a
sequence-optimized CD123 X CD3 bi-specif1c diabody of the invention, the nucleic
acid can be administered in vivo to promote expression of its encoded sequence-
optimized CD123 X CD3 cif1c diabody, by ucting it as part of an
appropriate nucleic acid expression vector and administering it so that it becomes
intracellular, e. g., by use of a retroviral vector (See US. Patent No. 4,980,286), or by
direct injection, or by use of microparticle bombardment (e.g., a gene gun; tic,
Dupont), or coating with lipids or cell-surface ors or transfecting agents, or by
administering it in linkage to a homeobox-like peptide which is known to enter the
s (See e.g, Joliot et al. (1991) “Antennapedz'a H0me0b0x Peptide tes
Neural Morphogenesis,” Proc. Natl. Acad. Sci. (U.S.A.) 88:1864-1868), etc.
Alternatively, a nucleic acid can be introduced intracellularly and incorporated within
host cell DNA for expression by gous recombination.
] Treatment of a subject with a therapeutically or prophylactically effective
amount of sequence-optimized CD123 X CD3 bi-specif1c diabodies of the ion
can include a single treatment or, preferably, can include a series of treatments. In a
preferred example, a subject is treated with sequence-optimized CD123 X CD3 bi-
specific diabodies of the invention one time per week for between about 1 to 10
weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks,
and even more preferably for about 4, 5, or 6 weeks. The pharmaceutical
compositions of the invention can be administered once a day, twice a day, or three
times a day. Alternatively, the pharmaceutical compositions can be administered
once a week, twice a week, once every two weeks, once a month, once every six
weeks, once every two months, twice a year or once per year. It will also be
appreciated that the ive dosage of the molecules used for ent may increase
or decrease over the course of a particular treatment.
VI. Uses of the Compositions of the Invention
The sequence-optimized CD123 X CD3 bi-specif1c diabodies of the present
invention have the y to treat any disease or condition associated with or
characterized by the expression of CD123. Thus, without limitation, such molecules
may be employed in the diagnosis or treatment of acute myeloid leukemia (AML),
chronic myelogenous leukemia (CML), including blastic crisis of CML and Abelson
oncogene associated with CML (Bcr-ABL translocation), myelodysplastic me
(MDS), acute B lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia
(CLL), including Richter’s syndrome or Richter’s transformation of CLL, hairy cell
leukemia (HCL), blastic plasmacytoid dendritic cell sm (BPDCN), non-
Hodgkin lymphomas (NHL), including mantel cell leukemia (MCL), and small
lymphocytic ma (SLL), Hodgkin’s lymphoma, systemic mastocytosis, and
t’s lymphoma (see Example 2); Autoimmune Lupus (SLE), allergy, asthma and
rheumatoid arthritis. The cific diabodies of the present invention may
additionally be used in the manufacture of medicaments for the treatment of the
described conditions.
Having now generally described the invention, the same will be more readily
understood through reference to the following examples, which are provided by way
of illustration and are not intended to be limiting of the present invention unless
specified.
Example 1
Construction Of CD123 x CD3 Bi-Specific Diabodies And l Protein
] Table 2 contains a list of bi-specif1c diabodies that were expressed and
purified. ce-optimized CD123 X CD3 bi-specif1c diabody (DART-A) and non-
ce-optimized CD123 X CD3 bi-specif1c diabody (DART-B) are capable of
simultaneously binding to CD123 and CD3. The control bi-specif1c diabody (Control
DART) is capable of simultaneously binding to FITC and CD3. The bi-specific
diabodies are heterodimers or heterotrimers of the recited amino acid sequences.
Methods for forming bi-specif1c ies are provided in WC 13665, WO
2008/157379, , , and WO
2012/162067.
Polypeptide Chain
EncoNtiiflelgfggnces. .
Bi—Specific Diabodies Amino Acid
g q
Se u uences
Sequence-Optimized CD123 x CD3 .
Bi—Specific Diabody A) Egg £3 £8;° Egg £3 £8:.
(Binds to CD3 at epitope 1) °
Non-Sequence-Optimized CD123 x . .
CD3 Bi-Specific Diabody (DART-B) Egg :3 $3; $3 :3 £33
(Binds to CD3 at epitope 2) ° °
Sequence-Optimized CD123 x CD3
Bi—Specific Diabody Having an
Albumin-Binding Domain (DART-A
w/ABD) SEQ ID N0:9 SEQ ID N0:10
(Binds to CD3 at epitope 1) SEQ ID N0:3 SEQ ID N0:4
Comprises an Albumin-Binding
Domain (ABD) for extension of half-
life in vivo
Table 2
Polypeptide Chain
Nucleic Acid
Bi-Specific Diabodies Amino Acid
Encoding Sequences
Se u uences
Sequence-Optimized CD123 x CD3
Bi-Specific Diabody Having an IgG
Fc Domain Version 1 (DART-A w/Fc SEQ ID N0:54 SEQ ID N0:12
version 1) SEQ ID N0:13 SEQ ID N0:14
(Binds to CD3 at epitope 1) SEQ ID N0:15 SEQ ID N0:16
Comprises an Fc Domain for extension
of half-life in vivo
Sequence-Optimized CD123 x CD3
Bi-Specific Diabody Having an IgG
Fc Domain Version 2 (DART-A w/Fc SEQ ID N0:54 SEQ ID N0:12
n 2) SEQ ID N0:17 SEQ ID N0:18
(Binds to CD3 at epitope 1) SEQ ID N0:1 SEQ ID N0:2
ses an Fc Domain for extension
of half-life in vivo
Control Bi-Specific y (Control
DART (or Control DART) SEQ ID N0:19
(Binds to CD3 at e 1) SEQ ID N0:20
(Binds to an irrelevant target - FITC)
Example 2
dy Labeling Of Target Cells For Quantitative FACS (QFACS)
] A total of 106 target cells were harvested from the culture, resuspended in
% human AB serum in FACS buffer (PBS + 1% BSA+ 0.1% NaAzide) and
incubated for 5 min for blocking Fc receptors. Antibody labeling of microspheres
with different antibody binding capacities (QuantumTM Simply Cellular® (QSC),
Bangs Laboratories, Inc., Fishers, IN) and target cells were labeled with anti-CD123
PE antibody (BD Biosciences) according to the manufacturer’s instructions. Briefly,
one drop of each QSC phere was added to a 5 mL polypropylene tube and PE
labeled-anti-CD123 antibody was added at 1 ug/rnL concentration to both target cells
and microspheres. Tubes were incubated in the dark for 30 minutes at 4 °C. Cells
and microspheres were washed by adding 2mL FACS buffer and fiaging at 2500
x G for 5 minutes. One drop of the blank microsphere population was added after
washing. Microspheres were analyzed first on the flow cytometer to set the test-
specific instrument settings (PMT voltages and compensation). Using the same
ment settings, geometric mean fluorescence values of microspheres and target
cells were recorded. A standard curve of dy binding sites on microsphere
populations was generated from geometric mean fluorescence of microsphere
populations. Antibody binding sites on target cells were ated based on
geometric mean fluorescence of target cells using the standard curve generated for
microspheres in QuickCal spreadsheet (Bangs Laboratories).
To determine suitable target cell lines for evaluating CD123 X CD3 bi-
specific diabodies, CD123 e expression levels on target lines Kasumi-3 (AML),
Molml3 (AML), THP-l (AML), TF-l (Erythroleukemia), and RS4-ll (ALL) were
evaluated by quantitative FACS (QFACS). Absolute numbers of CD123 antibody
binding sites on the cell surface were calculated using a QFACS kit. As shown in
Table 3, the absolute number of CD123 dy binding sites on cell lines were in
the order of Kasumi-3 (high) > Molml3 (medium) > THP-l(medium) > TF-l
(medium low) > RS4-ll (low). The three highest expressing cell lines were the AML
cell lines: Kasumi-3, MOLM13, and THP-l. The non-AML cell lines: TF-l and RS4-
11 had medium—low/ low expression of CD123, respectively.
Table 3
Target Cell CD123 Surface sion
Line Antibod _ Sites
Kasumi-3 1 18620
Molml 3 273 1 1
THP-l 58316
TF-l 14163
RS4-1 1 957
A498 Neative
HT29 Neative
CTL Cytotoxicity Assay (LDH Release Assay)
Adherent target tumor cells were detached with 0.25% Trypsin-EDTA
solution and collected by centrifilgation at 1000 rpm for 5 min. Suspension target cell
lines were harvested from the culture, washed with assay medium. The cell
concentration and viability were ed by Trypan Blue exclusion using a
Beckman Coulter Vi-Cell counter. The target cells were diluted to 4 x105 cells/mL in
the assay . 50 uL of the diluted cell suspension was added to a 96-well U-
bottom cell culture d plate (BD Falcon Cat#353077).
Three sets of controls to measure target maximal release (MR), antibody
independent cellular cytotoxicity (AICC) and target cell spontaneous release (SR)
were set up as follows:
1) MR: 200 uL assay medium without CD123 X CD3 bi-specific
diabodies and 50 uL target cells; detergent added at the end of the
experiment to determine the maximal LDH release.
2) AICC: 50 uL assay medium without CD123 X CD3 bi-specific
diabodies, 50 [LL target cells and 100 uL T cells.
3) SR: 150 uL medium without CD123 X CD3 bi-specific diabodies and
50 [LL target cells.
CD123 X CD3 bi-specific diabodies (DART-A, DART-A w/ABD and
DART-B) and controls were lly diluted to a concentration of 4 ug/mL, and serial
dilutions were then prepared down to a final concentration of 0.00004 ng/mL (z'.e., 40
fg/mL). 50 [LL of dilutions were added to the plate containing 50 uL target cells/well.
Purified T cells were washed once with assay medium and resuspended in
assay medium at cell y of 2 x 106 cells/mL. 2 x 105 T cells in 100 uL were
added to each well, for a final or-to-target cell (E:T) ratio of 10:1. Plates were
incubated for approximately 18hr at 37°C in 5% C02.
Following incubation, 25 uL of 10x lysis solution (Promega # G182A) or 1
mg/mL digitonin was added to the maximum release l wells, mixed by pipetting
3 times and plates were incubated for 10 min to tely lyse the target cells. The
plates were centrifuged at 1200 rpm for 5 minutes and 50 uL of supernatant were
transferred from each assay plate well to a flat bottom ELISA plate and 50 ul of LDH
substrate solution (Promega ) was added to each well. Plates were incubated
for 10-20 min at room temperature (RT) in the dark, then 50 [LL of Stop solution was
added. The optical density (O.D.) was measured at 490 nm within 1 hour on a
Victor2 Multilabel plate reader (Perkin Elmer #1420-014). The t cytotoxicity
was calculated as bed below and dose-response curves were ted using
GraphPad PRISM5® software.
Specific cell lysis was calculated from OD. data using the following
formula:
CytotOXiCity (%) = 100 X (OD of Sample - OD of AICC)/ (OD of MR - OD of SR)
Redirected Killing of Target Cell Lines with ent Levels of CD123 Surface
Levels:
The CD123 X CD3 bi-specif1c diabodies exhibited a potent redirected killing
ability with concentrations required to achieve 50% of maximal activity (EC50s) in
sub-ng/mL range, regardless of CD3 epitope g specificity (DART-A versus
DART-B) in target cell lines with high CD123 expression, Kasumi-3 (EC50=0.0l
ng/mL) (Figure 4 Panel D), medium CD123-expression, Molml3 0.l8
ng/mL) and THP-l (EC50=0.24 ng/mL) (Figure 4, Panel C and E, respectively) and
medium low or low CD123 sion, TF-l (EC50=0.46 ng/mL) and RS4-ll
(EC50=0.5 ng/mL) (Figure 4, Panel B and A, respectively). Similarly, CD123 X
CD3 bi-specif1c molecules mediated redirected killing was also observed with
multiple target cell lines with T cells from different donors and no cted killing
activity was observed in cell lines that do not express CD123. Results are
summarized in Table 4.
Target cell line CD123 surface EC50 of Sequence- Max % g
expression optimized CD123 x
(antibody binding CD3 bi-specific
sites) diabodies (ng/mL)
E:T=10:1
-3 118620 94
M01m13 43
THP-l 40
TF-l 46
Rs4-11
A498 No activit
HT29 No activit
Should it be necessary to replicate this example it will be appreciated that
one of skill in the art may, within reasonable and acceptable limits, vary the above-
described ol in a manner appropriate for replicating the bed results. Thus,
the exemplified protocol is not intended to be adhered to in a ely rigid manner.
Example 4
T Cell Activation During Redirected Killing By ce-Optimized CD123 x
CD3 Bi-Specific Diabodies (DART-A, DART-A w/ABD and DART-A w/Fc)
The sequence-optimized CD123 X CD3 bi-specific diabodies exhibited a
potent redirected killing ability regardless of the presence or absence of ife
extension technology (DART-A versus DART-A w/ABD versus DART-A w/Fc) in
target cell lines with high CD123 expression, Kasumi-3, and medium, THP-l,
CD123-expression, (Figure 5, Panels A and B, respectively) To characterize T cell
activation during sequence-optimized CD123 X CD3 bi-specific diabody mediated
redirected killing process, T cells from redirected killing assays were stained for T
cell activation marker CD25 and analyzed by FACS. As shown in Figure 5, Panel D,
CD25 was up-regulated in CD8 T cells in a ependent manner indicating that
sequence-optimized CD123 X CD3 bi-specific diabodies induce T cell tion in
the process of redirected killing. Conversely, in the absence of target cells there is no
activation of CD8 T cells (Figure 5, Panel C) indicating the sequence-optimized
CD123 X CD3 bi-specific diabodies do not activate T cells in the absence of target
cells. se, CD8 T cells are not activated when ted with target cells and a
control bi-specific diabody (Control DART) (Figure 5, Panel D) indicating the
requirement of cross-linking the T cell and target cell with the sequence-optimized
CD123 X CD3 bi-specific diabodies.
Example 5
Intracellular Staining for me B and Perforin
To determine the intracellular levels of granzyme B and perforin in T cells, a
CTL assay was setup as described above. After approximately 18 h, cells from the
assay plate were stained with anti-CD4 and D8 antibodies by incubating for 30
minutes at 4°C. Following surface staining, cells were incubated in 100 uL fixation
and permeabilization buffer (BD ences) for 20 min at 4°C. Cells were washed
with permeabilization/wash buffer (BD BioSciences) and incubated in 50 uL of
granzyme B and a perforin antibody mixture (prepared in 1X permeabilization/wash
buffer) at 4°C for 30 minutes. Then cells were washed with 250 uL
permeabilization/wash buffer and resuspended in permeabilization/wash buffer for
FACS acquisition.
Upregulation Of Granzyme B And in By Sequence-Optimized CD123 x
CD3 Bi-Specific Diabody (DART-A) In T Cells During Redirected Killing
To igate the possible ism for ce-optimized CD123 X
CD3 bi-specific diabody (DART-A) mediated cytotoxicity by T cells, ellular
granzyme B and perforin levels were measured in T cells after the redirected killing.
Dose-dependent upregulation of granzyme B and perforin levels in both CD8 and
CD4 T cells was observed following incubation of T cells and Kasumi-3 cells with
DART-A (Figure 6, Panel A). Interestingly, the upregulation was almost two-fold
higher in CD8 T cells compared to CD4 T cells (Figure 6, Panel A). When the assay
was performed in the presence of granzyme B and in inhibitors no cell killing
was observed. There was no lation of me B or perforin in CD8 or CD4
T cells when T cells were incubated with Kasumi-3 target cells and a control bi-
specific diabody (Control DART) (Figure 5, Panel B). These data indicate that
DART-A mediated target cell killing may be mediated through granzyme B and
perforin isms.
Example 6
in vivo Antitumor Activity Of Sequence-Optimized CD123 x CD3 Bi-Specific
Diabody (DART-A)
Isolation of PBMCs and T Cells from Human Whole Blood
PBMCs from healthy human donors were isolated from whole blood by
using Ficoll nt centrifilgation. In brief, whole blood was diluted 1:1 with sterile
PBS. Thirty-five mL of the diluted blood was layered onto 15 mL Ficoll-PaqueTM
Plus in 50-mL tubes and the tubes were centrifuged at 1400 rpm for 20 min with the
brake off. The buffy coat layer between the two phases was collected into a 50 mL
tube and washed with 45 mL PBS by centrifuging the tubes at 600 x g (1620 rpm) for
min. The supernatant was discarded and the cell pellet was washed once with PBS
and viable cell count was determined by Trypan Blue dye exclusion. The PBMCs
were resuspended to a final concentration of 2.5x106 cells/mL in complete medium
(RPMI 1640, 10%FBS, 2 mM ine, 10mM HEPES, 100u/100u/mL
penicillin/Streptomycin (P/S).
T cell isolation: hed T cells were isolated by negative selection
from PBMCs from human whole blood using Dynabeads Untouched Human T Cell
isolation kit (Life logies) according to manufacturer’s instructions. After the
isolation, T cells were cultured overnight in RPMI medium with 10% PBS, 1%
penicillin/Streptomycin.
Tumor Model
Human T cells and tumor cells (Molm13 or RS4-11) were combined at a
ratio of 1:5 (1 x 106 and 5 x 106, respectively) and suspended in 200 uL of e
saline and injected subcutaneously (SC) on Study Day 0 (SDO). Sequence-optimized
CD123 X CD3 bi-specific diabody (DART-A) or a control bi-specific diabody
(Control DART) were administered enously (IV) via tail vein injections in 100
uL as outlined in Table 5 (MOLM13) and Table 6 (RS4-11).
Stud Desi_n for MOLM13 Model
Number of
Schedule Animals
Vehicle Control
(MOLM-13 cells alone implanted SDO, 1, 2, 3
or + T cells)
DART A 0 U1 SDO, 1, 2, 3
oo - HM SDO, 1, 2, 3
- SDO, 1, 2, 3
0-02 SDO, 1, 2, 3
SDO, 1, 2, 3
SDO, 1, 2, 3
DART-A 0.00016 SDO, 1, 2, 3
Table 6
Stud Desi_n for RS4-11 Model
Number of
Treatment Group Dose (mg/kg) Schedule Animals
Vehicle Control
SDO, 1, 2, 3
(RS4-11 cells alone implanted)
—_-—Vehicle l SDO, 1, 2, 3
(RS4-11 + T cells implanted)
Control DART SDO, 1, 2, 3
DART-A SDO, 1, 2, 3
———-_DART-A SDO, 1, 2, 3
———-_DART-A SDO, 1, 2, 3
ART-A SDO, 1, 2, 3
———-_DART-A SDO, 1, 2, 3
Data Collection and tical Analysis:
Animal weights - Individual animal weights were recorded twice weekly
until study completion beginning at the time of tumor cell ion.
Moribundity/Mortality - Animals were observed twice weekly for general
moribundity and daily for mortality. Animal deaths were assessed as elated or
technical based on factors including gross observation and weight loss; animal deaths
were recorded daily.
Tumor volume - Individual tumor volumes were recorded twice weekly
beginning within one week of tumor implantation and continuing until study
tion.
Length (mm)><width2
Tumor Volume (mm3) =
Animals experiencing technical or drug-related deaths were censored from
the data calculations.
Tumor growth inhibition - Tumor growth inhibition (TGI) values were
calculated for each group containing treated animals using the formula:
_Mean Final Tumor Volume (Treated) - Mean Initial Tumor Volume (Treated)x 1 100
Mean Final Tumor Volume (Control) - Mean Initial Tumor Volume (Control)
Animals experiencing a partial or complete response, or animals
experiencing technical or elated deaths were censored from the TGI
calculations. The National Cancer Institute criteria for compound activity is
TGI>58% (Corbett et al. (2004) Anticancer Drug Development Guide; Totowa, NJ:
Humana 99-123).
Partial/Complete Tumor Response - Individual mice possessing tumors
measuring less than 1mm3 on Day 1 were fied as having partial response (PR)
and a percent tumor regression (%TR) value was determined using the formula:
Final Tumor Volume (mm3)
1- X’IOO%
Initial Tumor Volume (mm3)
Individual mice lacking palpable tumors were classified as undergoing a
te response (CR).
Tumor Volume Statistics — Statistical analyses were carried out between
treated and control groups ing tumor volumes. For these analyses, a y
analyses of variance followed by a roni post-test were employed. All analyses
were performed using GraphPad PRISM® software (version 5.02). Weight and tumor
data from individual animals experiencing technical or drug-related deaths were
censored from analysis. However, tumor data from animals reporting l or
complete responses were included in these calculations.
MOLM13 Results
The AML cell line MOLM13 was pre-mixed with activated T cells and
implanted SC in NOD/SCID gamma (NSG) knockout mice (N = 8/group) on SDO as
ed above. The MOLM13 tumors in the vehicle-treated group (MOLM13 cells
alone or plus T cells) demonstrated a relatively aggressive growth profile in vivo
(Figure 7, Panels A and B). At SD8, the e volume of the tumors in the
vehicle-treated group was 129.8 :: 29.5 mm3 and by SD15 the tumors had reached an
average volume of 786.4 :: 156.7 mm3. By the end of the experiment on SD18, the
tumors had reached an average volume of 1398.8 :: 236.9 mm3.
ent with DART-A was initiated on the same day the tumor cell/T cell
mixture was implanted [(SDO)] and proceeded subsequently with daily injections for
an additional 7 days for a total of 8 daily injections. The animals were treated with
DART-A at 9 dose levels (0.5, 0.2, 0.1, 0.02, and 0.004 mg/kg and 20, 4, 0.8 and 0.16
). Results are shown in Figure 7, Panel A (0.5, 0.2, 0.1, 0.02, and 0.004 mg/kg)
and Figure 7, Panel B (20, 4, 0.8 and 0.16 ug/kg). By Study Day 11, the growth of
the MOLM13 tumors was significantly inhibited at the 0.16, 0.5, 0.2, 0.1, 0.02, and
0.004 mg/kg dose levels (p < 0.001). Moreover, the treatment of the MOLM13
tumor-bearing mice at the 20 and 4 [Lg/kg dose levels resulted in 8/8 and 7/8 CRs,
respectively. By the end of the ment on SD18, the average volume of the
tumors d with DART-A at the 0.8 — 20 ug/kg) ranged from 713.60 :: 267.4 to 0
mm3, all of which were cantly smaller than the tumors in the vehicle-treated
control group. The TGI values were 100, 94, and 49% for the 20, 4, and 0.8 [Lg/kg
dose groups, respectively. In comparison to the vehicle-treated MOLM13 tumor cell
group, the groups that received DART-A at the 20 and 4 [Lg/kg dose level d
statistical significance by SD15 while the group treated with 0.8 [Lg/kg reached
significance on SD18.
RS4-11 Results
The ALL cell line RS4-11 was pre-mixed with activated T cells and
implanted SC in NOD/SCID gamma knockout mice (N = p) on SDO as detailed
above. The RS4-11 tumors in the vehicle-treated group (RS4-11 cells alone or plus T
cells) demonstrated a relatively aggressive growth profile in vivo (Figure 8).
Treatment with DART-A was initiated on the same day the tumor cell/T cell
mixture was implanted [(SDO)] and proceeded subsequently with daily injections for
an additional 3 days for a total of 4 daily injections. The animals were treated with
DART-A at 5 dose levels (0.5, 0.2, 0.1, 0.02, and 0.004 mg/kg). Results are shown in
Figure 8.
Sequence-optimized CD123 X CD3 bi-specific diabody (DART-A)
ively inhibited the growth of both MOLM13 AML and RS4-11ALL tumors
implanted SC in NOD/SCID mice in the context of the Winn model when dosing was
initiated on the day of implantation and continued for 3 or more consecutive days.
Based on the criteria established by the National Cancer Institute, DART-A at the 0.1
mg/kg dose level and higher (TGI >58) is considered active in the RS4-ll model and
an DART-A dose of 0.004 mg/kg and higher was active in the MOLMl3 model. The
lower DART-A doses associated with the inhibition of tumor growth in the MOLMl3
model compared with the RS4-ll model are consistent with the in vitro data
demonstrating that MOLMl3 cells have a higher level of CD123 expression than
RS4-ll cells, which correlated with increased sensitivity to DART-A mediated
cytotoxicity in vitro in MOLMl3 cells.
Should it be necessary to ate this example it will be appreciated that
one of skill in the art may, within reasonable and acceptable limits, vary the above-
described protocol in a manner appropriate for replicating the described results. Thus,
the ified protocol is not ed to be adhered to in a precisely rigid manner.
Example 7
CD123 Surface Expression On Leukemic Blast Cells And Stem Cells In Primary
Tissue Sample From AML Patient 1
] To define the CD123 expression pattern in AML patient 1 y samples,
cryopreserved primary AML patient bone marrow and PBMC s were ted
for CD123 surface expression on leukemic blast cells.
AML Bone Marrow Sample — Clinical Report
Age: 42
Gender: Female
AML Subtype: M2
Cancer cell percentage based on morphology: 67.5%
Bone marrow immunophenotyping:
CDlS=l9%, CD33=98.5%, CD38=28.8%, CD45=81.8%, CD64=39.7%,
CDl l7=42.9%, HLA-DR=l7%, CD2=l.8%, CD5=0.53%, CD7=0.2%,
CD10=0.4l%, CDl9=l.l%, CD20=l.4%, CD22=0.7l% CD34=0.82%
CD123 Expression in Leukemic Blast Cells in Bone Marrow Mononucleocytes
(BM MNC)
A total of 0.5x106 bone marrow mononucleocytes (BM MNC) and peripheral
blood mononucleocytes (PBMC)) from AML patient 1 were evaluated for CD123
expression. The Kasumi-3 cell line was included as a control. ic blast cells
were identified using the myeloid marker CD33. As shown in Figure 9, Panel A,
87% of the cells fiom AML bone marrow fiom patient 1 expressed CD123 and CD33.
CD123 expression levels were slightly lower than the CD123 high-expressing
Kasumi-3 AML cell line (Figure 9, Panel B).
Example 8
Autologous CTL Killing Assay Using AML Patient Primary Specimens
] Cryopreserved primary AML specimen (bone marrow mononucleocytes
(BMNC) and peripheral blood mononucleocytes (PBMC)) from AML patient 1 were
thawed in RPMI 1640 with 10% FBS and allowed to recover overnight at 37°C in 5%
C02. Cells were washed with assay medium (RPMI l640+lO%FBS) and viable cell
count was determined by Trypan Blue exclusion. 150,000 cells / well in 150 uL assay
medium were added to 96-well U-bottom plate (BD Biosciences). Sequence-
optimized CD123 X CD3 bi-specific diabody (DART-A) was diluted to 0.1, and 0.01
ng/mL and 50 uL of each dilution was added to each well (final volume = 200 uL).
l bi-specific diabody (Control DART) was diluted to 0.1 ng/mL and 50 uL of
each dilution was added to each well (final volume = 200 uL). A separate assay plate
was set up for each time point (48, 72, 120 and 144 hours) and plates were incubated
at 37 0C in a 5% C02 incubator. At each time point, cells were d with CD4,
CD8, CD25, CD45, CD33, and CD123 antibodies. d cells were ed in
FACS Calibur flow cytometer equipped with est Pro acquisition software,
n 5.2.1 (BD Biosciences). Data analysis was performed using Flowjo v9.3.3
re (Treestar, Inc).T cell expansion was measured by gating on CD4+ and CD8+
populations and activation was determined by measuring CD25 mean fluorescent
intensity (MFI) on the CD4+ and CD8+ -gated populations. Leukemic blast cell
population was identified by CD45+CD33+ gating.
Autologous Tumor Cell Depletion, T Cell ion And tion By
Sequence-Optimized CD123 x CD3 Bi-Specific Diabody (DART-A) In Primary
Specimens From AML Patient 1
To ine the sequence-optmized CD123 X CD3 bi-speciflc diabody
(DART-A) mediated ty in AML patient 1, patient samples were incubated with
0.1 ng/mL or 0.01 ng/mL of DART-A and percentages of leukemic blast cells and T
cells were measured at different time points following the treatment. Leukemic blast
cells were identified by CD45+/CD33+ . Incubation of primary AML bone
marrow samples with DART-A resulted in depletion of the leukemic cell population
over time (Figure 10, Panel A), accompanied by a concomitant expansion of the
residual T cells (Figure 10, Panel B) and the induction of T cell activation markers
(Figure 10, Panel C). In DART-A treated samples, T cells were expanded from
around 7 % to around 80% by 120 hours. T cell activation measured by CD25
expression on CD4 and CD8 cells peaked at 72 h and decreased by the 120 h
timepoint.
Should it be necessary to replicate this example it will be appreciated that
one of skill in the art may, within reasonable and able limits, vary the above-
described ol in a manner riate for replicating the described results. Thus,
the exemplified protocol is not intended to be d to in a precisely rigid manner.
Example 9
CD123 Surface Expression On Leukemic Blast Cells And Stem Cells In Primary
Tissue Sample From ALL Patient
To define the CD123 expression pattern in ALL patient primary samples,
cryopreserved y ALL patient PBMC sample was evaluated for CD123 surface
expression on leukemic blast cells.
CD123 Expression in Leukemic Blast Cells in Peripheral Blood Mononucleocytes
(PBMC)
A total of 0.5xlO6 peripheral blood mononucleocytes (PBMC)) from a
healthy donor and an ALL patient were ted for CD123 expression. As shown in
Figure 11, Panels E-H, the vast majority of the cells from ALL bone marrow
expressed CD123. Conversely, as expected in the normal donor B cells are CD123
negative and pDCs and monocytes are CD123 positive (Figure 11, Panel D).
The T cell population was fied in the ALL patent sample by staining
the cells for CD4 and CD8. As shown in Figure 12, Panel B, only a small fraction of
the total PBMCs in the ALL patient sample are T cells (approximately 0.5% are CD4
T cells and approximately 0.4% are CD8 T cells.
Example 10
Autologous CTL Killing Assay Using ALL Patient Primary Specimens
Cryopreserved primary ALL en (peripheral blood mononucleocytes
(PBMC)) were thawed in RPM 11640 with 10% FBS and allowed to recover
overnight at 37°C in 5% C02. Cells were washed with assay medium (RPMI
1640+10%FBS) and viable cell count was ined by Trypan Blue exclusion.
150,000 cells / well in 150 uL assay medium were added to 96-well U-bottom plate
(BD Biosciences). Sequence-optimized CD123 X CD3 bi-specific diabody (DART-A)
was diluted to 10, 1 ng/mL and 50 ML of each dilution was added to each well (final
volume = 200 uL). A separate assay plate was set up for each time point (48, 72, 120
and 144 hours) and plates were incubated at 37 0C in a 5% C02 incubator. At each
time point, cells were stained with CD4, CD8, CD25, CD45, CD33, and CD123
antibodies. Labeled cells were analyzed in FACS Calibur flow cytometer equipped
with CellQuest Pro acquisition software, n 5.2.1 (BD Biosciences). Data
analysis was performed using Flowjo v9.3.3 software (Treestar, Inc).T cell expansion
was measured by gating on CD4+ and CD8+ populations and tion was
determined by measuring CD25 MFI on the CD4+ and CD8+ -gated populations.
Leukemic blast cell tion was identified by CD45+CD33+ .
Autologous Tumor Cell ion, T Cell Expansion And Activation By
Sequence-Optimized CD123 x CD3 Bi-Specific Diabody (DART-A) In Primary
Specimens From ALL Patients
] To determine the sequence-optimized CD123 X CD3 bi-speciflc diabody
(DART-A) mediated activity in ALL patient primary patient samples, patient samples
were ted with 1 ng/mL of DART-A and percentages of leukemic blast cells and
T cells were measured at different time points following the treatment. Leukemic
blast cells were identified by CD45+/CD33+ gating. Incubation of primary ALL bone
marrow samples with DART-A resulted in depletion of the leukemic cell population
over time compared to untreated control or Control DART (Figure 13, Panel H
versus Panels F and G). When the T cells were counted (CD8 and CD4 staining)
and activation (CD25 staining) were assayed, the T cells ed and were activated
in the DART-A sample (Figure 14, Panels I and L, respectively) compared to
untreated or Control DART samples (Figure 14, Panels H, G, K and J, respectively).
Example 11
CD123 Surface Expression On Leukemic Blast Cells And Stem Cells In Primary
Tissue Sample From AML t 2
To define the CD123 expression pattern in AML t 2 primary samples,
cryopreserved primary AML patient bone marrow and PBMC samples were evaluated
for CD123 e expression on leukemic blast cells.
CD123 Expression in Leukemic Blast Cells in Bone Marrow Mononucleocytes
(BMNC)
A total of 0.5x106 bone marrow mononucleocytes (BM MNC) and peripheral
blood mononucleocytes (PBMC)) from an AML patient 2 were ted for
leukemic blast cell identification. Leukemic blast cells were identified using the
myeloid s CD33 and CD45. As shown in Figure 15, Panel B, 94% of the cells
from AML bone marrow are leukemic blast cells. The T cell population was
identified by CD3 expression. As shown in Figure 15, Panel C, approximately 15%
of the cell from the AML bone marrow and PBMC sample are T cells.
Example 12
Autologous CTL Killing Assay Using AML Patient 2 Primary Specimens
Cryopreserved y AML specimen (bone marrow mononucleocytes
(BM MNC) and peripheral blood mononucleocytes (PBMC)) from AML t 2
were thawed in RPMI 1640 with 10% FBS and allowed to recover overnight at 37°C
in 5% C02. Cells were washed with assay medium (RPMI 1640+10%FBS) and
viable cell count was determined by Trypan Blue exclusion. 150,000 cells / well in
150 uL assay medium were added to 96-well U-bottom plate (BD ences).
Sequence-optimized CD123 X CD3 cific diabody (DART-A) and control bi-
specific diabody (Control DART) were diluted to 0.1, and 0.01 ng/mL and 50 uL of
each dilution was added to each well (final volume = 200 uL). A separate assay plate
was set up for each time point (48, 72, 120 and 144 hours) and plates were incubated
at 37 0C in a 5% C02 incubator. At each time point, cells were stained with CD4,
CD8, CD25, CD45, CD33, and CD123 antibodies. Labeled cells were analyzed in
FACS Calibur flow cytometer equipped with est Pro acquisition software,
Version 5.2.1 (BD Biosciences). Data analysis was med using Flowjo v9.3.3
software (Treestar, Inc). T cell expansion was measured by gating on CD4+ and
CD8-- tions and activation was determined by measuring CD25 MFI on the
CD4-- and CD8+ -gated populations. Leukemic blast cell population was identified
by CD45+CD33+ gating.
Autologous Tumor Cell Depletion, T Cell Expansion and Activation in Primary
Specimens from AML Patient 2
To determine the sequence-optimized CD123 X CD3 bi-specific diabody
(DART-A) mediated activity in AML patient primary patient 2 samples, t
samples were incubated with 0.1 or 0.01 ng/mL of DART-A and percentages of
ic blast cells and T cells were measured at different time points following the
treatment. Incubation of primary AML bone marrow samples with DART-A resulted
in ion of the leukemic cell population over time (Figure 16, Panel A),
accompanied by a concomitant expansion of the residual T cells (both CD4 and CD8)
(Figure 16, Panel B and Figure 16, Panel C, respectively). To determine if the T
cells were ted, cells were stained for CD25 or Ki-67, both markers of T cell
activation. As shown in Figure 17, Panels A and B, incubation of y AML
bone marrow samples with DART-A resulted in T cell activation. These data
represent the 144h time point.
Intracellular Staining for me B and Perforin
To determine the ellular levels of granzyme B and Perforin in T cells,
CTL assay was setup. After approximately 18 h, cells from the assay plate were
stained with anti-CD4 and anti-CD8 antibodies by incubating for 30 minutes at 4 °C.
Following surface ng, cells were incubated in 100 ul Fixation and
Permeabilization buffer for 20 min at 4 °C. Cells were washed with
permeabilization/wash buffer and incubated in 50 ul of granzyme B and perforin
antibody mixture prepared in 1X Perm/Wash buffer at 4 C for 30 minutes. Then cells
were washed with 250 ul Perm/Wash buffer and resuspended in Perm/Wash buffer for
FACS acquisition.
Upregulation Of Granzyme B And Perforin By Sequence-Optimized CD123 x
CD3 Bi-Specific Diabody A) In T Cells During Redirected Killing.
To investigate the possible mechanism for sequence-optimized CD123 X
CD3 bi-specific diabody A) mediated cytotoxicity by T cells, intracellular
granzyme B and perforin levels were measured in T cells after the cted killing.
There was no upregulation of me B and perforin when T cells were incubated
with control bi-specific diabody (Control DART). Upregulation of granzyme B and
perforin levels in both CD8 and CD4 T cells was observed with ce-optimized
CD123 X CD3 bi-specific diabody (DART-A) e 17, Panels C and D).
Interestingly, the upregulation was almost two-fold higher in CD8 T cells compared
to CD4 T cells e 17, Panel C and Figure 17, Panel D). These data indicate that
DART-A-mediated target cell killing was mediated through granzyme B and perforin
pathway.
Example 13
Sequence-Optimized CD123 x CD3 Bi-Specific Diabody Cross-Reacts With Non-
Human Primate CD123 And CD3 Proteins.
In order to quantitate the extent of binding between sequence-optimized
CD123 X CD3 bi-specific diabody (DART-A) and human or cynomolgus monkey
CD3, BIACORETM analyses were conducted. BIACORETM analyses measure the
iation off-rate, kd. The binding affinity (KD) between an antibody and its
target is a function of the kinetic constants for association (on rate, ka) and
dissociation (off-rate, kd) according to the formula: KD = [kd]/[ka]. The BIACORETM
analysis uses surface plasmon resonance to directly measure these kinetic parameters.
Recombinant human or cynomolgus monkey CD3 was directly immobilized to a
support. Purified human or lgus monkey CD123 was ed and
immolbilized to a support. The time course of dissociation was measured and a
bivalent fit of the data ted. Binding constants and affinity were obtained using
a 1:1 binding fit. The s of the BIACORETM es comparing binding to
human versus cynomologus monkey CD123 and CD3 proteins are shown in Figure
18. Binding affinities to the cynomolgus monkey CD123 (Figure 18D) and CD3
(Figure 18B) ns is comparable to binding affinities for human CD123 (Figure
18C) and CD3 (Figure 18A) proteins.
Example 14
Autologus Monocyte Depletion In Vitro With Human And Cynomolgus Monkey
PBMCs
PBMCs from human or cynomolgus monkey whole blood samples were
added to U-bottom plates at cell y of 200,000 well in 150 uL of assay
medium. Dilutions of sequence-optimized CD123 X CD3 bi-specific diabodies
(DART-A or DART-A w/ABD) were prepared in assay medium. 50 [LL of each
DART-A or DART-A w/ABD dilution was added to the plate containing PBMCs in
duplicate wells. The plates were incubated for ~ 18 - 24 h at 37°C. Supematants were
used to determine the cytotoxicity as described above. As shown in Figure 19
(Panels A and B), ion of pDCs cells was observed in both human (Figure 19,
Panel A) and cynomolgus monkey PBMCs (Figure 19, Panel B). These results
indicate that ating pDC can be used as a pharmacodynamic marker for
preclinical toxicology studies in cynomolgus monkeys.
] Should it be necessary to replicate this example it will be appreciated that
one of skill in the art may, within reasonable and acceptable limits, vary the above-
described protocol in a manner appropriate for replicating the described results. Thus,
the exemplified protocol is not intended to be adhered to in a precisely rigid manner.
Example 15
cytoid Dendritic Cell Depletion In Cynomolgus Monkeys Treated With
Sequence-Optimized CD123 x CD3 Bi-Specific Diabody (DART-A)
As part of a dose-range finding toxicology study, cynomolgus monkeys were
administered sequence-optimized CD123 X CD3 bi-specific diabody (DART-A) as 4-
day infusions at doses of 0.1, 1, 10, 30 100, 300, or 1000 ng/kg .
The Control DART
was administered at 100 ng/kg. To fy pDCs and te populations in
cynomolgus monkey PBMCs, cells were labeled with CD14-FITC antibody.
tes were fied as the CD14+ population and pDCs were identified as the
CDl4'CD123+ population. As shown in Figure 20 Panels K and L, the pDCs were
depleted as early as 4 days post infusion with as little as 10 ng/kg DART-A. No pDC
depletion was seen in the control bi-specif1c diabody-(Control DART) treated
monkeys or the vehicle + carrier-treated monkeys at the 4d time point (Figure 20,
Panels G, H, C and D, respectively). Cytokine levels of interferon-gamma,TNF-
alpha, 1L6, 1L5, 1L4 and IL2 were ined at 4 hours after infilsion. There was
little to no elevation in cytokine levels at the DART-A treated animals compared to
l DART or vehicle-treated animals.
Figure 21 and Figure 22 provide the results of the FACS analysis for B cells
(CD20+) (Figure 21, Panel A), monocytes ) (Figure 21, Panel B), NK cells
(CD159+CD16+) (Figure 21, Panel C), pDC (CD123HI, CD14) (Figure 21, Panel
D), and T cells (total, CD4+, and CD8+) (Figure 22, Panel A, Figure 22, Panel B,
and Figure 22, Panel D, respectively).
] Treatment of monkeys with Control DART had no noticeable effects on T or
B lymphocytes, NK cells, tes and pDCs. ent of monkeys with DART-
A at doses of 10 ng/kg/d or higher resulted in the abrogation of pDCs (Figure 21,
Panel D). The depletion of pDC was complete and e, returning to pre-dose
levels several weeks after completion of dosing. Circulating levels of T lymphocytes
decreased upon DART-A administration, but returned to pre-dose level by the end of
each weekly cycle, suggesting changes in trafficking rather than true depletion. Both
CD4 and CD8 T lymphocytes followed the same pattern. The T-lymphocyte
tion marker, CD69 (Figure 22, Panel C), was only marginally positive among
circulating cells and did not track with DART-A . B lymphocytes, monocytes
and NK cells fluctuated over the course of DART-A dosing with substantial
variability observed among monkeys. A trend toward increased circulating levels of
B cytes and monocytes was observed in both monkeys at the highest doses.
In summary, the above results trate the therapeutic efficacy of the
sequence-optimized CD123 X CD3 cif1c diabody (DART-A). The sequence-
optimized CD123 X CD3 bi-specif1c diabody (DART-A) may be employed as a
therapeutic agent for the treatment of multiple diseases and conditions, including:
AML, ABL (ALL), CLL, MDS, pDCL, mantel cell leukemia, hairy cell leukemia,
Ricter transformation of CLL, Blastic crisis of CML, BLL (subset are CD123+) (see
Example 2); Autoimmune Lupus (SLE), allergy (basophils are CD123+), asthma, etc.
Example 16
Comparative ties of ce-Optimized CD123 x CD3 Bi-Specific
Diabody (DART-A) and Non-Sequence-Optimized CD123 xCD3 cific
Diabody (DART-B)
Unexpected Advantage and Attributes of the Sequence-Optimized
CD123 x CD3 cific Diabodies
As discussed above, DART-A and DART-B are similarly designed and the
first polypeptide of both constructs comprise, in the N—terminal to inal
direction, an N—terminus, a VL domain of a monoclonal antibody capable of binding
to CD3 ), an intervening linker e (Linker l), a VH domain of a
monoclonal antibody capable of binding to CD123 ), a Linker 2, an E-coil
Domain, and a C-terminus. Likewise, the second polypeptide of both constructs
comprise, in the N—terminal to C-terminal direction, an inus, a VL domain of a
monoclonal antibody capable of binding to CD123 (VLCDm), an intervening linker
peptide (Linker l), a VH domain of a monoclonal antibody capable of binding to CD3
(VHCDg), a Linker 2, a K-coil Domain and a C-terminus.
As indicated in Example 1, both CD123 X CD3 bi-specific diabodies were
found to be capable of simultaneously binding to CD3 and CD123. Additionally, as
disclosed in Example 3 and in Figure 4, Panels C and D, the two CD123 X CD3 bi-
specific diabodies exhibited a potent cted killing ability with concentrations
required to achieve 50% of maximal activity (ECSOs) in sub-ng/mL range, regardless
of CD3 epitope binding city (DART-A versus DART-B) in target cell lines
with high CD123 expression. Thus, slight variations in the specific sequences of the
CD123 X CD3 bi-specific diabodies do not completely abrogate biological activity.
However, in all cell lines tested, DART-A was found to be more active and
more potent at redirected killing than DART-B (see, e.g., Figure 4, Panels A, C, and
D). Thus DART-A ted an unexpected advantage over similar DART-B.
Example 17
Non-Human Primate Pharmacology of DART-A for the Treatment of
Hematological Malignancies
] The interleukin 3 (IL-3) receptor alpha chain, CD123, is overexpressed on
malignant cells in a wide range of hematological malignancies (Munoz, L. et al.
(2001) “Interleukin-3 Receptor Alpha Chain (CD123) Is Widely Expressed In
Hematologic Malignancies,” Haematologica 86:1261-1269; Testa, U. et al. (2014)
“CD123 Is A Membrane Biomarker And A Therapeutic Target In Hematologic
Malignancies,” Biomark. Res. 2:4) and is associated with poor prognosis (Vergez, F.
et al. (2011) “High Levels 0fCD34+CD38low/—CDI23+ Blasts Are Predictive OfAn
Adverse Outcome In Acute Myeloid Leukemia: A Groupe Ouest-Est Des Leucemies
Aigues Et Maladies Du Sang (GOELAMS) Study,” Haematologica 96:1792-1798).
Moreover, CD123 has been reported to be expressed by leukemia stem cells (LSC)
(Jordan, C.T. et al. (2000) “The eukin-3 Receptor Alpha Chain Is A Unique
Marker For Human Acute Myelogenous Leukemia Stem Cells,” Leukemia 14:1777-
1784; Jin, L. et al. (2009) “Monoclonal Antibody-Mediated Targeting 0fCD123, IL-3
Receptor Alpha Chain, Eliminates Human Acute Myeloid Leukemic Stem ” Cell
Stem Cell 2), which is an attractive feature that s targeting the root cause
of such es. Consistent with this conclusion, CD123 also takes part in an lL-3
autocrine loop that sustains leukemogenesis, as shown by the ability of a CD123-
blocking monoclonal antibody to reduce ic stem cell tment and improve
survival in a mouse model of acute myelogenous leukemia (AML) (Jin, L. et al.
(2009) “Monoclonal Antibody-Mediated Targeting 0f CD123, IL-3 Receptor Alpha
Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells,” Cell Stem Cell 5:31-
42). In a phase 1 study in high-risk AML patients, however, the monoclonal antibody
exhibited no anti-leukemic activity (Roberts, A. W. et al. (2010) “A Phase I Study Of
Anti-CD123 Monoclonal dy (mAb) CSL360 ing ia Stem Cells
(LSC) In AML,” J. Clin. Oncol. 28(Suppl):e13012). Thus, alternate CD123-targeting
approaches, including depleting strategies are desired. Although CD123 is expressed
by a subset of normal hematopoietic progenitor cells (HPC), hematopoietic stem cells
(HSC) express little to no CD123 (Jordan, C.T. et al. (2000) “The eukin-3
Receptor Alpha Chain Is A Unique Marker For Human Acute Myelogenous Leukemia
Stem Cells,” Leukemia 14:1777-1784; Jin, W. et al. (2009) “Regulation 0fThI7 Cell
Difi’erentiation And EAE Induction By MAP3K NI ,” Blood 113:6603-6610),
indicating that CD123 cell-depleting strategies allow reconstitution via normal
hematopoiesis.
] ng a patient’s own T lymphocytes to target leukemic cells ents a
promising immunotherapeutic strategy for the treatment of hematological
malignancies. The therapeutic potential of this approach has been ted using
blinatumomab (a cific antibody-based BiTE having the ability to bond CD3 and
the B cell CD19 antigen) in patients with B cell lymphomas and B-precursor acute
lymphoblastic leukemia (Klinger, M. et al. (2012) “Immunopharmacologic Response
0fPatients With B-Lineage Acute blastic Leukemia To Continuous Infusion
Of T Cell-Engaging CD19/CD3-Bispecific BiTE Antibody umomab,” Blood
119:6226-6233; Topp, M.S. et al. (2012) “Long-Term Follow-Up 0f Hematologic
Relapse-Free al In A Phase 2 Study OfBlinatumomab In Patients With MRD In
B-Lineage ALL,” Blood 120:5185-5187; Topp, M.S. et al. (2011) “Targeted Therapy
With The T-Cell—Engaging Antibody Blinatumomab 0f Chemotherapy-Refractory
Minimal Residual Disease In age Acute blastic Leukemia Patients
Results In High Response Rate And ged Leukemia-Free Survival,” J. Clin.
Oncol. 29:2493-2498).
The CD123 X CD3 bi-specif1c diabody molecules of the present invention,
such as , comprise an alternate bi-specific, antibody-based modality that
offers improved stability and more robust manufacturability properties (Johnson, S. et
al. (2010) “Eflector Cell Recruitment With Novel Fv-Based Dual-Afiinity Re-
Targeting Protein Leads To Potent Tumor Cytolysis And In Vivo B-Cell Depletion,” J.
Mol. Biol. 399:436-449; Moore, RA. et al. (2011) “Application Of Dual Afiinity
Retargeting les To Achieve Optimal Redirected T—Cell Killing 0f B-Cell
Lymphoma,” Blood 117:4542-4551).
In order to demonstrate the superiority and effectiveness of the CD123 X
CD3 bi-specif1c diabody molecules of the present invention, the biological activity of
the above-described DART-A in in vitro and preclinical models of leukemia was
confirmed, and its pharmacokinetics, pharmacodynamics and safety pharmacology in
cynomolgus macaques (Macaca ularis) was assessed relative to either the
above-described Control DART (bi-specific for CD3 and cein) or a “Control
DART-2” that was bi-specific for CD123 and fluorescein).
Amino Acid Sequence of First Polypeptide Chain of ol DART-2”
(CD123VL — Linker — 4-4420VH — Linker — E-coil; linkers are ined)
(SEQ ID NO:58):
SPDS LAVSLGLRVT MSCKSSQSLL NSGNQKVYLT WYQQKPGQPP
{LLT YWASTR LSGVPDRFSG SGSGTDFTTT SSTQAmDVA VYYCQWDYSY
RYTFGQGT<L m {GGGSGGG GL'VKTDL'TGG GLVQRGRRMK LSCVASGFTF
SDYWMNWV<Q SRLKGTLWVA Q_TRNKRYNY_E TYYSDSV<GR FTTSRDDSKS
SVYLQMNWL< VfiDMG YYCT GSYYG DYWG QGTSVTVSSG GCGGGLVAAL
fi<fiVAALfi<fi VAALmeVAA LTK
Amino Acid ce of Second Polypeptide Chain of “Control DART-2”
(4420VL — Linker— CD123VH — Linker — ) (SEQ ID NO:59):
DVVMTQTRFS LPVSLGDQAS T_SCRSSQSLV HSNGNTYLRW YLQKPGQSPK
VLT_YKVSNRF SGVPDRFSGS GSGTDb'TTK SRVL'ALDTGV YFCSQSTHVP
WTFGGGT<Lm KGGGSGGGG LVQLVQSGA_E LKKRGASVKV SC<ASGYTFT
DYYMKWVRQA PGQGTL'W GD RSWGATFY NQKh'KG{VT_ TVDKSTSTAY
mLSSLRSfiD TAVYYCARSd LLRASWFAYW GQGTLVTVSS GGCGGGKVAA
L<LKVAAL<L KVAAL<LKVA AL<L
Bifunctional ELISA
A rp ELISA plate (Nunc) coated overnight with the soluble human or
cynomolgus IL3R—alpha (0.5 ug/mL) in bicarbonate buffer was blocked with 0.5%
BSA; 0.1% Tween-20 in PBS (PBST/BSA) for 30 minutes at room temperature.
DART-A molecules were applied, followed by the sequential on of human
CD388—biotin and Streptavidin HRP (Jackson ImmunoResearch). HRP activity was
detected by conversion of tetramethylbenzidine (BioFX) as substrate for 5 min; the
reaction was ated with 40uL/well of 1% H2S04 and the absorbance read at 450
Surface Plasmon Resonance Analysis
The ability of DART-A to bind to human and cynomolgus monkey CD3 or
CD123 proteins was analyzed using a BIAcore 3000 biosensor (GE, Healthcare) as
described by Johnson, S. et al. (2010) ctor Cell Recruitment With Novel Fv-
Based Dual-Afiinity Re-Targeting n Leads T0 Patent Tumor Cytolysis And In
Vivo B-Cell Depletion,” J. Mol. Biol. 6-449) and Moore, RA. et al. (2011)
(“Application OfDual Afiinity Retargeting Molecules To Achieve Optimal Redirected
T-Cell Killing OfB-Cell Lymphoma,” Blood 42-4551). Briefly, the carboxyl
groups on the CM5 sensor chip were activated with an injection of 0.2M N-ethyl-N-
(3dietylamino-propyl) carbodiimide and 0.05M N—hydroxy-succinimide. Soluble
CD3 or CD123 (1 ug/ml) was injected over the ted CM5 e in 10mM
sodium-acetate, pH 5.0, at flow rate 5 uL/min, followed by 1 M ethanolamine for
vation. Binding ments were performed in 10mM HEPES, pH 7.4,
150mM NaCl, 3mM EDTA and 0.005% P20 surfactant. Regeneration of the
immobilized receptor surfaces was performed by pulse injection of 10mM glycine, pH
1.5. KD values were determined by a global fit of binding curves to the Langmuir 1:1
binding model (BIAevaluation software v4.1).
Cell Killing Assay
Cell lines used for cell killing assays were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA). PBMCs were isolated from healthy
donor blood using the Ficoll-Paque Plus kit (GE Healthcare); T cells were purified
with a negative ion kit (Life Technologies). CD123 cell-surface density was
determined using Quantum Simply Cellular beads (Bangs Laboratories, Inc., Fishers,
IN). Cytotoxicity assays were performed as bed by Moore, PA. et al. (2011)
(“Application OfDual Afiinity Retargeting Molecules To Achieve Optimal cted
T-Cell Killing 0f B-Cell Lymphoma,” Blood 117:4542-4551). Briefly, target cell
lines (105 cells/mL) were treated with serial dilutions of DART-A or Control DART
proteins in the presence of T cells at the indicated effector cells:target cells ratios and
incubated at 37°C overnight. Cell killing was determined as the release of lactate
dehydrogenase (LDH, Promega) in culture supernatant. For flow-based killing, target
cells were labeled with CMTMR (Life Technologies) and cell killing was monitored
using a libur flow cytometer. Data were analyzed by using PRISM® 5
software (GraphPad) and presented as percent cytotoxicity.
Cynomolgus Monkey Pharmacology
Non-human primate ments were performed at Charles River
Laboratories (Reno, NV), according to the guidelines of the local Institutional Animal
Care and Use Committee (IACUC). Purpose-bred, na'ive cynomolgus monkeys
a fascicularz’s) of Chinese origin (age range 2.5-9 years, weight range of 2.7-5
kg) were provided with vehicle or DART-A via intravenous infilsion through femoral
and r ports using battery-powered programmable infusion pumps (CADD-
Legacy®, SIMS Deltec, Inc., St. Paul, MN). Peripheral blood or bone marrow
samples were collected in anticoagulant containing tubes at the indicated time points.
Cell-surface phenotype es were performed with an LSR Fortessa analyzer (BD
Biosciences) equipped with 488nm, 640nm and 405nm lasers and the following
antibodies: CD4-V450, 50, CD123-PE-Cy7, erCP, CD4-APC-H7,
CD8-FITC, CD25-PE-Cy7, CD69-PerCP, PD-l-PE, TIM3-APC, CD3-Pacif1c Blue,
CD95-APC, CD28-BV421, CDl6-FITC, CD3-Alexa488, CD38-PE, CD123-PE-Cy7,
CDll7-PerCP-Cy5.5, CD34-APC, CD90-BV421, CD45RA-APC -H7 and CD33-
APC (BD Biosciences). The absolute number of cells was ined using
TruCOUNT (BD Biosciences). Serum levels of IL-2, IL-4, IL-5, IL-6, TNF-u, and
IFN—y cytokines were measured with the Non-Human Primate Thl/Th2 Cytokine
Cytometric Bead Array Kit (BD Bioscience). The concentration of DART-A in
monkey serum samples was measured using a ch immunoassay with
electrochemiluminescence detection (MesoScale Diagnostics, MSD, Rockville, MD).
Briefly, the assay plate (MSD) was coated with recombinant human IL-3 Ra (R&D
) and blocked with 5 % BSA. Calibration standards or diluted test samples
were applied, followed by the on of a biotinylated monoclonal antibody
exhibiting specific binding for the above-described E-coil (SEQ ID NO:34) and K-
coil (SEQ ID NO:35) domains of the molecule A SULFO-TAGTM labeled
streptavidin conjugate (MSD) was added and the formation of complexes was
analyzed in an MSD SECTOR® imager. DART-A trations were determined
from standard curves generated by fitting light intensity data in a five-parameter
logistic model.
Physicochemical characterization of the purified DART-A demonstrated a
homogeneous heterodimer with a molecular mass of 58.9 kDa (Figure 23; Figures
24A-24B), which was stable at 2—8°C for up to 12 months in PBS. SPR analysis
demonstrated nearly identical binding affinities of DART-A to the corresponding
e human and cynomolgus monkey CD3 and CD123 antigens (Figures D
and Table 7). Furthermore, DART-A simultaneously bound both antigens in an
ELISA format that employed human or monkey CD123 for capture and human CD3
for detection (Figures 26A-26B), and trated similar binding to human and
monkey T lymphocytes (Figures 26C-26E). The data in Table 7 are averages of 3
independent experiments each performed in duplicates.
Table 7
Equilibrium Dissociation Constants (KD) for the g of DART-A to Human
and C nomol_us Monke CD3 and CD123
ka (i SD) k
d (:|: SD) K1) (1; SD)
Antigens -1 -1 -1
(M S ) (s )
Human CD3s/5 5.7 :0.6 x105 5.0 :09 x10"3
CynomolgusCD38/5
. :05 x105 5.0 :09 x10"3
Human CD123-His 1.6 :04 x106 1.9 :04 x10"4
CynomolgusCD123-His 1.5 :03 x106 4.0 :07 x10"4
DART-A Mediates Redirected Killing by Human 0r lgus Monkey T
Lymphocytes
DART-A mediated redirected target cell killing by human or monkey
effector cells against CD123+ Kasumi-3 leukemic cell lines (Figure 27A-27D),
which was accompanied by induction of activation s. No activity was
ed against CD123-negative targets (U937 cells) or with Control DART,
indicating that T cell tion is strictly dependent upon target cell engagement and
that monovalent engagement of CD3 by DART-A was insufficient to trigger T cell
activation. Since CD123 is expressed by subsets of normal circulating leukocytes,
including pDCs and monocytes (Figure 27E), the effect of DART-A were filrther
investigated in normal human and monkey’s PBMCs.
A graded effect was observed among human PBMC, with a dose-dependent
rapid depletion of CD14'CD123high cells (pDC and basophils) observed as early as
3 hours ing initiation of treatment, while monocytes (CD14+ cells) remained
unaffected at this time point (Figures 27F-27G). CD14'CD123high cells depletion
increased over time across all DART-A le concentrations, while monocytes
were slightly decreased by 6 hours and depleted only after 18 hours and at the
concentrations higher than 1 ng/mL. Incubation of monkey PBMCs with DART-A
resulted in a comparable dose-dependent ion of D123high cells (Figure
27H), further supporting the relevance of this species for DART-A pharmacology
(CDl4+ monkey cells express little to no CD123 and were not depleted).
Pharmacokinetics of DART-A in Cynomolgus Monkeys
] The cynomolgus monkey was selected as an appropriate pharmacological
model for DART-A analysis based on the equivalent distribution of both target
antigens in this species compared to humans based on immunohistochemistry with the
precursor mAbs, consistent with published information (Munoz, L. et al. (2001)
leukin-3 Receptor Alpha Chain (CD123) Is Widely Expressed In Hematologic
Malignancies,” Haematologica 86:1261-1269; Korpelainen, E.I. et al. (1996) “IL-3
Receptor Expression, Regulation And Function In Cells Of The Vasculatare,”
Immunol. Cell Biol. 74:1-7).
The study conducted in accordance with the present ion included 6
treatment groups consisting of 8 cynomolgus monkeys per group (4 males, 4 females)
(Table 8). All groups received vehicle control for the first infusion; then vehicle or
DART-A were administered intravenously for 4 weekly cycles. Group 1 animals
received vehicle control for all 4 subsequent infusions, whereas Groups 2-5 received
weekly escalating doses of DART-A for 4 days a week for all uent ons.
Group 6 animals were treated with 7-day rrupted weekly escalating doses of
DART-A for all infusions. The 4-day-on/3-day-off and 7-day-on schedules were
designed to distinguish between durable from ent effects associated with DART-
A administration. Two males and 2 s per group were sacrificed at the end of
the treatment phase (Day 36), while the remaining monkeys were necropsied after a 4-
week recovery (Day 65). A subset of monkeys developed anti-drug dies (ADA)
directed against the humanized Fv of both CD3 and CD123 and the data points
following the appearance of ADA were excluded from the PK is. All monkeys
were exposed to DART-A during the study period.
DART-A Infusion
(4-day-on/3-day-ofi) (7-day-on)
Vehicle
Infusion ng/kg/day ng/kg/day
N0. [n__/k/7da s]
Group Group
Vehicle Vehicle e Vehicle Vehicle Vehicle
[400] [400] [400] [700]
300 300
Vehicle
[1]200 [1]200 [1200] [2100]
Vehicle
[13200]00 [2400] [4200]
-____-ehicle [1200196400100300
00 1000 1000
[7000]
36-65 [_4000]
A two-compartment model was used to te PK parameters (Table 9 and
Figure 28). T1001 was short (4-5min), reflecting rapid binding to circulating targets;
T1013 was also rapid, as expected for a molecule of this size, which is subject to renal
clearance. Analysis of serum s collected at the end of each infusion from group
6 monkeys showed a dose-dependent increase in DART-A Cmax. In Table 9, Vehicle
was PBS, pH 6.0, containing 0.1 mg/mL recombinant human albumin, 0.1 mg/mL PS-
80, and 0.24 % benzyl alcohol was used for all vehicle infusions during the first 4
days of each infiJsion week followed the same formulation without benzyl alcohol for
the remaining 3 days of each weekly on. DART-A was administered for the
indicated times as a continuous IV infilsion of a solution of PBS, pH 6.0, containing
0.1 mg/mL recombinant human albumin, 0.1 mg/mL PS-80, and 0.24 % benzyl
alcohol at the required concentration.
Table 9
Two-Compartment Analysis of PK Parameters of DART-A
in C nomolus Monke s
. 300 ng/kg/d 600 ng/kg/d
Cmax (pg/mL) 77.4 9.4 113.8 __ 33.5
AUC (11* . _/mL) 7465 913 11188 3282
V (L/kg) 1.078 0.511 2.098 1.846
tm, alpha (h) 0.07 0.018 0.067 0.023
t1/2, beta h 13.79 4.928 21.828 18.779
MRT (h) 6.73 3.327 9.604 8.891
Cytokine Release in DART-A-Treated Cynomolgus Monkeys
Given the T cell tion properties of DART-A, an increase in circulating
cytokines accompanying the infiasion was anticipated and a low starting dose was
therefore used as a “desensitization” strategy, based on previous experience with
similar compounds (see, e.g., Topp, M.S. et al. (2011) “Targeted Therapy With The T-
Cell—Engaging Antibody Blinatumomab 0f Chemotherapy-Refractory Minimal
Residual Disease In B-Lineage Acute Lymphoblastic Leukemia Patients s In
High Response Rate And Prolonged Leukemia-Free Survival,” J. Clin. Oncol.
29:2493-2498; Bargou, R. et al. (2008) “Tumor Regression In Cancer Patients By
Very Low Doses OfA T Cell-Engaging Antibody,” Science 321:974-977). Of the
cytokine tested, lL-6 demonstrated the largest s upon infusion, albeit transient
in nature, of l magnitude and with large inter-animal and inter-group
variations (Figures 29A-29C). Small, transient increases in lL-6 were also observed
after vehicle ons (all Group 1 and all Day 1 infusions), indicating a sensitivity of
this cytokine to manipulative stress. Nonetheless, DART-A-dependent increases
(<80pg/mL) in serum lL-6 were seen in some monkeys following the first DART-A
infilsion (lOOng/kg/day), which returned to baseline by 72 hours. Interestingly, the
magnitude of lL-6 release decreased with each successive DART-A infusion, even
when the dose level was increased to up to 1000 ng/kg/day. l and transient
DART-A-related ses in serum TNF-u (<lOpg/mL) were also ed; as with
lL-6, the largest magnitude in TNF-u release was ed following the first
infiasion. There were no DART-A-related changes in the levels of lL-S, lL-4, lL-2, or
lFN—y throughout the study when compared with controls. In sion, cytokine
release in response to treatment of monkeys with DART-A was l, transient
and represented a first-dose effect manageable via intra-subject dose escalation.
DART-A-Mediated Depletion of Circulating CD14'/CD123Jr Leukocytes in vivo
The circulating absolute levels of CD123+ cells were ed
throughout the study as a pharmacodynamic endpoint. While the number of CD123+
cells in control Group I remained stable over time, DART-A treatment was associated
with extensive depletion of circulating CDl4-/CD123+ cells (94-lOO% from dy
baseline) observable from the first time point measured (72 hours) following the start
of the first DART-A on (100 ng/kg/day) in all animals across all active
treatment groups (Figures 30A-30C). The depletion was durable, as it persisted
during the 3-day weekly dosing holiday in Group 2-5, returning to baseline levels
only during the prolonged recovery period. To ate the possibility of DART-A
g or modulating CD123 (an unlikely scenario, given the low circulating
DART-A levels), pDCs were enumerated by the orthogonal marker, CD303.
Consistent with the CD123 data, CD303+ pDC were similarly depleted in monkeys
d with DART-A (Figures 30D-30F).
Circulating T-Lymphocyte Levels, Activation and Subset Analysis
In contrast to the persistent depletion of circulating CD123+ cells, DART-A
administered on the on/3-day-off schedule s 2-5) were associated with
weekly fluctuations in circulating T cells, while administration as continuous 7-day
infilsions resulted in similarly decreased circulating T cell levels following the first
administration that slowly recovered without fluctuation even during the dosing
period (Figures 31A-31C). The difference between the two dosing strategies
indicates that the effect of DART-A on T lymphocytes is consistent with trafficking
and/or margination, rather than ion. Following cessation of , T cells
rebounded to levels approximately 2-fold higher than baseline for the duration of the
recovery . Infusion of DART-A was associated with an exposure-dependent,
progressive increased frequency of T cells expressing the late activation marker, PD-
I, particularly in CD4+ cells, with dose Group 6 displaying the highest overall levels
(Figures 31D-311 and Figures 32A-32F and Figures 33A-33F). Tim-3, a marker
associated with T cell exhaustion, was not detected on CD4+ T cells and only at low
ncy among CD8+ cells (5.5-9.7%) and comprising 20.5-35.5% of the
D-l+ double-positive cells. There was no tent change in the early T
cell activation , CD69, and only modest variations in CD25 expression among
circulating cells.
To rule out exhaustion after in viva exposure, the ex vivo cytotoxic potential
of effector cells ed from cynomolgus monkeys receiving multiple infusions of
DART-A was compared to that of cells from na'ive monkeys. As shown in Figure 34,
PBMC isolated from DART-A-treated monkeys show cytotoxicity comparable to that
of cells isolated from na'ive monkeys, indicating that in viva exposure to DART-A
does not negatively impact the ability of T cells to kill target cells.
DART-A exposure increased the relative frequency of central memory CD4
cells and effector memory CD8+ cells at the expense of the corresponding naive T
cell population (Figures 35A-35F and Figures 32A-32F and Figures 33A-33F),
ting that DART-A exposure promoted expansion and/or mobilization of these
cells.
Effects on Hematopoiesis and Bone Marrow Precursors
DART-A was well tolerated in monkeys at all doses tested; however,
reversible ions in red cell parameters were ed at the highest doses
(Figures 36A-36C). Frequent blood sampling could have been a ial
contributing factor, since vehicle-treated animals showed a modest e in red cell
mass. Reticulocyte response was observed in all animals; at the highest exposure
(Group 6), however, the response appeared slightly less robust for similar decrease in
red cell mass es 36D-36F). Morphological analysis of bone marrow smears
throughout the study was unremarkable. Flow cytometry analysis, however, revealed
that the frequency of CD123+ cells within the immature lineage-negative (Lin-) bone
marrow populations decreased in -treated animals at the end of the dosing
period, returning to baseline levels by the end of the recovery time (Figure 37A-37B).
HSC (defined as Lin-/CD34+/CD38-/CD45RA-/CD90+ cells (Pang, W.W. et al.
(2011) “Human Bone Marrow Hematopoietic Stem Cells Are Increased In Frequency
And Myeloz'd—Bz'ased With Age,” Proc. Natl. Acad. Sci. (U.S.A.) lO8:20012-20017))
showed large inter-group variability; Group 4-6 DART-A-treated s show
some apparent reduction ed to the corresponding pre-dose levels, however, no
decrease was seen in all treated groups compared to vehicle-treated animals. These
data indicate that HSC are less susceptible to targeting by DART-A and are consistent
with the observed reversibility of the negative effects of DART-A treatment on
hematopoiesis.
As demonstrated above, with respect to infusions for 4 weeks on a 4-day-
on/3-day-off weekly schedule or a 7-day-on schedule at starting doses of
lOOng/kg/day that were escalated se weekly to 300, 600, and l,000ng/kg/day,
the administration of DART-A to cynomolgus monkeys was well tolerated. Depletion
of circulating CD123+ cells, including pDCs, was observed after the start of the first
administration and persisted throughout the study at all doses and schedules.
Reversible reduction in bone marrow CD123+ precursor was also ed. Cytokine
release, as significant safety concern with CD3-targeted therapies, ed
manageable and consistent with a first-dose effect. Modest reversible anemia was
noted at the highest doses, but no other (on- or off-target) adverse events were noted.
The cynomolgus monkey is an appropriate animal model for the
cological assessment of DART-A, given the high homology n the
orthologs and the ability of DART-A to bind with similar affinity to the ns and
e redirected T cell killing in both species. Furthermore, both antigens are
concordantly expressed in monkeys and , ing similar expression by
hematopoietic precursors and in the cytoplasm of the endothelium of multiple tissues.
Minor exceptions are the expression in testicular Leydig cells in humans but not
monkeys and low-to-absent CD123 in monkey monocytes compared to humans.
A primary concern associated with therapeutic strategies that involve T cell
activation includes the e of cytokines and off-target cytotoxic effects. A recent
study with a CD3xCD123 bi-specif1c scFv fusion construct with bivalent
CD3 recognition demonstrated anti-leukemic activity in vitro, but caused non-specific
tion of T cells and IFN—y secretion (Kuo, S.R. et al. (2012) “Engineering A
CD123xCD3 Bispecific scFv Immunofusion For The Treatment Of ia And
Elimination 0f Leukemia Stem Cells,” Protein Eng. Des. Sel. 25:561-569). The
lent nature of each binding arms and the highly homogeneous monomeric
form of DART-A ensure that T cell activation depends exclusively upon target cell
engagement: no T cell activation was observed in the e of target cells or by
using a Control DART molecule that included only the CD3-targeting arm.
rmore, high doses (up to 100ug/kg/day) of the Control DART molecule did not
trigger cytokine release in cynomolgus monkeys.
The DART-A molecule starting dose of kg/day was well tolerated,
with minimal cytokine release. Cytokine storm, however, did occur with a high
starting dose (Sug/kg/day); however, such dose could be reached safely via stepwise
weekly dose escalations, indicating that DART-A-mediated cytokine release s
to be ily a first-dose effect. Depletion of the CD123+ target cells, thereby
eliminating a source of CD3 ligation, may explain the first-dose effect: nearly
complete CD123+ cell depletion was ed at doses as low as 3-10ng/kg/day,
indicating that cytokine release in vivo follows a shifted dose-response compared to
cytotoxicity. Dose-response profiles for cytotoxicity and cytokine release by human T
cells were also consistent with this observation.
T cell desensitization, in which DART-A-induced PD1 upregulation may
play a role, appears to also contribute to limit cytokine release after the first infilsion
of DART-A. Recent studies show that increased PD-l expression after antigen-
induced arrest of T cells at inflammation sites contributes, through interactions with
PD-Ll, to terminating the stop signal, thus releasing and desensitizing the cells
(Honda, T. et al. (2014) “Tuning 0fAntigen Sensitivity By T Cell or-Dependent
Negative ck Controls T Cell r Function In Inflamed Tissues,” ty
40:235-247; Wei, F. et al. (2013) “Strength OfPD-I Signaling Difi’erentially Aflects
T-Cell Efi’ector Functions,” Proc. Natl. Acad. Sci. (USA) 110:E2480-E2489). The
PD-l countering of TCR ing strength is not uniform: while proliferation and
cytokine production appear most sensitive to PD-l inhibition, cytotoxicity is the least
affected (Wei, F. et al. (2013) “Strength OfPD-I Signaling Difi’erentially Aflects T-
Cell Efi’ector ons,” Proc. Natl. Acad. Sci. (U.S.A.) 110:E2480-E2489).
Consistently, the ex vivo cytotoxic potential of T cells from monkeys exposed to
multiple infusions of DART-A was comparable to that of T cells from na'ive monkeys,
despite increased PD-l levels in the former. Furthermore, PD-l upregulation was not
accompanied by TIM3 expression, a hallmark of T cell exhaustion, as shown for T
cells exposed to cted stimulation with CD3 antibodies or chronic infections
(Gebel, H.M. et al. (1989) “T Cells From Patients Successfully Treated With 0KT3
Do Not React With The T—Cell Receptor Antibody,” Hum. Immunol. 26:123-129;
Wherry, E]. (2011) “T Cell Exhaustion,” Nat. l. -499).
The depletion of circulating CD123+ cells in DART-A-treated monkeys was
rapid and persisted during the weekly dosing holidays in the 4-day-on/3-day-off
schedule, consistent with target cell ation. In contrast, the transient fluctuations
in circulating T cells were likely the result of trafficking o tissues and lymphoid
organs as a function of DART-A. DART-A exposure promotes the expansion and/or
zation of antigen experienced T lymphocytes, cells that preferentially home to
tissues and more readily exert cytotoxic effector function (Mirenda, V. et al. (2007)
“Physiologic And Aberrant Regulation Of Memory T-Cell Trafiicking By The
Costimulatory Molecule CD28,” Blood 109:2968-2977; Marelli-Berg, F.M. et al.
(2010) “Memory T-Cell king.‘ New Directions For Busy Commuters,”
Immunology 130:158-165).
] Depletion of CD123+ normal cells may carry potential liabilities. pDCs and
basophils express high levels of CD123, compared to lower levels in monocytes and
eosinophils (Lopez, A.F. et al. (1989) “Reciprocal tion 0f Binding Between
Interleukin 3 And Granulocyte-Macrophage Colony-Stimulating Factor To Human
Eosinophils,” Proc. Natl. Acad. Sci. (U.S.A.) 86:7022-7026; Munoz, L. et al. (2001)
“Interleukin-3 Receptor Alpha Chain (CD123) Is Widely sed In Hematologic
Malignancies,” Haematologica 86:1261-1269; Masten, B.J. et al. (2006)
“Characterization OfMyeloid And Plasmacytoid Dendritic Cells In Human Lung,” J.
Immunol. 177:7784-7793; Korpelainen, E.I. et al. (1995) “Interferon-Gamma
Upregulates Interleukin-3 (IL-3) Receptor Expression In Human Endothelial Cells
And Synergizes With IL-3 In Stimulating Major Histocompatibility Complex Class II
Expression And Cytokine Production,” Blood 86:176-182). pDCs have been shown
to play a role in the l of certain viruses in mouse or monkey models of
infection, although they do not appear critical for controlling the immune response to
flu (Colonna, M. et al. (1997) “Specificity And Function 0f Immunoglobulin
Superfamily NK Cell tory And Stimulatory Receptors,” Immunol. Rev. 155:127-
133; Smit, J.J. et al. (2006) “Plasmacytoid Dendritic Cells Inhibit ary
Immunopathology And Promote Clearance 0f Respiratory Syncytial Virus,” J. Exp.
Med. 203:1153-1159). In tumor models, pDCs may promote tumor growth and
asis, while pDC depletion resulted in tumor inhibition (Sawant, A. et al. (2012)
“Depletion 0f Plasmacytoid Dendritic Cells ts Tumor Growth And Prevents
Bone asis 0f Breast Cancer Cells,” J. Immunol. 189:4258-4265). Transient,
modest, dose-independent facial swelling was observed in some monkeys treated with
DART-A; however, no increased histamine levels were observed in these monkeys or
when human basophils were lysed via DART-A-mediated T cell killing. Monocyte
depletion may carry increased risks of infection; the consequence of pDC, basophil or
eosinophils depletion in humans should thus be monitored.
Committed poietic precursors that express CD123, such as the
common myeloid precursor (CMP) (Jordan, C.T. et al. (2000) “The Interleukin-3
Receptor Alpha Chain Is A Unique Marker For Human Acute enous Leukemia
Stem Cells,” Leukemia 14:1777-1784; Rieger, MA. et al. (2012) “Hematopoiesis,”
Cold Spring Harb. Perspect. Biol. 4:a008250), may be targeted by DART-A, a
possible explanation for the modest anemia observed following administration of
DART-A at the highest dose. The erythropoietic reticulocyte response appeared to
function at all DART-A dose levels; however, for surate drops in red cell
parameters, s subjected to the st DART-A exposure (Group 6, 7-day-on
infiJsion) showed a reduced reticulocyte response, suggesting a possible cytotoxic
activity on precursors (e.g., CMP). The effect was reversible following cessation of
DART-A treatment, consistent with repopulation from spared CD123low/negative
HSC.
Alternate approaches for depletion of CD123+ cells e a second-
generation CD123-specif1c Fc-enhanced monoclonal antibody (Jin, L. et al. (2009)
“Monoclonal Antibody-Mediated Targeting 0f CD123, IL-3 Receptor Alpha Chain,
Eliminates Human Acute Myeloid Leukemic Stem Cells,” Cell Stem Cell 5:31-42;
s, A. W. et al. (2010) “A Phase I Study 0fAnti-CDI23 Monoclonal Antibody
(mAb) CSL360 Targeting Leukemia Stem Cells (LSC) In AML,” J. Clin. Oncol.
28(Suppl):e13012), IL-3 bound diphtheria toxin (Frankel, A. et al. (2008) “Phase I
al Study Of Diphtheria Toxin-Interleukin 3 Fusion Protein In Patients With
Acute Myeloid Leukemia And Myelodysplasia,” Leuk. Lymphoma 49:543-553),
cytokine-induced killer (CIK) cells expressing CD123-specific chimeric antigen
receptors (CAR) (Tettamanti, S. et al. (2013) “Targeting 0fAcute Myeloid Leukaemia
By Cytokine-Induced Killer Cells Redirected With A Novel CD123-Specific Chimeric
Antigen Receptor,” Br. J. Haematol. 161:389-401) and CD123 CAR T cells (Gill, S.
et al. (2014) “Efiicacy Against Human Acute Myeloid Leukemia And Myeloablation
0f Normal Hematopoiesis In A Mouse Model Using Chimeric Antigen Receptor-
Modified T Cells,” Blood ): 2343-2354; Mardiros, A. et al. (2013) “T Cells
Expressing CD123-Specific Chimeric Antigen Receptors Exhibit Specific Cytolytic
Eflector Functions And Antitumor Eflects Against Human Acute Myeloid ia,”
Blood 122:3138-3148). CAR T cells exhibited potent leukemic blast cell killing in
vitro and anti-leukemic activity in a xenogeneic model of disseminated AML
(Mardiros, A. et al. (2013) “T Cells Expressing CD123-Specific Chimeric Antigen
Receptors Exhibit Specific Cytolytic Eflector Functions And Antitumor Eflects Against
Human Acute d Leukemia,” Blood 122:3138-3148). A recent study ed
ablation of normal hematopoiesis in NSG mice engrafted with human CD34+ cells
following CD123 CAR T cell er (Gill, S. et al. (2014) “Efiicacy Against Human
Acute Myeloid Leukemia And Myeloablation 0fNormal Hematopoiesis In A Mouse
Model Using Chimeric Antigen or-Modified T Cells,” Blood ): 2343-
2354), gh others have not observed similar effects in vitro or in vivo
(Tettamanti, S. et al. (2013) “Targeting 0f Acute Myeloid Leukaemia By Cytokine-
Induced Killer Cells cted With A Novel Specific Chimeric Antigen
Receptor,” Br. J. ol. 161:389-401; Pizzitola, I. et al. (2014) ric Antigen
Receptors Against CD33/CDI23 ns Efiiciently Target Primary Acute Myeloid
Leukemia Cells in vivo,” Leukemia doi:10.1038/leu.2014.62). In the above-discussed
experiments, depletion of CD123+ bone marrow precursor populations was observed,
but reversed during recovery; fithhermore, depletion of this minority population
resulted in no changes in bone marrow cellularity or erythroid to myeloid cell (E:M)
ratio at all DART-A dose levels tested. These differences underscore the potential
advantages of DART-A over cell therapies, as it provides a titratable system that
relies on autologous T cells in contrast to “supercharged” ex vivo transduced cells that
may be more difficult to control. CD123 is overexpressed in l hematologic
malignancies, including AML, hairy cell ia, blastic plasmacytoid dendritic cell
neoplasms ( BPDCNs), a subset of ursor acute lymphoblastic leukemia (B-
ALL) and chronic lymphocytic leukemia, Hodgkin’s disease Reed-Stemberg cells, as
well as in myelodysplastic syndrome and systemic mastocytosis (Kharfan-Dabaja,
MA. et al. (2013) “Diagnostic And Therapeutic Advances In Blastic Plasmacytoid
Dendritic Cell Neoplasm: A Focus On poietic Cell lantation,” Biol.
Blood Marrow Transplant. 19:1006-1012; Florian, S. et al. (2006) “Detection 0f
Molecular Targets On The Surface 0fCD34+/CD38-- Stem Cells In s d
Malignancies,” Leuk. Lymphoma 47:207-222; Munoz, L. et al. (2001) “Interleukin-3
Receptor Alpha Chain (CD123) Is Widely Expressed In Hematologic Malignancies,”
Haematologica 86:1261-1269; Fromm, JR. (2011) “Flow Cytometric is Of
CD123 Is Useful For Immunophenotyping Classical Hodgkin Lymphoma,” Cytometry
B Clin. Cytom. 80:91-99). The predictable pharmacodynamic activity and
manageable safety profile observed in non-human primates further supports the
clinical utility and efficacy of DART-A as immunotherapy for these disorders.
In sum, DART-A is an antibody-based le ng the CD38 subunit
of the TCR to redirect T lymphocytes against cells expressing CD123, an antigen up-
regulated in l hematological malignancies. DART-A binds to both human and
cynomolgus monkey’s antigens with similar affinities and redirects T cells from both
species to kill CD123+ cells. Monkeys infiJsed 4 or 7 days a week with weekly
escalating doses of DART-A showed depletion of circulating CD123+ cells 72h after
treatment initiation that persisted throughout the 4 weeks of treatment, irrespective of
dosing les. A decrease in circulating T cells also occurred, but recovered to
baseline before the subsequent infusion in monkeys on the 4-day dose schedule,
consistent with DART-A-mediated mobilization. DART-A administration increased
circulating PD1+, but not TIM-3+, T cells; fiarthermore, ex vivo is of T cells
from treated monkeys exhibited unaltered cted target cell lysis, indicating no
exhaustion. Toxicity was d to a minimal transient release of nes
following the DART-A first infusion, but not after subsequent administrations even
when the dose was escalated, and a minimal reversible decrease in red cell mass with
concomitant reduction in CD123+ bone marrow progenitors. Clinical g of
DART-A in hematological malignancies appears warranted.
] All publications and patents mentioned in this specification are herein
incorporated by reference to the same extent as if each indiVidual ation or
patent application was specifically and individually indicated to be incorporated by
reference in its entirety. While the invention has been described in connection with
specific embodiments thereof, it will be understood that it is capable of fiarther
ations and this application is intended to cover any variations, uses, or
adaptations of the invention following, in general, the principles of the ion and
including such departures from the present disclosure as come within known or
customary practice within the art to which the invention pertains and as may be
applied to the essential features hereinbefore set forth.
Claims (20)
1. Claim 1. A sequence-optimized diabody capable of specific binding to an epitope of CD123 and to an epitope of CD3, wherein the diabody comprises a first polypeptide chain and a second ptide chain, covalently bonded to one another, wherein: A. the first polypeptide chain comprises, in the N-terminal to C-terminal direction: i. a Domain 1, comprising (1) a sub-Domain (1A), which comprises a VL Domain of a monoclonal antibody capable of binding to CD3 (VLCD3) (SEQ ID NO:21); and (2) a sub-Domain (1B), which comprises a VH Domain of a monoclonal antibody capable of g to CD123 (VHCD123) (SEQ ID NO:26), wherein said sub-Domains 1A and 1B are ted from one another by a peptide linker (SEQ ID NO:29); ii. a Domain 2, wherein said Domain 2 is an E-coil Domain (SEQ ID NO:34) or a K-coil Domain (SEQ ID NO:35), wherein said Domain 2 is separated from said Domain 1 by a peptide linker (SEQ ID NO:30); and B. the second polypeptide chain comprises, in the N-terminal to C-terminal direction: i. a Domain 1, comprising (1) a sub-Domain (1A), which comprises a VL Domain of a onal antibody capable of binding to CD123 (VLCD123) (SEQ ID NO:25); and (2) a main (1B), which comprises a VH Domain of a monoclonal antibody capable of binding to CD3 ) (SEQ ID NO:22), wherein said sub-Domains 1A and 1B are ted from one another by a peptide linker (SEQ ID NO:29); ii. a Domain 2, wherein said Domain 2 is a K-coil Domain (SEQ ID NO:35) or an E-coil Domain (SEQ ID NO:34), wherein said Domain 2 is separated from said Domain 1 by a peptide linker (SEQ ID NO:30); and wherein said Domain 2 of said first and said second polypeptide chains are not both E-coil Domains or both K-coil Domains; and wherein: (a) said VL Domain of said first polypeptide chain and said VH Domain of said second polypeptide chain form an Antigen Binding Domain capable of specifically binding to an epitope of CD3; and (b) said VL Domain of said second polypeptide chain and said VH Domain of said first polypeptide chain form an Antigen Binding Domain e of specifically binding to an e of CD123.
2. Claim 2. The diabody of claim 1, wherein said first polypeptide chain additionally comprises an Albumin-Binding Domain (SEQ ID NO:36) linked t o said Domain 2 via a peptide linker (SEQ ID NO:31).
3. Claim 3. The diabody of claim 1, wherein said second polypeptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 1 via a peptide linker (SEQ ID NO:33).
4. Claim 4. The diabody of claim 1, wherein said first polypeptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 1 via a peptide linker (SEQ ID NO:33).
5. Claim 5. The y of claim 1, wherein said second ptide chain additionally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID , wherein said Domain 3 is linked to said Domain 2 via a e linker (SEQ ID NO:32).
6. Claim 6. The diabody of claim 1, wherein said first polypeptide chain onally comprises a Domain 3 comprising a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO:37), wherein said Domain 3 is linked to said Domain 2 via a peptide linker (SEQ ID NO:32).
7. Claim 7. The diabody of any one of claims 3 to 6, wherein said diabody further comprises a third polypeptide chain sing a CH2 and CH3 Domain of an immunoglobulin Fc Domain (SEQ ID NO: 11).
8. Claim 8. The diabody of any one of claims 3 to 7, wherein said y further comprises a cysteine-containing peptide (SEQ ID NO:55) N -terminal to said CH2 and CH3 Domain of said immunoglobulin Fc Domain.
9. Claim 9. The diabody of any of claims 1 to 8, wherein said Domain 2 of said first polypeptide chain is a K-coil Domain (SEQ ID NO:35) and said Domain 2 of said second polypeptide chain is an E-coil Domain (SEQ ID NO:34).
10. Claim 10. The diabody of any of claims 1 to 8, wherein said Domain 2 of said first polypeptide chain is an E-coil Domain (SEQ ID NO:34) and said Domain 2 of said second polypeptide chain is a K-coil Domain (SEQ ID NO:35).
11. Claim 11. The diabody of any preceding claim, wherein the diabody is capable of crossreacting with both human and primate CD123 and CD3 proteins.
12. Claim 12. The y of claim 1, n: A. said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:1; and B. said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:3.
13. Claim 13. The diabody of claim 1, n the diabody further comprises a third polypeptide chain, wherein: A. said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:15; B. said second polypeptide chain comprises the amino acid sequence of SEQ ID NO:13; and C. said third ptide chain comprises the amino acid sequence of SEQ ID NO:54.
14. Claim 14. The diabody of claim 1, wherein the diabody further comprises a third polypeptide chain, wherein: A. said first polypeptide chain comprises the amino acid sequence of SEQ ID NO:1; B. said second ptide chain comprises the amino acid sequence of SEQ ID NO:17; and C. said third polypeptide chain comprises the amino acid sequence of SEQ ID NO:54.
15. Claim 15. A ceutical composition comprising the diabody of any one of claims 1 to 14 and a physiologically acceptable carrier.
16. Claim 16. Use of diabody of any one of claims 1 to 14, or the pharmaceutical composition of claim 15, in the preparation of a medicament for the treatment of a disease or condition associated with or characterized by the expression of CD123.
17. Claim 17. The use of claim 16, wherein said disease or ion associated with or characterized by the expression of CD123 is cancer.
18. Claim 18. The use of claim 17, wherein said cancer is selected from the group consisting of: acute myeloid leukemia (AML), c myelogenous leukemia (CML), ing blastic crisis of CML and Abelson oncogene associated with CML (Bcr-ABL translocation), ysplastic syndrome (MDS), acute B lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), including Richter’s syndrome or Richter’s transformation of CLL, hairy cell ia (HCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non- Hodgkin lymphomas (NHL), including mantel cell leukemia (MCL), and small lymphocytic lymphoma (SLL), Hodgkin’s lymphoma, systemic ytosis, and Burkitt’s ma.
19. Claim 19. The use of claim 16, wherein said disease or condition associated with or characterized by the expression of CD123 is an inflammatory condition.
20. Claim 20. The use of claim 19, n said inflammatory condition is selected from the group consisting of: Autoimmune Lupus (SLE), allergy, asthma, and rheumatoid arthritis.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869510P | 2013-08-23 | 2013-08-23 | |
US61/869,510 | 2013-08-23 | ||
US201361907749P | 2013-11-22 | 2013-11-22 | |
US61/907,749 | 2013-11-22 | ||
EP13198784.4A EP2839842A1 (en) | 2013-08-23 | 2013-12-20 | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP13198784 | 2013-12-20 | ||
US201461990475P | 2014-05-08 | 2014-05-08 | |
US61/990,475 | 2014-05-08 | ||
PCT/US2014/051790 WO2015026892A1 (en) | 2013-08-23 | 2014-08-20 | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ716914A NZ716914A (en) | 2021-09-24 |
NZ716914B2 true NZ716914B2 (en) | 2022-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210047426A1 (en) | Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof | |
US11639386B2 (en) | Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof | |
JP7184866B2 (en) | PD1 and/or LAG3 binding substances | |
JP7360441B2 (en) | Mesothelin and CD137 binding molecules | |
JP7360440B2 (en) | Antibody molecules that bind to PD-L1 and CD137 | |
KR20240090732A (en) | Anti-pvrig antibodies and methods of use | |
KR20210030957A (en) | Anti-mesothelin antibody | |
JP7474235B2 (en) | Fc-binding fragment containing the OX40 antigen-binding site | |
NZ716914B2 (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
ES2860973T3 (en) | Bispecific monovalent diabodies that can bind CD123 and CD3 and uses of these | |
RU2815066C2 (en) | Molecules binding mesothelin and cd137 | |
EP4378953A1 (en) | Cd229 targeting moiety for the tratment of cd229 positive cancer | |
OA20146A (en) | Bi-specific monovalent diabodies that are capable of binding to GPA33 and CD3, and uses thereof. |